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Summary 
 
Summary 
Gastric adenocarcinoma is one of the most common causes of cancer-related deaths 
worldwide and develops as a consequence of chronic gastric inflammation caused by 
persistent infection with the bacterium Helicobacter pylori. In humans as well as in 
experimentally infected mice, gastric carcinogenesis progresses through a series of 
preneoplastic lesions which manifest histologically as chronic atrophic gastritis, epithelial 
hyperplasia, intestinal metaplasia and dysplasia. Gastric tumorigenesis is preceded by 
excessive local and systemic immune responses against Helicobacter pylori. It has become 
increasingly obvious that host genetic predisposition combined with the virulence properties 
of the colonizing Helicobacter strain determine the severity of disease outcome. Bacterial 
eradication shows beneficial effects in a subset of patients with atrophic gastritis, but fails to 
reverse intestinal metaplasia and to prevent malignant transformation. We and others have 
shown recently that Helicobacter-induced stomach-infiltrating pathogenic CD4+ T-effector 
cells and their cytokines constitute central mediators of gastric preneoplasia.    
Therefore, the aim of this study was to identify therapeutic targets that modulate the 
Helicobacter-specific T-cell response and thus can be exploited to prevent the progression of 
Helicobacter-induced premalignant lesions. We utilized a C57BL/6 mouse model of 
experimental Helicobacter felis infection in which the development of gastric preneoplasia is 
reminiscent of the human setting. In this model, infected mice develop chronic atrophic 
gastritis accompanied by epithelial hyperplasia and intestinal metaplasia as early as three 
months post infection. I chose to focus on two molecular players known to play crucial roles 
at the interface of inflammation and cancer, the cyclooxygenases (COX) and poly(ADP-
ribose) polymerases (PARPs). Both enzymes are obvious candidates to assess in the 
context of Helicobacter-induced gastric preneoplasia for the following reasons:  
COX-2 and its main product PGE2 function as potent immunosuppressants and 
modulators of inflammatory responses on the one hand, and possess tumor promoting 
properties on the other. The process catalyzed by PARPs, the poly(ADP-ribosyl)ation of 
specific acceptor proteins, is an important post-transcriptional modification involved in the 
regulation of pro-inflammatory genes, and also participates in the DNA damage response 
after genotoxic damage. We utilized pharmacological as well as genetic approaches to 
manipulate these key players at the interface of inflammation and cancer and to elucidate 
their contribution to Helicobacter-induced preneoplasia.  
The pharmacological inhibition of COX-2 enzymatic activity during Helicobacter 
infection in mice led to significantly accelerated and aggravated disease symptoms 
characterized by more severe gastritis and epithelial pathology as well as elevated IFN-γ 
levels.  In line with these findings, the administration of synthetic PGE2 to infected mice 
completely suppressed and even reversed pre-existing Helicobacter-associated 
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precancerous lesions, including intestinal metaplasia. The protective effect of PGE2 
treatment was accompanied by decreased gastric IFN-γ levels, reduced gastric neutrophil 
and T-cell infiltration and a reduction of T-cellular Th-1 differentation in the draining 
mesenteric lymph nodes. Similarly, systemic administration of the inhibitor of poly(ADP-
ribosyl)ation, PJ34, reversed pre-existing metaplastic lesions and provided sustainable cure 
if the treatment was combined with bacterial eradication therapy. The protective effect of both 
treatments was found to be due to the potent suppression of pathogenic T-cell responses. 
Data obtained from complementary ex vivo and in vitro experiments indicate that PGE2 and 
PJ34 treatments abolish T-cellular proliferation, activation-dependent cytokine secretion and 
migration of CD4+ T-effector cells. This effect was accompanied and probably caused by the 
transcriptional suppression of the genes encoding IFN-γ and IL-2, the latter being a cytokine 
essential for continuous effector and regulatory T-cell stimulation and perpetuation of 
adaptive immune responses.  
Another focus of this study was to elucidate Helicobacter pylori’s intrinsic genotoxic 
propterties and to thus determine a possible direct contribution of the bacteria to gastric 
carcinogenesis. We investigated the potential of Helicobacter pylori to directly damage host 
cellular DNA and thereby contribute to the acquisition of tumor-promoting mutations. To this 
end, various cell lines and primary cells were infected with H. pylori and the induction of DNA 
double strand breaks (DSB) and subsequent DNA damage signalling was investigated. Pulse 
field gel electrophoresis revealed that H. pylori infection causes DSB in an infection dose-
dependent manner. The appearance of DSB depended on contact of live bacteria with the 
host cell, but occurred independently of the H. pylori virulence factors VacA and the Cag 
pathogenicity island and was not observed upon infection with E. coli. H. pylori infection-
induced DSB resulted in a DNA damage response evident as phosphorylation of H2AX 
(γH2AX) and foci formation of 53BP1 and MDC1 proteins at sites of DSB. DSB were 
efficiently repaired by the host cells, but only after antibiotic eradication of H. pylori. The data 
suggest an active role of Helicobacter in the process of host cellular transformation, and may 
involve a specific bacterial factor delivered upon host-pathogen contact.  
Taken together, the data obtained in the course of my PhD thesis show that 
Helicobacter possesses genotoxic properties and that pharmacological targeting of CD4+ T-
cells inhibits and reverses pre-existing precancerous lesions in a mouse model of 
Helicobacter-induced gastric preneoplasia. The results thus provide insights into new 
therapeutic targets for the treatment of patients that are refractory to Helicobacter eradication 
therapy or present with untreatable gastric cancer precursor lesions. 
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Zusammenfassung 
Das Magenkarzinom zählt zu den häufigsten tödlichen Krebserkrankungen weltweit. 
Die Entstehung basiert auf einer chronischen Entzündung der Magenmukosa, verursacht 
durch eine persistierende Infektion mit Helicobacter pylori. Bei Menschen wie bei Mäusen 
verläuft die gastrale Karzinogenese ausgehend von präneoplastischen Krebsvorstufen. 
Histologisch manifestieren sich diese Vorstufen als atrophische Gastritits, epitheliale 
Hyperplasie, intestinale Metaplasie und Dysplasie. Die gastrale Krebsentstehung ist somit 
ein immunpathologischer Prozess, welcher durch eine übertrieben starke Immunantwort 
gegen das magenkolonisierende Bakterium Helicobacter pylori verursacht wird. Die Virulenz 
des Helicobacter-Stammes sowie die genetische Prädisposition des Wirtes bestimmen den 
Schweregrad der fortschreitenden Erkrankung.  Bei Personen mit bestimmten gastralen 
Präkanzerosen kann durch die Eradikation des Keimes ein Rückgang der Erkrankung 
herbeigeführt werden. Intestinale Metaplasien und deren Weiterentwicklung zu einer 
malignen Erkrankung hingegen können dadurch nicht verhindert werden.  Daten, die in 
unserm Labor generiert wurden zeigen, dass pathogene T-Zellen und deren Zytokine für die 
Entstehung von Magenkrebs und dessen Vorstufen mitverantwortlich sind. 
 Das Ziel der vorliegenden Arbeit war es, mögliche verantwortliche Faktoren und 
gegen dieselben gerichtete Wirkstoffe zu identifizieren, welche pathogene T-Zell Antworten 
hemmen und dadurch das Fortschreiten von gutartigen Krebsvorstufen zu bösartigen 
Läsionen unterbinden können. Zudem untersuchten wir, ob H. pylori selbst die DNS der 
infizierten Wirtszellen schädigen und somit selbst kanzerogen wirken kann.  
 Für die Studien infizierten wir C57BL/6 Mäuse mit Helicobacter felis, einem nahen 
Verwandten des human-pathogenen H. pylori. Die Entstehung der Präkanzerosen in 
unserem Modell ist mit derjenigen im Menschen vergleichbar. Infizierte Mäuse entwickeln 
nach drei Monaten verschiedene Krebsvorstufen in der Magenmukosa: Gastritis, Hyperplasie 
des Epithels und intestinale Metaplasie. Wir untersuchten die Funktion von zwei wichtigen 
Komponenten, die einerseits während der Entzündungsreaktion und andererseits auch in 
bestehenden Tumoren eine wichtige Rolle spielen und somit als Beschleuniger der 
Krebsentwicklung fungieren könnten: die Cyclooxygenasen (insbesondere COX-2) und die 
Poly(ADP-ribose)polymerasen (PARPs). Das von der COX-2 synthetisierte PGE2 hemmt die 
Immunantwort, koordiniert die Entzündungsreaktion und besitzt andererseits aber auch  
krebsunterstützende Funktionen. Eine ähnlich wichtige Rolle spielt die post-transkriptionelle 
Poly(ADP-ribosyl)ierung von Proteinen, die in der Entzündungsreaktion mitwirken.  Den 
Beitrag dieser Proteine zur Helicobacter-induzierten Krebsentstehung untersuchten wir, 
indem wir die Funktion der beiden Vorgänge pharmakologisch unterdrückten.  
 Eine Blockierung der COX-2 und folglich auch der PGE2 Synthese während der 
Infektion führte zu einem signifikant beschleunigten Krankheitsverlauf und zu verstärkten 
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Krankheitsmerkmalen im Bereich der Magenmukosa der infizierten Mäuse. Zusätzlich 
konnten wir hohe IFN-γ Konzentrationen und eine geringere Anzahl Bakterien in der 
Magenmukosa nachweisen.  Übereinstimmend mit dieser Beobachtung bewirkte eine 
Verabreichung von exogenem PGE2 eine markante Regredienz der Gastritis und 
unterdrückte nicht nur die Entstehung von Helicobacter-assoziierten Präkanzerosen, sondern 
bewirkte auch einen Rückgang der intestinalen Metaplasie. Dies ging mit tiefen IFN-γ 
Konzentrationen und hoher bakterieller Kolonisierung im Magen einher.   
Zusammenfassend zeigen die erhobenen Daten, dass die Verabreichung von 
exogenem, synthetischen PGE2 an infizierte Mäuse nicht nur die Entstehung von 
Präkanzerosen unterdrückte, sondern es zeigt sich auch, dass bestehende präkanzeröse 
Läsionen einschliesslich der intestinalen Metaplasien geheilt werden konnten und die 
Magenschleimhaut sich in der Folge normalisierte. Diese Resultate sprechen für eine 
immunsuppressive Rolle von PGE2, was dazu führt, dass keine Immunzellen in die 
Magenschleimhaut einwandern können um die Helicobacter-Infektion zu bekämpfen, was 
wiederum eine hohe Helicobacter-Kolonisierung zur Folge hat.  
Einen ähnlichen Effekt zeigte die Behandlung von infizierten Mäusen mit PJ34. In 
behandelten Mäusen konnte ebenfalls die Entstehung von Helicobacter-induzierten 
Krebsvorstufen verhindert werden und auch bereits bestehende Veränderungen der 
Magenschleimhaut konnten geheilt werden. 
Unsere in vitro Untersuchungen haben weiterhin gezeigt, dass eine Behandlung mit 
PGE2 und PJ34 die Aktivierung von T-Zellen hemmt und damit die entzündungsinduzierte 
Zytokinsekretion und die Migration von CD4+ Effektor-T-Zellen zum Infektfokus verhindert. 
Zudem führte die Behandlung zu einer Blockierung der Transkription von IFN-γ und IL-2. 
IFN-γ spielt eine wichtige Rolle bei der Bekämpfung der Kolonisierung, führt aber gleichzeitig 
auch zur Entstehung von Veränderungen in der Magenschleimhaut. IL-2 ist ein essentielles 
Zytokin, das für die Aktivierung und die Proliferation von regulatorischen und Effektor-T-
Zellen sowie für die Aufrechterhaltung der erworbenen Immunantwort verantwortlich ist. Dies 
erklärt auch den lindernden Effekt von PGE2 und PJ34. Mit andern Worten, die  beiden 
Substanzen verhindern die Entstehung einer Entzündungsreaktion im Magen, indem sie 
Proliferation und die Sekretion von Effektorzytokinen durch T-Zellen unterdrücken. 
Neben den immunpathologischen Ursachen der gastralen Karzinogenese 
untersuchten wir auch, ob Helicobacter pylori die DNS der Wirtszelle direkt schädigen kann 
und dadurch die Tumorentstehung provozieren könnte. Dazu infizierten wir verschiedene 
Zelllinien mit H. pylori und untersuchten dann die Intaktheit der Wirts-DNS und ob dabei 
DNS-Doppelstrangbrüche (DSB) entstanden sind. Ausserdem untersuchten wir, ob die 
betroffenen Zellen auf die DNA Schäden mit der Aktivierung assozierter Signalkaskaden 
reagierten. Wir konnten feststellen, dass die Helicobacter-Infektion tatsächlich DNS Schäden 
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induziert. Darüber hinaus haben wir gezeigt, dass die DSB durch wirtseigene 
Reparaturmechanismen repariert werden konnten, aber nur nachdem die Bakterien vorher 
abgetötet worden waren.  
Die Voraussetzung für die Entstehung von DSB war der Kontakt der lebenden 
Bakterien mit den Zellen, wobei die DSB aber unabhängig von den bekannten H. pylori-
Virulenzfaktoren VacA und CagPAI hervorgerufen wurden. Des weiteren induzierte die 
bakterielle Infektion DSB-abhängige Signalkaskaden wie die Phosphorylierung  von H2AX 
(γH2AX) und die Fokusbildung der 53BP1 und MDC1 Proteine. Unsere Daten deuten darauf 
hin, dass H. pylori die Wirts-DNA direkt schädigt, also auch ohne Einwirkung von 
Entzündungszellen und so möglicherweise eine Wirtszellentransformation bewirken oder 
fördern kann. 
Zusammengefasst zeigen unsere Resultate also auf, dass H. pylori genotoxisches 
Potenzial besitzt und dass spezifische Therapien, welche die pathogene T-Zell-
Immunantwort hemmen nicht nur die von H. pylori  induzierten Präkanzerosen unterdrückten, 
sondern dass bereits bestehende Läsionen sich zurückbilden konnten. Diese gewonnenen 
Erkenntnisse dienen somit als Grundlage für die Entwicklung entsprechender Medikamente 
zur Behandlung von resistenten Helicobacter-Infektionen und Präkanzerosen, die das 
Entstehen eines Magenkrebses in Zukunft verhindern sollen.   
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1.  Introduction 
1.1  Gastric Cancer 
1.1.1 Gastric Cancer and Helicobacter Infection 
Stomach cancer has been recognized for several millennia and Hippocrates’ first 
description of a patient with melaina (black vomiting) as early as 400 BC most likely 
characterized cancer of the stomach.9 Only in the last thirty years, persistent Helicobacter 
pylori (H. pylori) infection has been epidemiologically linked to gastric and duodenal ulcers, 
gastric mucosa-associated lymphoid tissue lymphoma (MALT), and gastric cancer.10, 11 The 
present study will focus on cancer precursor lesions that will ultimately result in gastric 
adenocarcinoma. Gastric adenocarcinoma develops over decades as a consequence of 
chronic inflammation of the stomach lining that is caused by persistent H. pylori infection and 
belongs to the leading causes of cancer-related deaths world-wide.12 However little is known 
about benign cancer pre-cursor lesions. The following section will provide an overview of the 
prevalence of gastric cancer, elucidate possible risk factors and describe the most important 
risk factor of gastric cancer, Helicobacter pylori infection.  
 
1.1.2  Gastric Cancer Development in Mouse and Man  
A causal relationship between H. pylori and gastric cancer was first postulated by 
Marshall and Warren after they had succeeded to isolate and cultivate the Helicobacter 
species from a gastric biopsy in 1982.13 Two histologically distinct variants of distal (also non-
cardia) gastric adenocarcinoma have been described and are commonly associated with H. 
pylori infection: the intestinal-type (well differentiated) and diffuse-type (undifferentiated) 
adenocarcinomas.14 Intestinal-type gastric adenocarcinoma are structures resembling 
functional glands of the gastrointestinal tract and are found predominantly in areas with high 
incidence of gastric cancer, usually occur at a late age, predominate in men and progress 
through a relatively well-defined series of histological steps. Diffuse adenocarcinomas 
consist of individually infiltrating neoplastic cells that do not form glandular structures and are 
not associated with intestinal metaplasia. Furthermore, the tumor cells are no longer capable 
of performing basic gastric functions14 and have been shown to commonly affect younger 
people, whereas men and women are equally affected.14,15 Helicobacter infection significantly 
increases both types of cancers; this introduction will however only focus on the progression 
of intestinal-type adenocarcinoma, which we can model in experimentally infected mice.  
In human as in mice, gastric carcinogenesis progresses through a sequence of 
preneoplastic lesions, also called the Correa pathway.16 The chain of events that occurs 
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during the development of Helicobacter-associated intestinal-type adenocarcinoma involves 
the transition from normal mucosa to normal superficial gastritis, to atrophic gastritis 
(including pit cell hyperplasia) to intestinal metaplasia (=cancer precursor lesions) and finally 
to dysplasia and adenocarcinoma as depicted in Figure 1.7 
C57BL/6 mice infected with Helicobacter felis, a close relative of H. pylori, develop 
pre-cancerous lesions of the intestinal-type reminiscent of the human setting.17 The sequelae 
of gastric cancer pre-cursor lesions are characterized by a corpus-dominated superficial 
gastritis,  atrophic gastritis with epithelial hyperplasia and intestinal metaplasia. Progression 
to malignant dysplasia18 is rarely observed and observed only with additional carcinogen 
treatment (MNNG) or in mice with hypergastrinemia (INS-GAS).19  
 
 
 
 
 
 
The risk for developing gastric cancer increases exponentially as the extent of 
atrophic gastritis and intestinal metaplasia increase.15 Even though there is no defined 
sequence of mutations occurring in different tumor suppressor or oncogenes as it is 
observed in colon cancer, mutations in TP53, RAS and loss of DCC potentiate the risk for 
cancer progression (Figure 1).7  
Several case-controlled studies have shown that H. pylori seropositivity is associated 
with a 2.1-16.7% fold increased risk of gastric cancer; 10, 20-26 however the actual H. pylori 
prevalence may be underestimated due to the diminished Helicobacter presence in 
premalignant lesions. The importance of Helicobacter infection in gastric carcinogenesis is 
further reflected by the correlated decrease of gastric cancer incidence and Helicobacter 
infections in Western countries27, 28 and the beneficial effect of bacterial eradication on gastric 
cancer regression.29 However, although H. pylori is thought to account for 80% of gastric 
cancers, only 15-20% of infected individuals develop more severe forms of gastric disease 
and only 1-2% ever develop gastric cancer, suggesting that H. pylori infection on its own is 
generally not sufficient to cause cancer.7 
 
Figure 1  Helicobacter-induced gastritis and the progression to intestinal-type gastric adenocarcinoma. 
Helicobacter pylori colonization usually occurs during childhood and, over a period of days to weeks, leads to superficial 
gastritis. The presence of host TP53 mutations, host polymorphisms that promote high expression levels of the cytokine 
interleukin (IL)-1β, but also TNF-α and IL-10, and the cag island within infecting H. pylori isolates all contribute to the 
development of atrophic gastritis, intestinal metaplasia, dysplasia and, eventually, gastric adenocarcinoma over the course 
of many years. Additional mutations in oncogenes that encode RAS or deleted in colorectal cancer (DCC), but also 
epigenetic modifications of MLH-1, E-cadherin and p16 might also contribute to intestinal-type gastric carcinogenesis 
(modified from Peek and Blaser, 2002).7 
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1.2  Helicobacter spp. 
1.2.1  Prevalence and Transmission 
H. pylori is a gram-negative, spiral shaped and microaerophilic bacterium that infects 
approximately half of the world’s population, yet only a fraction of the infected population 
ever develop malignant disease.30 The infection is spread via faecal-oral or oral-oral routes 
and can persist throughout life if not treated with antibiotics.31 Individuals of all geographical 
areas may carry the bacteria, though the Helicobacter prevalence is higher in developing 
countries compared to the Western world.32, 33 In the United States, Helicobacter is present in 
10-15% of all children less than 12 years of age, compared to 50-60% of adults over 60 
years of age. Acquisition of Helicobacter in adulthood is lower than 1%   per year and also 
drops in children due to the widespread use of antibiotics.32-34 Risk factors for H. pylori 
acquisition include low socioeconomic status, household crowding, country of origin and 
ethnicity.32, 35  
 
1.2.2  Virulence Determinants 
Distinct bacterial factors enable H.plyori to persist in the gastric lumen, either free-
living in the gastric mucous layer or attached to gastric epithelial cells. The urease enzyme 
hydrolyzes urea to ammonia and carbon dioxide and thereby neutralizes the gastric acid in 
the bacterial periplasm; flagella allow the bacteria to move, navigate and persistently 
colonize the mucous layer overlying the gastric epithelium.36 Furthermore, Helicobacter has 
evolved a variety of other virulence determinants that facilitate colonization or are associated 
with disease. These include the vacuolating toxin A (VacA), the H. pylori neutrophil-activating 
protein (HP-NAP) and the cag pathogenicity island (cagPAI). HP-NAP is a cytosolic 150kDa 
decamer able to promote neutrophil adhesion to epithelial cells37 and mediates H. pylori 
adhesion to epithelial cells.38 VacA is a 95-kDa, secreted protein that induces cellular 
vacuolization in epithelial cells and is able to modulate the host’s immune response by 
interfering with IL-2 dependent T-cell activation39, 40 and MHC class II dependent antigen 
presentation,41 which allow it to avoid specific killing by the host’s immune system.  
The cagPAI is encoded by the 31 genes containing 40kb cag locus. A functional 
cagPAI codes for a type IV secretion system (T4SS) that allows the bacteria to translocate 
proteins into the host cell,42 including the the cytotoxin-associated antigene A (CagA). Once 
inside the cell, CagA has been shown to deregulate the SHP2 oncoprotein among a variety 
of other host cell signalling pathways e.g. Ras/MEK/ERK and others.43 Thus, infection with H. 
pylori strain harbouring the a CagA delivery-proficient CagPAI confers a higher risk for 
severe gastric diseases in human.44, 45 In mouse models, however, cagA negative strains 
such as H.felis, the strain we have been using to perform the here presented studies and 
COX-2 Inhibitors - Introduction 
 
close relative of H. pylori, appear to be as carcinogenic (or more so) compared with cag-
positive H. pylori strains. H.felis in mice causes prominent chronic inflammation that is 
followed by atrophic gastritis, hyperplasia and metaplasia;18, 46 most cagPAI positive H. pylori 
strains in contrast do not successfully colonize the murine host.  
 
1.3   Host Immune Response to Helicobacter Infection 
Despite mechanisms H. pylori has evolved to escape killing by the host immune 
response, infected individuals mount a substantial immune reaction following H. pylori 
infection. Cells of the innate immune system recognize the bacteria through receptors of so-
called pathogen-associated molecular patterns (PAMPs). PAMPs include microbial 
components such as LPS, peptidoglycan, flagellin and double-stranded RNA that are 
recognized by Toll-like receptros (TLRs).47 The initial response is characterized by neutrophil 
and macrophage infiltration and the release of high levels of pro-inflammatory cytokines 
including IL-8, IL-1β, TNF-α, and IL-6, iNOS,48-53 and chemokines such as RANTES and 
MIP-1α and β.54  The acute immune response is followed by an adaptive immune response 
mediated by T-lymphocytes with predominant production of the Th1 cytokines IFN-γ, IL12 
and IL18,55, 56 to a lesser extent Th2 cytokines and activation of B-cell mediated humoral 
responses.  Despite the massive immunological response, humans as well as mice fail to 
clear the infection and subsequently, chronic inflammation persists plays an important role as 
a potential risk factor to initiate gastric carcinogenesis.44  
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1.4  Chronic Inflammation and Cancer Risk 
Clinical and epidemiological studies suggest a strong correlation between chronic 
infection (with viruses, bacteria etc.), chronic inflammation and cancer development36, 57, 58 
and it there is no doubt that cigarette smoking59, 60 and asbestos,61, 62 exposure cause 
inflammation of the lung leading to lung cancer; alcohol abusus causes inflammation of the 
liver and pancreas and cancer of these organs,63 inflammatory bowel disease (IBD) causes 
colon cancer;64, 65 Schistosoma spp. infection is associated with bladder and colon cancers66, 
67 and chronic viral hepatitis is associated with liver cancer.68  
The concept of chronic inflammation driving or even initiating cancer development 
was first proposed by Rudolf Virchow back in 1863.69 Gilmour and colleagues found that 
gastric adenocarcinomas are frequently found in areas of chronic inflammation and atrophic 
gastritis70 and Correa further suggested that the incidence of atrophic gastritis is closely 
linked to a greater risk for developing gastric cancer.71 Interestingly, it has further been 
proposed that any infectious microorganisms or combinations of microorganisms (bacterial 
overgrowth) causing chronic inflammation are capable of promoting preneoplastic changes in 
the stomach,72 emphasizing an initiating role of chronic inflammation in gastric malignancies. 
The presence of Helicobacter in the stomach results in a host immune response 
aiming to swiftly eradicate the invading organisms by phagocytosis or secreted anti-microbial 
substances.73 The immune response is characterized by mucosal infiltration of various cells 
of the innate immune system leading to an acute gastric inflammation (acute gastritis). If the 
bacteria can be eliminated successfully, acute inflammation is readily resolved and the 
normal tissue architecture is restored. However, incomplete bacterial eradication leads to a 
persistent inflammatory process resulting in chronic inflammation.74 The massive infiltration 
of T- and B-cells leads to the loss and/or displacement of specialized cell types, to the 
formation of scar tissue and impairment of organ functions. In addition, inducible nitric oxide 
synthase (iNOS)- or neutrophil-derived reactive oxygen/nitrogen intermediates (ROI/RNI) 
and certain cytokines such as interferon (IFN)-γ,18, 75 tumor necrosis factor (TNF)-α, 
interleukin (IL)-1 and IL-669 produced by the infiltrating immune cells have the potential to 
support cancer development. A very interesting observation supporting the above stated 
concept is that factors resulting in intensified immune responses to the Helicobacter infection 
render patients more susceptible to cancer development. Studies on single nucleotide 
polymorphisms (SNPs) in prominent pro-inflammatory genes leading to higher protein 
expression show that a combination of SNPs in the IL-1β gene cluster (including IL-1β and 
IL-1 receptor antagonist (IL-1RN)), TNF-α and IL-10 confer a 27-fold increased risk of gastric 
cancer in H. pylori-infected patients.7, 76 In combination with high-risk bacterial genotypes, 
polymorphisms increase the risk up to 87-fold over baseline.77 On the other hand, the 
conditional suppression of the NF-κB-mediated pro-inflammatory response to H.felis has 
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been shown to prevent the development of gastric atrophy and dysplasia in mice.78 Thus, 
specific suppression of key mediators of the inflammatory process may alleviate and even 
inhibit Helicobacter-induced chronic inflammation and thus prevent gastric carcinogenesis. 
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1.5  Key Components of the Inflammatory Process Contribute to Gastric 
Carcinogenesis 
Besides the above mentioned host and pathogen-specific pro-carcinogenic factors, 
COX-2/PGE2-dependent signalling and Poly(ADP-ribose)polymerase (PARP)-dependent 
ADP-ribosylation have been shown to critically participate in inflammatory processes and 
malignant disease rendering them interesting as mediators of gastric carcinogenesis and 
thus targets for pharmacological intervention. In the following, the two pathways will be 
described in more detail with focus on their implication during inflammation and Helicobacter-
associated disease as well as state of the art of pharmacological approaches in the 
respective fields of investigation. 
 
1.5.1 COX-2 Enzymes at the Interface of Inflammation and Cancer 
1.5.1.1 COX-2/PGE2, Inflammation and Cancer 
Cyclooxygenase (COX) derived prostanoids are common molecular mediators of 
inflammation and carcinogenesis. The production of prostaglandins (PGs) is initiated by the 
liberation of arachidonic acid from membrane phospholipids by phospholipase A2 in 
response to inflammatory stimuli.79 PGs are potent bioactive lipid messengers that were 
originally extracted from semen and prostate by Goldblatt and von Euler in the 1930s, thus 
explaining their designation. Cyclooxygenase (COX) enzymes are membrane-bound, 
bifunctional enzymes that catalyze the rate-limiting conversion of AA to Prostaglandin 
endoperoxidase H2 (PGH2), by subsequent cyclooxygenation and peroxidation reactions 
(Figure 2). PGH2 is the immediate substrate for a series of cell- and tissue-specific 
prostaglandin sythases resulting in prostanoids, a collective term for prostaglandins (PGs), 
leukotriens and thromboxanes (TXAs) (Figure 2).   
 
 
 
 
Three COX isoforms are known to date: COX-1 is present in most cell types and is 
typically constitutively expressed.80  An important function in the gastrointestinal (GI) tract 
includes the regulation of gastrointestinal homeostasis via PGs.81 COX-1 has recently been 
recognized to also play a role during carcinogenesis, e.g. of the female reproductive 
system.82,83 The second isoform, COX-2, is transiently expressed in most tissues upon 
Figure 2  Cyclooxygenase (COX) enzymes catalyze the conversion of arachidonic acid to PGH2 via a two-step 
process: in a cyclooxygenation reaction, COX introduces two molecules of oxygen to arachidonate, forming the bicyclic 
peroxide intermediate prostaglandin G2 (PGG2). In the following peroxidation reaction, PGG2 is reduced to the freely 
diffusible PGH2. PGH2 is a highly unstable endoperoxidase and immediate substrate for a number of cell specific 
prostaglandin and thromboxane synthases resulting in PGs of the E2, F2 and D2 series and also to PGI2 (prostacyclin) 
and thromboxane (TX) A2 (adapted from Williams et al., 1999).4 
COX-2/PGE2 - Introduction 
 
stimulation84, 85 and primarily regulates inflammatory processes86 but is constitutively 
expressed in a variety of epithelial malignancies87 and has been suggested as prognostic 
factor for gastric adenocarcinoma.88 COX-2 is expressed between 2-7 hours before it is 
degraded by ubiquitination and proteolysis by the 26S proteasome.89 COX-2-inducing stimuli 
include LPS,90-92 IL-1, TNF-α,93-95 mitogens, IFN-γ96 and transforming growth factor-alpha 
(TGF-α)97 and others. In addition, PGE synthases may itself be directly activated by pro-
inflammatory stimuli adding an additional layer of complexity to PG-mediated responses.98 
The third isoform, COX-3 is a splice variant of COX-1 with yet unclear function.89, 99, 100 PGs 
play critical roles in numerous biologic processes, including the regulation of immune 
functions, kidney development, reproductive biology, and gastrointestinal integrity (see Table 
2).101 
In the following, the focus will be on Prostaglandin E2 (PGE2), one of the main lipid 
mediators of COX-2.  PGE2 exerts its function by binding to four different G-protein coupled 
receptors, the E-Prostanoid receptors 1-4 (EP1-4). In mice, EP receptors are expressed on 
the plasma membrane of most tissues and EP1 and 4 may also be expressed on nuclear 
membranes102. EP1 couples to Gq/p and regulates intracellular Ca2+ concentrations, whereas  
cAMP is the second messenger of EP2-4.103 The ubiquitous expression of EP receptors 
allows PGE2 to dynamically influence a plethora of physiological and also pathophysiological 
processes (Table 2).104 COX/PGE2-mediated signalling critically participates in cancer 
development, especially in cancers of the gastro-intestinal tract (Figure 3). This is underlined 
by the observations that COX-2 is constitutively expressed in a variety of epithelial tumors, 
such as tumors of the colon, breast, lung, pancreas, esophagus and squamous cell 
carcinoma105-108 and correlates with poor prognosis (Juuti, 2006).  
Several tumor models have sustained that notion. For one, COX-2 over-expression in 
rat intestinal epithelial cells (RIE) cells resulted in cellular alterations with potentially tumor-
promoting character exemplified by the loss of E-cadherin, increased BCL2 protein levels 
and reduced transforming growth factor-β (TGF-β) levels leading to increased adhesion and 
inhibition of apoptosis (Figure 3).109 Constitutive COX-2 enzymatic activity has been 
suggested to drive tumorigenic transformation by promoting neovascularisation in murine 
mammary glands,110 but also promoting cancer cell metastasis and invasion by regulating 
matrix metalloproteinase-2 (MMP-2) and CD44,111 thereby promoting cell invasion.112    
The role of COX-2 has further been intensively investigated in rodent models of colon 
cancers.  For example, COX-2 gene ablation in APC∆716 mice, a model of human familial 
adenomatous polyposis (FA), has been shown to lead to dramatically decreased numbers of 
intestinal polyps113 and vascular density.114 Concordant with this observation, other groups 
have shown that COX-2 derived PGE2 transactivates PPARδ indirectly via PI3K/Akt, resulting 
in increased colorectal adenoma growth  in APCmin mice.115 Evidence also exists that PGE2 
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promotes cell proliferation by two means: either by transactivating Wnt by phosphorylation of 
GSK-3β116 or EGF-receptor pathway by the activation of Akt/MAPK.115, 117 
 
 
There is also compelling evidence for a role of COX/PGE2-dependent pathways in 
Helicobacter-associated gastric diseases.  Helicobacter infection has been shown to lead to 
elevated levels of COX-2 in infected host cells118, 119 and in the gastric mucosa of H. pylori-
infected patients120 correlating with increased levels of PGE2 production in these biopsies. 
Furthermore, Liu and colleagues found that patients were homozygous for the (-1195AA) 
variant in the COX-2 regulatory region that affects COX expression levels had a 2-fold higher 
risk for progressing to gastric cancer than if the variant was heterozygously manifested. The 
high risk group was further largely represented smokers that were simultaneously infected 
with H. pylori.121, 122 Moreover, the transgenic expression of COX-2/microsomal PGE 
synthase 1 (mPGES-1) in mice lead to the spontaneous developed of gastric hyperplasia, 
tumorous growth and disturbed mucosal differentiation.123 In addition to the above mentioned 
pro-tumorigenic properties, the COX-2 byproduct, malondialdehyde, has been shown to 
directly form DNA adducts resulting in mutations that could initiate carcinogenesis.82  
Besides inhibition of apoptosis, promotion of cell proliferation and induction of pro-
angiogenic pathways, PGE2 plays a critical role in regulating immune functions1: it shapes 
the T-cell repertoire by regulation of Fas-ligand (FasL) mRNA and protein levels124 and 
thereby Fas-mediated apoptosis of CD4+ and CD8+ T-cells.125 Furthermore, PGE2 negatively 
regulates CD4+ and CD8+ T-cell proliferation upon various stimuli126 and has been shown to 
bias T helper (Th) cells responses. Experimental data suggest that PGE2 suppresses Th1 
immune responses and drives the overall immune response towards a Th2 polarized 
response (see Figure 4). Evidence for that comes from studies showing that PGE2 has no 
Figure 3 The role of PEG2 in 
carcinogenesis. PGE2 pro-
motes tumor growth by 
stimulating EP receptor 
downstream signalling and 
subsequent enhancement of 
cellular proliferation, pro-
motion of angiogenesis, in-
hibition of apoptosis, stimu-
lation of invasion/ motility, and 
suppression of immune res-
ponses. 
  
Abbreviations: NSAIDs, non-
steroidal anti-inflammatory drugs; 
COXIBs, COX-2 selective 
inhibitors; AA, arachidonic acid; 
EGFR, epidermal growth factor 
receptor; IL-10, interleukin 10; 
DAF, decay accelerating factor; 
VEGF, vascular endothelial 
growth factor; bFGF, basic 
fibroblast growth factor; PPARδ, 
peroxisome proliferator activated 
receptor δ. 
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effect or enhances Th2 cytokines (IL-4, IL-5 and IL-12), but drastically inhibits the production 
of Th1 cytokines, such as IFN-γ and IL-2, by Th1 cells.127 Other studies have suggested that 
PGE2 also promotes the maturation of regulatory T-cell subsets that suppress effector T-cell 
activity.128-130 Moreover, PGE2 has also been shown to block the initial steps of the adaptive 
immune response by inhibiting MHC class II expression on professional antigen-presenting 
cells (APC),131 and suppressing IL-12 and IL-10 secretion resulting in inhibited dentritic cell 
(DC) activation in lymph nodes. DC-derived PGE2 is thought to itself exert 
immunomodulatory functions.132 
Besides regulating lymphoid cells of the adaptive immune system, PGE2 also 
intervenes with innate immune responses and suppresses IL-12 and TNF-α levels in 
macrophages.133, 134 
 
 
In the context of carcinogenesis, the immune-suppressive potential of COX-2/PGE2 
facilitates evasion of host immune surveillance and anti-tumor responses.135 Altogether, 
COX/PGE2 overexpression in tumors promote carcinogenensis by conferring resistance to 
apoptosis,109 increased angiogenesis,136 decreased host immunity, 2000),137,138 and 
enhanced invasion and and metastasis.111, 112 However, it is still unclear which role 
COX/PGE2-dependent signalling plays in premalignant conditions, during the initiation of 
carcinogenesis and if its immunosuppressive features play a noteworthy role in inflammation-
associated cancers. Taken together, the available data strongly support a tumor-favoring role 
of COX-2/PGE2 in malignant disease. However, surprisingly little is known about the 
contribution of COX-2/PGE2 in precancerous stages and more importantly, in the progression 
of premalignant to malignant lesions. 
 
Figure 4. A model for immuno-
modulatory functions of PGE2. PGE2 
enhances the production of type-2 
cytokines and antibodies. PGE2 acts on T 
cells to enhance their production of in IL-4, 
IL-5 and IL-10, but inhibits their production 
of IL-2 and IFN-γ. Acting on B cells, PGE2 
stimulates isotype-class switching to 
induce the production of IgG1 and IgE. 
PGE2 acts on antigen presenting cells, 
such as macrophages (Mφs) and dendritic 
cells (DCs), to induce the expression of IL-
10 and inhibit expression of IL-12, IL-12 
receptor (IL-12R), tumor necrosis factor α 
(TNF-α)and IL-1β. The overall result is an 
enhancement of T helper 2 (Th2) 
responses and inhibition of Th1 responses 
by PGE2 (adapted from Harris, 2002).1 
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1.5.1.2  COX inhibitors in inflammation and cancer  
 An interesting fact proving that COX enzymes indeed play a significant role in tumors 
is that the regular low-dose intake of non-steroidal anti-inflammatory drugs (NSAIDs) over a 
period of 10-15 years protects from sporadic colon cancer and other GI cancers,5, 139, 140 as 
well as neurodegenerative diseases.141 Conventional NSAIDs (e.g. Aspirin) are non-selective 
inhibitors of COX-1 and COX-2 that inhibit the COX enzymatic activity and differentially 
regulate non-COX target at high doses (e.g. NF-kB and PPARβ/δ) (Figure 5). The protective 
effect of NSAIDs in cancers has been attributed to the abrogated COX-mediated immune 
protection of the tumor, as well as to the inhibition of COX-2 is pro-tumorigenic properties 
and to non-COX specific effects.142  Already in 1971, Vane and colleagues demonstrated that 
aspirin and indomethacin-dependent inhibition of inflammation rests primarily on the ability of 
those drugs to inhibit COX-dependent PG production.143 
At present, NSAIDs are among the most widely prescribed class of pharmaceutical 
agents worldwide, having broad clinical utility in treating pain, fever and inflammation.144 
However, traditional NSAIDs (e.g. aspirin, indomethacin, ibuprofen, meclofenamate etc.) 
have been linked to severe gastrotoxicity due to the fact that COX-1- and COX-2-derived 
PGs regulate homeostatic functions, such as gastrointestinal cytoprotection and regulation of 
gastric acidity. To alleviate the negative side effects, COX-2-specific inhibitors (COXibs) have 
been developed, which bind to the COX-2 active site. Two COXibs, celecoxib (Celebrex) and 
rofecoxib (Vioxx), have proven beneficial effects in diseases resulting from chronic 
inflammation, such as osteoarthritis and rheumatoid arthritis, and have also reduced the 
incidence of gastrointestinal ulcers and erosions seen with standard NSAID therapy.145-149 In 
contrast, the influence of NSAIDs on the development of gastric cancers is largely unknown.  
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Figure 5 NSAIDs, COX inhibition and 
prostaglandins. The main targets of COX-2-
specific inhibitors (COXibs) and non-steroidal anti-
inflammatory drugs (NSAIDs) are COX-1 and COX-
2 — enzymes that are central to the conversion of 
arachidonic acid to prostaglandins. An alternative 
pathway of arachidonic acid metabolism involves 
the lipoxygenases. Both the lipoxygenase and COX 
pathways are regulated by peroxide concentrations, 
with COX-2 being induced at lower peroxide 
concentrations than COX-1. Prostaglandins (PGs) 
influence angiogenesis, apoptosis, cell proliferation 
and migration. The balance between prothrombotic 
factors (for example, thromboxane A2) and anti-
thrombotic factors (for example, prostacyclin) might 
be of particular relevance to cardiovascular toxicity.  
 
Abbreviations: IL-6, interleukin 6; NF-κB, nuclear 
factor-κB; PDGF, platelet-derived growth 
factor;PLA2, phospholipase A2, which cleaves fatty 
acids, such as arichidonic acid, fromphospholipids; 
VEGF, vascular endothelial growth factor (adapted 
from Ulrich et al, 2006).5 
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1.5.2  Poly(ADP-ribosyl)ation, Inflammation and Cancer 
1.5.2.1  Poly(ADP-ribosyl)ation and PARPs 
 The PARP family of enzymes constitute key players during inflammatory processes 
and as guardians of genome stability. Poly(ADP-ribose)polymerases (PARPs) mediate the 
modification of acceptor proteins with Poly-ADP-ribose (PAR),150 a very rapid and multilateral 
posttranscriptional modification, also called Poly(ADP-ribosyl)ation or PARylation. The 
addition of the negatively charged PAR to acceptor proteins is the most drastic post-
translational modifications of proteins that is observed in almost all nucleated cells of 
mammals, plants and lower eukaryotes, but is absent in yeast (for reviews see Diefenbach 
and Buerkle, 2005).3 The most important acceptor for PARylation is PARP1 itself151 at 
glutamate and lysine residues152 but a variety of other acceptors have been described such 
as p53,153 histones,154 and DNA-dependent protein kinases.155 PARP-dependent PARylation 
modulates protein function by regulating either enzymatic activities or macromolecular 
interactions with proteins, DNA or RNA or through non-covalent binding.156 
PARylation is catalyzed by Poly(ADP-ribose) polymerases (PARPs) that are encoded 
in the human genome by a set of 18 different genes.157 The prototypic PARP is the 
constitutively expressed PARP1 (Figure 6), a nuclear chromatin-associated zinc-finger 
binding protein.  PARP2 shares 60% sequence homology with PARP1,158 possesses less 
enzymatic activity but is responsible for residual PAR formation in PARP1 deficient cells.159, 
160  
 
PARP1 contains three functionally distinct domains: an amino-terminal DNA-binding 
domain (DBD) containing a zinc-finger-like motif, a central auto-modification domain (AD) 
containing a BRCA1 carboxy-terminal (BRCT) repeat motif and a carboxylterminal PARP 
homology domain containing the catalytic domain (active site). The active site mediates 
NAD+ hydrolysis, initiation, elongation, branching and termination of PAR synthesis.161, 162  
Interestingly, this domain shows homology with the active site of the bacterial ADP-
Figure 6 The domain structure of the human PARP1. The most significant domains detected are indicated. The 
catalytic core domain (also PARP domain) catalyzes Poly(ADP-ribosyl)ation. The PRD domain is called the PARP 
regulatory domain and may be involved in regulation of the PARP-branching activity. The WGR domain is named 
after the most conserved central motif (W/G/R) of the domain. This motif is found in a variety of poly(A) polymerases 
and other proteins of unknown function. The BRCT domain is named after the breast cancer suppressor protein-1 
(BRCA1) carboxy-terminal domain and is found within many DNA damage repair and cell cycle checkpoint proteins. 
The unique diversity of this domain superfamily allows BRCT modules to interact by forming homo- or hetero-BRCT 
multimers and phosphorylation-dependent BRCT–non-BRCT interactions. The sterile alpha motif (SAM) is a 
widespread domain in signalling and nuclear proteins and mediates homo- or heterodimerization in many cases. ZF-I 
and ZF-II, PARP-1-type zinc finger domains (they can act as DNA nick sensors and general DNA-binding domains; 
NLS, nuclear localization signal (modified from Hassa, 2006).6 
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ribosylating toxins from C. diphtheriae, B. pertussis and V. cholerae.162 Interestingly, the 
BRCT motif found in the AD domain is also found in other components of the DNA damage 
checkpoint and repair pathways.  
PARPs use the respiratory coenzyme nicotinamide adenine dinucleotide (NAD+) as a 
source of ADP-ribose moieties to synthesize protein-bound polymers of variable size (from 2 
to more than 200 residues) and structural complexity (linear or branched) resulting in strongly 
negatively charged PAR (Figure 7). 
PARP1 catalyzes the formation of ADP-ribose from NAD+ by cleavage of the glycosidic bond 
between nicotinamide and ribose.163 Target proteins are either modified non-covalently or by 
Figure 7 Metabolism of poly(ADP-ribose) (PAR). PARP1 cleaves the glycosidic bond of NAD+ between nicotinamide and 
ribose followed by the covalent modification of mainly glutamate residues of acceptor proteins with an ADP-ribosyl unit, resulting 
in the formation of an ester bond between the protein and the ADP-ribose residue. PARP1 also catalyses the elongation and 
branching reaction, giving rise to polymers with chain lengths of up to 200 ADP-ribosyl units and several branching points. 
PARG is the only protein known to catalyse hydrolysis of (ADP-ribose) polymers to free ADP-ribose exhibiting endoglycosidic 
activity along with exoglycosidic activity. PARG was reported to be able to remove even the primary ADP-ribosyl group bound to 
acceptor proteins, indicating a functional overlap with ADP-ribosyl protein lyase that was shown to remove the primary ADP-
ribosyl group from acceptor proteins (from Diefenbach and Buerkle, 2005).3 
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covalent modification of glutamate, aspartate and carboxyterminal lysine residues152, 164 with 
ADP-ribose subunits. PARP1 further catalyzes elongation and branching using additional 
ADP-ribose units from NAD+.165 These negatively charged polymers can drastically alter the 
properties of the protein acceptor.   
PARP dependent PARylation is induced most efficiently upon DNA damage and is 
proposed to participate in the DNA damage surveillance network. Together with PARP-2, 
PARP1 is the only enzyme to be highly stimulated by DNA interruptions, but can also be 
activated by other DNA structures such as hairpins, cruciforms and supercoiled DNA,166, 167 
suggesting that DNA breaks are not essential for PARP activation. In the absence of DNA 
single or double-strand breaks, PARylation is a very rare event but reaches an up to 500-fold 
increase upon DNA damage.3 PARP1 synthesizes 90% of PAR following DNA breaks.6, 168  
Furthermore, PARylation has been implicated in various other cellular processes such 
as transcriptional regulation, telomere cohesion and mitotic spindle formation during cell 
division, intracellular trafficking and energy metabolism169 and cell survival and apoptosis. 
During apoptosis, PARP is involved in the release apoptosis-inducing factor (AIF) from 
mitochondria which, upon translocation into the nucleus, activates caspase-dependent and 
independent apoptosis.170, 171 However, apoptosis occurs also in the absence of PARP.172  
Intracellular PAR is short-lived and under tight control of the Poly (ADP-ribose) 
glycohydrolase (PARG)173 and possibly ADP-ribose hydrolase (ARH3)174 to avoid energy-
depletion by extensive usage of NAD+ and ATP and to avoid cellular necrosis (PARP suicide 
model).175  The two enzymes catalyze the hydrolysis of (ADP-ribose) polymers to free ADP-
ribose.173, 176 PARP1 is cleaved by caspases into a 24kDa N-terminal and 89kDa C-terminal 
fragment, none of which is able to respond to DNA nicks any longer, thereby enabling NAD+ 
pools to be restored.173, 177 
However, PARP1 does not play essential roles in any of the processes stated above 
since PARP1 deficient mice are healthy, fertile and do not have any pre-disposition to 
develop spontaneous tumors although they show hypersensitivity to  DNA-damaging 
agents.178 
 
1.5.2.2  PARP, PAR and their role in DNA damage responses 
 As already mentioned, PARPs are activated upon DNA damage and participate in a 
signalling network developed by the eukaryotic cell to cope with numerous environmental 
and endogenous genotoxic agents and to preserve genome integrity. PARylation of PARP1/2 
following genotoxic insult such as reactive oxygen species (H2O2), irradiation (IR)-induced 
DNA strand breaks, alkylating agents, or intermediates of repair processes  serves as the 
signal to initiate DNA repair or cell death:161 DNA relaxation by PARylation of histones, 
negatively charged PAR changes binding affinities of proteins (to DNA, other proteins etc.), 
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recruitment of repair enzymes to sites of damage and others.179 Upon damage, PARP1 
enzymes play experimentally proven roles in DNA damage sensing, signalling and repair.180-
184 PARP1 interacts with a number of proteins involved in DNA repair: XRCC1,185, 186 DNA 
liagase III , DNA polymerase β,187 Ku 70/80188 and PCNA.189 Many of those proteins have 
been shown to bind PAR in vitro187, 190 and may even be targets of covalent PAR 
interactions.191 The important, but not essential, role of PARP-1 in DNA damage signalling is 
supported by the fact that PARP1 null mice are hypersensitive to ionizing radiation and N-
Methyl-N-nitrosourea (MNU) treatment.192 However, this finding is challenged by the fact that 
PARP1 deficient mice are viable, fertile, have a normal lifespan and do not develop 
spontaneous tumors.178, 193  
 
1.5.2.3 PARPs, PAR and their role in inflammation 
More important in the context of inflammation-associated carcinogenesis is the notion 
that the activation of PARPs plays an important role in various models of chronic 
inflammation. PARP1 is an important co-activator of nuclear factor kappaB (NF-kB) and 
thereby indirectly impacts on the transcription of pro-inflammatory genes, such as cytokines, 
chemokines, adhesion molecules and inflammatory mediators.194 Equally, PARP1 deficient 
mice are astoundingly resistant to experimentally induced inflammation and  injury: PARP1 
deficient mice are resistant to endotoxic shock as a consequence of defective NF-κB 
activation and consequently TNF-α and IFN-γ secretion;195 PARP1 deficiency further protects 
mice from LPS-induced septic shock,196 streptozotocin-induced diabetes mellitus,197 allergen-
induced airway inflammation198 and collagen antibody-induced arthritis.199 
In addition to NF-κB-dependent processes, PARP1 regulates the expression of a set 
of genes important for cell adaptation to hostile environments, such as inflammation (e.g. in 
neutrophils)200 and hypoxic conditions, by forming a functional complex with hypoxia 
inducible factor-1 (HIF-1) and promotes the respective gene expression.201 
PARP1 was recently further assigned a role in T-cell activation through regulation of 
the nuclear factor of activated T cells (NFAT) family of transcription factors,202, 203 however, it 
remains unclear if this effect depends on PARP enzymatic activity.  
So far, however, only little is known about the relation of PARP and PARylation in 
gastric diseases. Recently, Zhang et al. showed that the PARP1 762Ala/Ala polymorphism, 
previously reported to correlate with increased susceptibility to prostate cancer (Lockett, 
2004), was slightly over-represented in patients with gastric cancer (16.9%) compared to 
disease-free individuals (10.3%).204 Another recently published study reports PARP1 
activation by Helicobacter infection in cell lines in vitro.205 So far, however, the role of PARPs 
and PARylation has not been addressed in detail in mouse models of gastric diseases and 
cancer progression. 
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1.5.2.4  Inhibitors of Poly(ADP-ribosyl)ation, Inflammation and Cancer 
 The importance of PARP in different physiological processes has further been 
confirmed by pharmacological inhibition of PARP enzyme activity. As already mentioned, 
PARylation is catalyzed by PARP enzymes, utilizing NAD+ as substrate. NAD+ binds into a 
cleft located in the PARP1 catalytic fragment (CF) and catalyzes the PARylation reaction 
resulting in nicotinamide as byproduct.  
Nicotinamide is a well-known inhibitor of PARP and physiologically acts as 
endogenous feedback inhibitor.206 The first non-selective inhibitor of PARP activity, 3-
aminobenzamide, has been described 30 years ago.207  A variety of compounds mimicking 
the nicotinamide-moiety of NAD+ have been designed ever since to inhibit PARP enzymatic 
activity and thus poly(ADP-ribosyl)ation as for example PJ34 (Figure 8). Though being an 
endogenous coenzyme, it is also a substrate for other NAD-metabolizing enzymes and may 
encompass off-target effects. Various PARP inhibitors have shown disease-relieving effects 
in a variety of chronic inflammation-associated diseases: it abolished systemic pro-
inflammatory responses to thoracic aortic ischemia and reperfusion,208 attenuated 
inflammation in a model of chronic colitis (Crohn’s disease)209 and in allergen-induced airway 
inflammation models,198 and protected mice from endotoxic shock210 and experimentally-
induced diabetic neuropathy.211  
The water-soluble phenanthridinone derivative PJ34 (Figure 8)2 has been shown to 
block the increase of IL-6, intercellular adhesion molecule-1 (ICAM-1), E-selectin and TNF-α, 
IL1-β mRNA and/or protein levels in different models, accompanied with reduced infiltration 
of immune cells into the respective tissues.212-215 These observations conform to the fact that 
PARP1 deficient cells show suppressed transcript levels of those genes.195, 212-217 
 
 
 
Cancer therapies, such as radiotherapy/cytotoxic chemotherapeutics, aim to 
massively and specifically damage the DNA of cancer cells and thereby eliminate them by 
programmed cell death.218 However, normal tissue may also be affected by the treatment 
leading to the development of new cancers in regions surrounding the tumorous tissue.  To 
address this problem, major efforts have been made to develop cancer type-specific 
Figure 8 Structures of NAD+ and 
the competitive PARP-1 inhibitor 
PJ34. PJ34 is a water-soluble 
phenanthridinone derivate. The 
aromatic ring-linked carboxamide 
group (circled) or carbamoyl group 
built in a polyaromatic heterocyclic 
skeleton is shared by the natural 
PARP1 substrate NAD+ and the 
competitive PARP-1 inhibitors 
nicotinamide and PJ34 (modified from 
Alano, 2006).2 
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therapies by targeting tumor cells carrying tumor-specific features such higher proliferation 
rate, the BCR/ABL fusion protein219 or HER-2220 over expression. Defects in DNA repair 
pathways lead to multiple hereditary cancer susceptibility syndromes (for a review see Spry 
et al., 2007)221 and the efficacy of DNA damaging agents depends on the DNA repair ability 
of the targeted cell. In the light of that, a variety of DNA repair-inhibiting agents have been 
proven to potentiate the efficacy of cancer therapeutics and have been tested in clinical trials: 
PARP inhibitors,222 O-6-methylguanine methyltransferases (MGMT) and checkpoint kinase 
(CHK) 1 and 2 inhibitors.223 PARP inhibitors in combination with radiotherapy have shown 
convincing effects in treating tumors defective in homologous recombination (HR) (e.g. 
BRCA1- and BRCA-2 deficient tumors).224-226 Furthermore, cells that are defective in 
recombination-related proteins other than BRCA1 or BRCA2, such as RAD51, RAD54, 
XRCC2,XRCC3, replication protein A1 (RPA1), ATM, ATR, CHK1, CHK2, NBS1 and 
components of the Fanconi anaemia repair pathway, also show increased sensitivity to 
PARP inhibition.224, 227, 228 These observations suggest that PARP inhibitors might also be 
suitable in treating several types of tumors with defects in HR. 
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1.6 The Dynamics of Gastric Carcinogenesis: Tumor-promoters against 
Guardians of Genome Integrity 
 Genetic insults by carcinogens leading to alterations in tumor suppressor genes and 
oncogenes are the most important driving forces of carcinogenesis. Mammalian cells have 
evolved elaborate systems to avoid the promotion of erroneous genetic information and are 
able to deal with severe forms of DNA damage.  This surveillance system is composed of a 
DNA damage recognition/DNA damage signalling and a DNA damage response network. In 
the next paragraph, some of the known gastric tumor promoting factors will be discussed 
followed by an overview on the most detrimental DNA lesions that occur in a cell, the DNA 
double strand breaks (DSB), as well as the known DSB response and repair mechanisms. 
 
1.6.1  Promoters of Gastric Carcinogenesis 
 Activation by tumor-promoters or oncogenes and inactivation of tumor suppressor 
genes either by mutations, promoter hypermethylation or overexpression result in 
carcinogenesis.  
In the case of gastric cancer, there is no apparent ‘orderly’ sequence of genetic 
mutations that accumulate in colorectal carcinogenesis, no mutational events are 
consistently associated with intermediate steps in the progression to intestinal-type gastric 
adenocarcinoma. Frequently, however, mutations in the TP53 gene correlate with relatively 
early stages of infection. Mutations in RAS and ‘deleted in colorectal cancer’ (DCC) occur in 
metaplastic, dysplastic and cancerous lesions.7 
 TP53 mutations have been detected in over 60% of advanced gastric cancers, as 
well as in intestinal metaplasia (38%), gastric dysplasia (60%), and early gastric cancer; and 
these mutations are associated with a generally worse prognosis.229, 230 Furthermore, 
epigenetic silencing by hypermethylation of CpG islands in promoter regions of genes 
involved in maintaining genetic stability and minimizing mutagenesis has been reported for 
the mismatch repair protein MLH-1,231, 232 E-cadherin233 and p16 INK4A tumor suppressor gene 
.234 Another feature that may facilitate acquisition of mutationsincludes the observation that 
mismatch repair (MMR) proteins MLH1, PMS1, PMS2, MSH2 and MSH6 are down-regulated 
in Helicobacter-infected individuals, an effect that is reversed by eradication therapy.235, 236 
However, it is unclear if this effect is not solely due to cell cycle arrest and subsequent 
inhibition of protein synthesis. A possible mechanism of the potential Helicobacter-mediated 
mutagenic role is that Helicobacter infection of AGS cells up-regulates activation-induced 
cytidine deaminase (AID) expression237 leading to GC to TA transversions. In addition, AID 
transgenic mice indeed showed increased occurrence of preneoplastic lesion and AID up-
regulation correlated with higher p53 mutation rates in cell lines.237 
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Several studies suggest an association between oxidative DNA damage and 
Helicobacter infection and have observed activated antioxidant defences in gastric cells 
following infection.238-240 Cellular oxidants comprise reactive oxygen (ROS) and nitrogen 
species (RNS). Endogenous sources of ROS include oxidative phosphorylation in 
mitochondria, cytochrome P450 activity, peroxisomes and the antimicrobial oxidative burst of 
phagocytic cells (e.g. macrophages, neutrophils and eosinophils).241 Cells, however, have 
evolved enzymes such as catalase and superoxide dismutase which can detoxify reactive 
oxygen species by converting them into water and oxygen. The situation in which ROS 
exceed cellular antioxidant defences is termed oxidative stress and leads to several types of 
DNA modifications: DNA-protein crosslinks, abasic sites, purine-reactive aldehyde adducts 
and oxidized DNA bases.242 One of the most abundant lesions is 8-oxo-7,8 dihydroguanine 
(8-oxoG), a commonly used biomarker for DNA oxidation. Because 8-oxoG can pair with 
cytosine and adenine bases during DNA synthesis, it causes G:C to T:A transversions243 
when present in the template DNA and it induces A:T to C:G transversions when 8-oxoG in 
the nucleotide pool is incorporated into DNA.244 Interestingly, elevated levels of 8-oxoG levels 
have been reported in gastric cancer, intestinal metaplasia and atrophy.238, 245  Izotti et al. 
also provide evidence that homozygous Ser326Cys polymorphism in the 8-oxoguanosine-
glycosylase1 (OGG1) gene, encoding the enzyme removing 8-oxoG from DNA, leads to a 
significant increase in the occurrence of oxidative DNA damage in H. pylori infected 
patients.238, 245 All these factors together show a correlation of Helicobacter infection with 
possible pro-tumorigenic potential. However, the ultimate proof and actual contribution to 
carcinogenesis remains unclear and a possible direct genotoxic role of Helicobacter products 
remains to be elucidated.  
 
1.6.1.1 Double Strand Breaks (DSB) 
The most detrimental of all lesions, however, are DNA double strand breaks (DSB) 
that can promote genetic instability. Complex signal transduction, cell-cycle checkpoint and 
repair pathways respond to and repair lesions that are generated by exogenous or 
endogenous DNA-damaging agents. IR for example induces DSB of high complexity, 
involving multiple clustered sites of damage (e.g. damaged bases, sugar phoshphates and/or 
single strand breaks (SSB)) that are introduced directly by breakage of the sugar backbone 
and indirectly by generating ROS.242 Endogenously generated ROS are less likely to induce 
severe DNA damage, but DSB may arise from SSB in close proximity to one another. In 
addition, DSB can also form in a programmed manner during genetic diversification 
processes: V(D)J (variable, diversity, joining) recombination (=antigen-independent 
diversification) ensures highly diverse B, and T-cell receptor repertoires; class-switch 
recombination (CSR) (=antigen-dependent diversification) generates different 
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immunoglobulin (Ig) isotypes of the G, A or E class246 and during meiosis to form genetically 
variable gametes.247 
Little is known about the context of bacterial infections and DSB induction. Interesting 
to note is a recent study showing that commensal and extraintestinal E.coli induces DSB 
beaks apparent as γH2AX foci. DSB occurrence depended on a genomic island coding for 
non-ribosomal peptide and polyketide synthases. In addition to γH2AX foci, polyketide 
synthase positive bacteria induced cell cycle arrest in G2/M phase.248 Furthermore, the group 
showed that E.coli infection also leads to γH2AX foci in colons of BALB/c mice in vivo, 
causing aneupleudy and tetrapleudy that resulted in increased mutation frequencies in 
various genes.249 Despite its widely accepted role in gastric carcinogenensis, the existence of 
DNA damaging factors has never been elucidated in Helicobacter spp.. 
 
1.6.2  The Surveillance Network 
1.6.2.1 The Guardians I: DSB - Induced Signal Transduction Pathways 
Several redundant pathways alert the cell to the presence of DNA damage and 
subsequently coordinate an appropriate response.250 Components of the DSB-induced signal 
transduction pathways include the DNA-dependent protein kinase (DNA-PK), the  
phosphatidylinositol 3-kinase related kinases (PIKKs) – ataxia telangiectasia mutated (ATM) 
and ataxia telangiectasia and Rad3-related (ATR). The main DSB repair pathways include 
DNA non-homologous end joining (NHEJ) and homologous recombination (HR). The primary 
sensor of DSB is the MRE11-RAD50-NBS1 complex (MRN) which recruits ATM to the DSB 
(Falck, 2005). In another early step, H2A histone family member X (H2AX) is phosphorylated 
(γH2AX) redundantly by ATM or DNA-PK.251 H2AX phosphorylation happens over 
megabase-pair regions being apparent as microscopically detectable foci.252 γH2AX 
mediates the recruitment of and retains mediator proteins such as p53 binding protein-1 
(53BP1), mediator of DNA damage checkpoint 1(MDC1), breast cancer 1 (BRCA1) and the 
MRN complex at the site of DSB.253 ATM regulates cell cycle arrest at different checkpoints 
after IR: G1-S arrest allows cells to repair DNA before replication and is dependent on P53 
and checkpoint-2 (CHK2) proteins and requires activation of p21, the inhibitor of cyclin-
dependent kinase (CDK) and  intra-S-phase and G2 arrest via FancD2, p53 and E2F1.254 It is 
interesting to note, that ATM and ATM-dependent pathways (CHK2, H2AX and p53) are 
activated already in precursor lesions of some cancers, such as the urinary bladder, breast, 
lung and colon, and are believed to delay and even prevent cancer formation. In line with this 
hypothesis, is the observation that loss of heterozygosity (LOH) and mutations in the very 
same genes and proteins predispose to cancer formation and are present in later stage 
tumors.255 In accordance, ATM kinase targets p53, CHK1, CHK2, H2AX, NBS1, BRC1 and 
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53BP1 qualify as tumor promotors while targets of ATM itself or its down-stream 
kinases CHK1 and CHK2, such as Mdm2 and Cdc25A are known proto-oncogenes.256-258 
This suggests that DNA damage response fulfil an anti-cancer function in early 
tumorigenesis.  
The second DSB-induced pathway mediated by ATR is activated by single stranded 
regions of DNA that arise as a result of replication-fork stalling, or during repair of bulky 
lesions.259 
 
1.3.3   The Guardians II:  DSB Repair Pathways 
Breaks in both DNA strands potentially lead to loss of sequence information that 
cannot be recovered from the same DNA molecule. To avoid DSB-induced loss of genetic 
information and subsequent disruption of vital cellular processes (e.g. replication, 
transcription), cells possess robust mechanisms to repair DSBs (Figure 9)8. ATM and ATR 
signalling induce cell-cycle checkpoints to allow repair process to take place.  
 
 
 
 
 
 
 
Figure 9. Pathways that respond to double strand breaks. Homologous recombination (HR) takes place in late S–G2 phase and involves 
the generation of a single-stranded region of DNA, followed by strand invasion, formation of a Holliday junction, DNA synthesis using the intact 
strand as a template, branch migration and resolution. Non-homologous end-joining (NHEJ) takes place throughout the cell cycle and involves 
binding of the KU heterodimer to double-strandedDNA ends, recruitment of DNA-PKcs, processing of ends and recruitment of the DNA ligase 
IV (LIG4)–XRCC4complex, which brings about ligation. The ataxia telangiectasia mutated (ATM) protein affects NHEJ as it is required for 
Artemis-dependent end processing. ATM signalling is the main signal-transduction process that responds to a DSB. Ataxia telangiectasia and 
RAD3-related (ATR) signalling is activated later after irradiation, probably when radiation-inducedlesions block replication. Both pathways lead 
to cell-cycle-checkpoint activation, which allows more time for repair or permanently prevents the proliferation of damaged cells. An important 
step in ATM- and ATR-dependent signalling is phosphorylation of H2A histone family, member X (H2AFX) and recruitment of the mediator 
proteins, mediator of DNA damage checkpoint 1 (MDC1), tumor protein 53 binding protein 1 (TP53BP1) and the MRN (MRE11–RAD50–
NBS1)complex. Additional proteins, such as structural maintenance of chromosomes 1 (SMC1), are also recruited to the site of damage. Other 
proteins that are recruited to the foci, such as replication protein A (RPA) and Bloom syndrome (BLM),have not been shown for clarity. ATR 
signalling is activated by single-stranded regions of DNA that arise, for example, at stalled replication forks. RPA coats single-stranded DNA 
and recruits ATR and its partner ATRIP (ATR-interacting protein).H2AFX phosphorylation, recruitment of mediator proteins and downstream 
phosphorylation occur in a process that is similar to the ATM-dependent pathway, although with some distinctions (for example, CHEK1 and 
CHEK2 (checkpoint 1and 2) might be differently phosphorylated by ATM versus ATR). HR probably depends on ATR, either to stabilize stalled 
replication forks and/or to activate the process of HR. DNA crosslinks are repaired through a process that probably generates a DSB as an 
intermediate (adapted from Driscoll, 2008).8 
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The type of repair depends on the manner by which DSBs were created and the 
phase of the cell cycle. Two-ended DSB, induced for example by IR, can be re-joined 
through nonhomologous DNA end-joining (NHEJ) throughout the cell cycle (Figure 9)8: DNA 
ends are bound by Ku70/80 dimers which attract DNA-PK to ends and promotes their 
juxtaposition. If no end-processing is required, the NHEJ core complex consisting of XRCC4, 
DNA ligase IV and XLF can complete rejoining. End-processing is accomplished by Artemis 
(ATM-dependent), a nuclease and/or DNA polymerases TdT, pol lambda, and pol μ  and also 
Ku itself.260  
Homologous recombination (HR) restores the continuity of broken DNA using a 
homologous, intact template, the sister chromatid, to replace the lost information. HR takes 
place in late S-G2 phase and involves the generation of single-stranded DNA overhang 
followed by strand invasion and formation of a D-loop and Holliday junction, DNA synthesis 
using the intact sister strand as a template, branch migration and resolution (Figure 9).  The 
core protein complex of the HR machinery is encoded by the RAD52 group of genes (for 
review: Modesti, 2001).261 
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2.  Aim of the Study 
Gastric adenocarcinoma belongs to the most common causes of cancer-related 
deaths world-wide and develops as a consequence of chronic inflammation of the stomach 
lining that is caused by persistent infection with the bacterium Helicobacter pylori. In humans 
as well as in mice, gastric carcinogenesis progresses through a sequence of preneoplastic 
lesions which manifest histologically as atrophic gastritis, epithelial hyperplasia, intestinal 
metaplasia and dysplasia. Bacterial eradication shows beneficial effects in people with 
certain gastric precancerous lesions. However, to date there is no alternative therapy 
available for patients refractory to eradication, nor is there a sustainable cure for intestinal 
metaplastic lesions or for the prevention of malignant progression.  We and others have 
shown previously that Helicobacter-induced pathogenic CD4+ T-effector cells and their 
secreted cytokine products are the central mediators of gastric preneoplasia. 
    The aim of this study was to identify therapeutic molecular targets that regulate the 
pathogenic T-cell response and to impede the progression from Helicobacter-induced 
precancerous to malignant lesions by targeting pathogenic T-cells. To address this question, 
we utilized a C57BL/6 mouse model of Helicobacter felis infection. Infected mice develop 
severe gastritis and histologically evident precancerous lesions, such as epithelial 
hyperplasia and metaplasia, as early as three months post infection. The mice were treated 
with one of two pharmacological compounds either starting at the time of infection or once 
cancer precursor lesions were present to assess possible therapeutic effects. The effect of 
the treatments was quantified by histopathological scoring of gastric cancer precursor lesions 
and by examining the effect on T-cell proliferation, cytokine secretion and migration ex vivo.  
Another aim of this study focused on investigating Helicobacter pylori’s intrinsic 
genotoxic potential and its direct contribution to carcinogenesis. To this end, we infected 
primary epithelial cells and various cell lines with Helicobacter pylori. We assessed the 
integrity of the host cell DNA by pulse field gel electrophoresis (PFGE) and also examined 
the induction of DNA damage response pathways upon infection.  
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3.  Results 
3.1   Published Research Articles in Peer Review Journals 
3.1.1  Prostaglandin E2 Prevents Helicobacter-induced Gastric Preneoplasia and 
Facilitates Persistent Infection in a Mouse Model  
  
 
 
Authors: Isabella M. Toller, Iris Hitzler, Ayca Sayi and Anne Mueller 
 
Journal: Gastroenterology 2010; 138:1455-1467 
 doi:10.1053/j.gastro.2009.12.006 
 
Contribution: Planning, performing and analysis of experiment, except Figure 6A-5 with 
IH; figure assembly, assistance in manuscript writing, revision of the 
manuscript (with IH) 
 
 
Summary:            COX-2/PGE2 dependent signalling plays a crucial role during the 
inflammatory response raised against invading organisms but is also 
critically implemented in tumor development and maintenance. The 
proposed immunosuppressive effects of PGE2 on CD4+ T cells in the tumor 
environment that ensuring immune evasion prompted us to examine the 
role of COX-2/PGE2 in our model of Helicobacter-induced, T-cell-driven 
gastric preneoplasia in a C57BL/6 mouse model. We found that inhibition 
of COX-2 enzymatic activity strikingly accelerated development of gastritis 
and premalignant gastric lesions and that, conversely, systemic 
administration of synthetic PGE2 prevented premalignant changes and 
vaccine-induced protection during Helicobacter challenge infection. The 
protective effects of PGE2 in our model could be attributed to its 
immunosuppressive effects on CD4+CD25+ T cells, which failed to migrate, 
to proliferate, and to secrete IFN-γ when exposed to PGE2 in vitro or in 
vivo. Taken together, these data suggest that COX-2/PGE2-dependent 
pathways are critical in preventing excessive gastric immunopathology by 
regulating the activity of “pathogenic” T cells. 
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TACKGROUND & AIMS: Persistent infection with the
uman pathogen Helicobacter pylori increases the risk of
astric cancer. In this study, we investigated the role of
yclooxygenase-2 (COX-2) and its main product, prosta-
landin E2 (PGE2), in the development of Helicobacter-
nduced gastritis and gastric cancer precursor lesions.
ETHODS: We utilized mouse models of Helicobacter-
nduced gastric preneoplasia and vaccine-induced protec-
ion to study the effects of COX-2 inhibition and PGE2
reatment on the induction of Helicobacter-specific im-
une responses and gastric premalignant immunopa-
hology. RESULTS: COX-2 and PGE2 are up-regulated
pon Helicobacter infection in cultured epithelial cells and
n the gastric mucosa of infected mice. Inhibition of
OX-2 activity with celecoxib significantly accelerated
arly preneoplasia; conversely, systemic administration of
ynthetic PGE2 prevented development of premalignant
athology and completely reversed preexisting lesions
y suppressing interferon- production in the infected
tomachs. The protective effect of PGE2 was accompa-
ied by increased Helicobacter colonization in all models.
ll in vivo effects were attributed to immunosuppressive
ffects of PGE2 on CD4 T-helper 1 cells, which fail to
igrate, proliferate, and secrete cytokines when exposed
o PGE2 in vitro and in vivo. T-cell inhibition was found
o be due to silencing of interleukin-2 gene transcription,
nd could be overcome by supplementation with recom-
inant interleukin-2 in vitro and in vivo. CONCLU-
IONS: COX-2–dependent production of PGE2 has
n important immunomodulatory role during Helico-
acter infection, preventing excessive local immune
esponses and the associated immunopathology by
nhibiting the effector functions of pathogenic T-
elper 1 cells.
eywords: Helicobacter pylori; Gastric Cancer; Cyclooxygen-
se; Prostaglandin E2.
ersistent gastric colonization with the human patho-
gen Helicobacter pylori causes chronic active gastritis
n infected individuals and has been linked epidemiolog-
cally to gastric and duodenal ulcers, gastric mucosa-
ssociated lymphoid tissue lymphoma, and gastric can-
er.1–3 The chronic gastric inflammation induced by H
ylori infection constitutes a prerequisite for the forma-ion of preneoplastic and malignant lesions, both in
umans and in rodent models of Helicobacter-induced
isease.4,5 The transformation from normal mucosa to
astric cancer occurs via a sequence of precursor lesions
tarting with atrophic gastritis, intestinal metaplasia, and
ysplasia.6 Using mouse models of experimental Helico-
acter infection and vaccine-induced protection, we have
hown recently that stomach-infiltrating CD4CD25
nterferon-–secreting T cells play a dual role in the
elicobacter–host interaction. On the one hand, these
ells are crucial in controlling the infection; on the other
and, they promote development of Helicobacter-induced
astric cancer precursor lesions, possibly through a direct
ffect of IFN- on gastric epithelial cells.7
The 2 processes of inflammation and carcinogenesis
hare a common molecular mediator, the cyclooxygenase
COX) enzymes. The COX-1 isoform is constitutively
xpressed in most cell types, whereas COX-2 is induced in
esponse to proinflammatory stimuli, such as lipopoly-
accharide, interleukin-1, and tumor necrosis factor–.8
he most important lipid product of COX-2, prostaglan-
in E2 (PGE2), exerts its effects by binding to the E-pros-
anoid receptors 1–4, which are expressed ubiquitously in
ost murine tissues.9
Several lines of evidence indicate that COX-2–depen-
ent pathways play a role in carcinogenesis, especially in
he gastrointestinal tract. Many solid tumors overexpress
OX-2/PGE2, and polymorphisms in the COX-2 regula-
ory region determine the carrier’s risk of developing
everal epithelial cancers.10,11 The long-term low-level in-
ake of nonsteroidal anti-inflammatory drugs inhibiting
OX activity reduces the risk for colorectal cancer,12,13 as
ell as gastric cancer.14 Tumor-derived PGE2 is believed
o promote cancer progression by stimulating cell motil-
ty/invasion and tumor-associated angiogenesis and by
reventing tumor cell apoptosis (reviewed in Cha and
uBois15 and Wang and DuBois16). Several pathways and
ignaling networks are activated or enhanced by PGE2;
Abbreviations used in this paper: CFSE, carboxyfluorescein succi-
imidyl ester; COX, cyclooxygenase; IFN, interferon; IL, interleukin;
LN, mesenteric lymph node; PGE2, prostaglandin E2; IP, intraperito-
eal; PAI, pathogenicity island; Th1, T-helper 1; Treg, regulatory T cell.
© 2010 by the AGA Institute
0016-5085/10/$36.00doi:10.1053/j.gastro.2009.12.006
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1456 TOLLER ET AL GASTROENTEROLOGY Vol. 138, No. 4ost notably, PGE2 potentiates Wnt and peroxisome
roliferator–activated receptor- signaling to induce
arget genes involved in replication and survival and
riggers cell migration by activation of the epidermal
rowth factor receptor pathway.15 In addition to its di-
ect effects on cancer cell biology, PGE2 is known to have
trong immunosuppressive effects, giving rise to the hy-
othesis that PGE2 production may allow tumors to
vade immune surveillance.17
The reported immunosuppressive effects of PGE2 on
D4 T cells, in particular T-helper 1 (Th1)-polarized
ffector T cells (reviewed in Harris and Phipps18),
rompted us to examine the role of COX-2/PGE2 in our
odel of Helicobacter-induced, T-cell–driven gastric pre-
eoplasia. We found that inhibition of COX-2 enzymatic
ctivity strikingly accelerated development of gastritis
nd premalignant gastric lesions and that, conversely,
ystemic administration of synthetic PGE2 prevented pre-
alignant changes. The protective effects of PGE2 in our
odel could be attributed to its immunosuppressive
ffects on CD4CD25 T cells, which failed to migrate,
o proliferate, and to secrete IFN- when exposed to
GE2 in vitro or in vivo. Taken together, these data
uggest that COX-2/PGE2-dependent pathways are criti-
al in preventing excessive gastric immunopathology by
egulating the activity of “pathogenic” T cells.
Materials and Methods
Mice, Cell Culture, Bacterial Infections, and
Vaccination
Male C57BL/6, interleukin (IL)-10/BL/6, and
y5.1BL/6 mice (Charles River Laboratories, Sulzfeld,
ermany) were bred at a Helicobacter-free and specific
athogen-free facility and infected at 5 to 6 weeks of age.
ll animal experiments were approved by the cantonal
eterinary office. Helicobacter strains used for animal ex-
erimentation were H felis CS1 (ATCC 49179)19 and H
ylori strain SS1.20 Mouse infections were performed
rally with 108 bacteria. Primary gastric epithelial cells
ere isolated as described previously21; the immortalized
urine gastric epithelial cell line used in this study was
lso described previously.7 Both cell types were grown in
ulbecco’s modified Eagle medium/Ham’s F12 medium
1:1; Gibco, Basel, Switzerland) supplemented with 10%
etal calf serum and infected for 12 hours with H pylori
trains G27 or an isogenic mutant lacking the Cag patho-
enicity island (PAI), G27PAI.22 Vaccination of mice
as performed as stated in the Supplementary Materials
nd Methods.
Pharmacological Treatments
For inhibition of COX-2, mice were fed a diet
upplemented with 1500 ppm celecoxib (for details see
upplementary Materials and Methods; Research Diets,
ew Brunswick, NJ) or an identical control diet without
he active compound. For PGE2 treatment in vivo, 10 g s6,16-dimethyl PGE2 and 17-phenyl trinor PGE2 were
iluted in 100 L phosphate-buffered saline (details in
upplementary Materials and Methods; Cayman Chemi-
als, Ann Arbor, MI) and injected twice intraperitoneally
IP) and once combined IP/orogastrically per week. IL-2
BD Pharmingen, San Diego, CA) was injected IP 3 times
er week (4  104 units per injection; see Supplementary
aterials and Methods). For cell culture experiments,
GE2 was added at 25 M. IL-2 was used at 10 ng/mL.
Preparation of Gastric Tissue and Assessment
of Colonization, Gastric IFN- Production,
COX-2 Expression, Neutrophil Infiltration,
and Histopathology
After sacrifice, stomachs were dissected longitudi-
ally into equally sized pieces. For the assessment of H
elis colonization, total genomic stomach DNA was sub-
ected to quantitative polymerase chain reaction analysis
f the flaB gene, as described previously.7 Quantitative
nalysis of gastric IFN- expression and COX-2 expres-
ion and activity was performed as described in the Sup-
lementary Materials and Methods. Neutrophil infiltra-
ion was quantified as described.7 Paraffin sections
ere stained with the histological dyes Giemsa, Alcian
lue, and Periodic Acid Schiff, as well as an antibody
pecific for proliferating cell nuclear antigen (clone PC10;
ymed Labs, San Francisco, CA) for grading of gastric
istopathology based on the features described in the
pdated Sydney classification (see Supplementary Mate-
ials and Methods).23
Lymphocyte Proliferation and Activation
Assays
CD4CD25 T cells were immunomagnetically
urified from single-cell suspensions of spleens, mesen-
eric lymph nodes, or stomach sections containing both
orpus and antral tissue (R&D Systems, Minneapolis,
N). Cells were labeled with 5 M carboxyfluorescein
uccinimidyl ester (CFSE) and stimulated with anti-CD3/
D28-coated beads. The CFSE dilution was assessed flow
ytometrically. IFN- secretion was measured by enzyme-
inked immunosorbent assay (BD Biosciences, San Diego,
A). IL-2 and IFN- expression was determined by reverse
ranscription polymerase chain reaction using primers
pecified in the Supplementary Materials and Methods.
or staining of intracellular IFN-, cells were stained for
D4 (clone RM4-5; eBioscience, San Diego, CA) prior to
xation, permeabilization, and IFN- staining (XMG1.2,
D Biosciences). Fluorescence-activated cell sorting anal-
ses were performed on a CyanADP instrument (Dako,
lostrup, Denmark). T-cell migration assay is described
n the Supplementary Materials and Methods.
Statistical Analysis
P values were calculated using Graph Pad prism
.0 software (GraphPad Software, San Diego, CA). The
ignificance of differences in histopathology scores was
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umerical differences was calculated by Student’s t test.
ll in vitro assays were analyzed in triplicate and are
hown with standard deviations.
Results
Helicobacter Infection Induces COX-2 and
PGE2 In Vitro and In Vivo
To assess whether COX-2 and its product PGE2
re induced upon Helicobacter infection in cell culture
odels, we infected primary murine gastric epithelial
ells (Figure 1A) and immortalized murine gastric epithe-
igure 1. COX-2 protein expression and PGE2 production is induced u
nalyzed by Western blotting of extracts from primary murine gastric
nfected for 12 hours with either H pylori G27 wild-type (WT) or an isoge
lyceraldehyde phosphate dehydrogenase (GAPDH) levels are shown
inked immunosorbent assay (ELISA) is shown for supernatants of pr
ndomethacin (C). For the analysis of COX-2 protein expression and P
-monthH felis–infected and 3 control C57BL/6mice and subjected toW
oncentrations as a function of pathology, we compared groups that sh
nd (F), all samples were analyzed in triplicate; average values are shown wiial cells (Figure 1B) with wild-type H pylori G27 or an
sogenic mutant (PAI) lacking the Cag pathogenicity
sland, a known virulence determinant of pathogenic H
ylori strains.22 In both cell types, COX-2 protein expres-
ion and PGE2 secretion were induced by H pylori in a
ose-dependent manner, and independently of the Cag
AI (Figure 1A–C). PGE2 production was blocked in the
resence of the COX inhibitor indomethacin (Figure 1C),
ndicating that it is produced exclusively by COX en-
ymes in this setting. COX-2 and its product PGE2 were
lso strongly induced in the gastric mucosa of infected
ompared to uninfected mice (Figure 1D and E).
elicobacter infection in vitro and in vivo. COX-2 protein expression was
elial cells (A) and an immortalized murine gastric epithelial cell line (B)
g-PAI-deficient mutant (PAI) at the indicated multiplicity of infections.
ding controls. PGE2 production as assessed by competitive enzyme-
cells infected with WT G27, in the presence or absence of 28 M
roduction in vivo, whole stomach extracts were generated from four
rn blot analysis (D) and PGE2 ELISA (E). (F) To determinemucosal PGE2
d gastritis only, hyperplasia, or metaplasia to uninfected controls. In (E)ponH
epith
nic Ca
as loa
imary
GE2 p
este
oweth standard deviations.
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1458 TOLLER ET AL GASTROENTEROLOGY Vol. 138, No. 4In order to determine whether mucosal PGE2 concen-
rations correlate with the degree and type of gastric
athology in our model, we selected groups of Helicobac-
er-infected mice based on their predominant pathology.
e compared mice that showed gastritis, hyperplasia, or
cidic mucus-positive metaplasia, respectively (for sim-
licity referred to as “metaplasia” in the following; Figure
F). PGE2 production was significantly higher in animals
isplaying epithelial damage, eg, hyperplasia and meta-
lasia, compared to those that showed gastritis only
Figure 1F). Our data are consistent with previous studies
eporting COX-2 expression in H pylori–infected cultured
pithelial cells24 and in gastric preneoplastic and malig-
ant lesions.25
COX-2 Inhibition During Infection
Aggravates Helicobacter-Induced Epithelial
Pathology in C57BL/6 Mice
To test if COX-2 activity modulates the formation
f Helicobacter-associated chronic gastritis and precancer-
us lesions, we treated H felis–infected mice with cele-
oxib for 3 months (Figure 2A). Celecoxib specifically
argets COX-2 and is believed to act predominantly by
ecreasing PGE2 levels.15 The efficacy of celecoxib treat-
ent was confirmed by a COX-2–specific enzymatic ac-
ivity assay (Figure 2B). The inhibition of COX-2 signif-
cantly aggravated H felis–induced epithelial atrophy and
yperplasia compared to infected, untreated counter-
arts as determined by quantitative histopathological
coring of histologically stained sections (Figure 2C). The
ore severe pathology observed under conditions of
OX-2 inhibition was accompanied by a significant de-
rease in H felis colonization (Figure 2D), and a strong
ncrease of the gastric expression of the Th1 cytokine
FN- (Figure 2E), corroborating both the direct correla-
ion between IFN- levels and gastric histopathology,
nd the inverse correlation between IFN- expression and
olonization that we have reported previously.7 In con-
lusion, COX-2 inhibition accelerates development of
elicobacter-induced early gastric cancer precursor lesions,
hile simultaneously reducing the bacterial burden and
ncreasing the local expression of IFN-, implying that
OX-2 and PGE2 may act as immune modulators of the
elicobacter–host interaction.
Treatment of Helicobacter-Infected Mice
With Synthetic PGE2 Inhibits Chronic
Inflammation and Precancerous Lesions
To investigate a possible protective effect of
OX-2 activity on the H felis–infected gastric mucosa in
n independent experimental setup, we treated C57BL/6
ice with synthetic PGE2 during 6 or 12 weeks of infec-
ion (Figure 3A). To ensure complete activation of all
GE2 receptors (E-prostanoid receptors 1–4), we admin-
stered a mixture of 2 synthetic PGE2 analogs, 16,16-
imethyl PGE2 and 17-phenyl trinor PGE2 (referred to in
he following as “PGE2”). The PGE2 treatment prevented phe mild to moderate lymphocytic infiltration observed
fter 6 weeks postinfection (Figure 3A and B) and also
ompletely inhibited the moderate to severe chronic in-
ammation, atrophy, metaplasia, and/or hyperplasia in-
icative of 12-week–infected mice (Figure 3A and C).
mmunohistochemical staining and quantification of
roliferating cell nuclear antigen reactivity further con-
rmed the efficient inhibition of epithelial hyperprolif-
ration by PGE2 (Figure 3D). Consequently, the decrease
n H felis colonization that typically accompanies the
nset of severe gastric pathology between 6 and 12 weeks
ostinfection was prevented by PGE2 treatment (Figure
E). Long-term treatment with PGE2 completely pre-
ented the increase in local IFN- production that typi-
ally occurs in this time frame (Figure 3F) and that
recedes the onset of pathology and leads to the observed
eduction of the bacterial burden.7
We next tested the protective potential of PGE2 in mice
acking the gene for the anti-inflammatory cytokine IL-
0. IL-10/ mice launch excessive proinflammatory and
daptive immune responses to Helicobacter infection;26 as
result, they clear the bacteria and develop severe gastri-
is and preneoplastic lesions already 4 weeks postinfec-
ion (Figure 4). Treatment of infected IL-10/ animals
ith synthetic PGE2 efficiently inhibited development of
astric pathology and hyperproliferation (Figure 4A–C)
nd prevented neutrophil infiltration into the gastric
ucosa (Figure 4D), but did not block clearance of the
nfection (data not shown). As in wild-type mice, local
nduction of IFN- was largely prevented by PGE2 treat-
ent in IL-10/ mice (Figure 4E). The combined results
ndicate that prophylactic PGE2 treatment efficiently in-
ibits development of chronic gastritis and cancer pre-
ursor lesions, possibly by modulating Th1-polarized T-
ell responses.
Preexisting Gastric Cancer Precursor Lesions
in H felis–Infected Mice Can Be Reversed by
PGE2 Treatment
To test the effects of PGE2 as a potential thera-
eutic agent capable of curing preexisting lesions, we
nfected mice with H felis for 3 months and verified the
fficient induction of preneoplastic pathology in a small
ontrol group (data now shown). Five of the remaining
3 mice received PGE2 for another month (Figure 5A).
nterestingly, this treatment efficiently reversed preexisting
esions, reducing the scores of all histopathological param-
ters (Figure 5A and B) and the fraction of corpus area
ffected by proliferating cell nuclear antigen–positive hyper-
lasia (Figure 5C), as well as neutrophil infiltration (Figure
D). As in prophylactically treated mice, PGE2 had a bene-
cial, in this case even curative, effect on mucosal integrity,
hile at the same time boosting bacterial colonization (Fig-
re 5E). In line with all previous results (Figures 3 and 4),
he PGE2 treatment significantly reduced local gastric ex-
ression of IFN- (Figure 5F).
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April 2010 PGE2 PREVENTS PRENEOPLASTIC IMMUNOPATHOLOGY 1459To confirm regression of preexisting lesions upon
GE2 treatment during the last of 4 months of H felis
nfection, we repeated the experiment with 3 additional
eadouts (Supplementary Figure 1). As before, the lesions
egressed in all PGE2-treated mice compared to the in-
igure 2. Inhibition of COX-2 by the diet-supplemented inhibitor ce
y H felis infection. C57BL/6 mice were infected for 3 months with H
upplemented with celecoxib (A). COX inhibition was verified by C
istopathology (representative Giemsa-, Alcian Blue-, and Periodic A
olonization (D) the average colonization is indicated per group andected control group (data not shown); we further found iy flow cytometry that the gastric infiltration of leukocytes
nd CD4 T cells had significantly decreased in the PGE2-
reated group (Supplementary Figure 1A and B). Finally, we
xamined the presence of Th1-polarized, IFN-–producing–
D4 T cells in the mesenteric lymph nodes (MLN) by
ib aggravates gastritis and gastric preneoplastic pathology induced
, or remained uninfected, and were either fed a control diet or a diet
activity assay (B). All mice were analyzed with respect to gastric
chiff–stained sections and pathology scores are shown. (C) H felis
ric expression of IFN- (E). Scale bar  50 m.lecox
felis
OX
cid Sntracellular cytokine staining followed by fluorescence-ac-
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1460 TOLLER ET AL GASTROENTEROLOGY Vol. 138, No. 4ivated cell sorting. We found that the 4-month infection
ndeed led to a strong increase of IFN-–producing CD4 T
ells in the MLN, which could be blocked at least partially
igure 3. PGE2 treatment of H felis–infected C57BL/6 wild-type mice
nfected with H felis and were treated with PGE2 as indicated (A). Mice
epresentative Giemsa-stained sections and a summary of all histopa
ntigen (PCNA)–stained sections after 12 weeks of infection, along with
xpression are shown in (E) and (F).y PGE2 treatment (Supplementary Figure 1C). We con- Tlude from both studies that systemically administered
GE2 efficiently reverses preexisting gastric cancer precursor
esions, possibly by blocking the priming and activity of
its chronic inflammation and epithelial pathology. C57BL/6 mice were
euthanized 6 weeks (A, B, E, F) or 12 weeks postinfection (A, C, E, F).
gy scores are shown in (A–C); representative proliferating cell nuclear
r quantification, are shown in (D). H felis colonization and gastric IFN-inhib
were
tholoh1-polarized T-cell responses in the draining lymph nodes.
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April 2010 PGE2 PREVENTS PRENEOPLASTIC IMMUNOPATHOLOGY 1461PGE2 Impairs Vaccine-Induced Protection
Against Helicobacter by Blocking Local
Effector T-Cell Responses
We have shown in the experiments outlined here
hat PGE2 treatment in vivo boosts bacterial colonization
nd, conversely, that COX-2 inhibition promotes clear-
igure 4. PGE2 treatment of H felis–infected IL-10/ BL/6 mice inhib
nfected for 1 month with H felis and were treated with PGE2 starting
istopathology scores are shown in (A) and (B); the quantification of pro
eutrophil infiltration was quantified by myeloperoxidase activity assay [
astric IFN- expression was assessed by real-time polymerase chainnce (Figures 2D, 3E, and 5E). To test whether PGE2 gould also impair vaccine-induced protection upon chal-
enge infection of immunized mice, we utilized a vacci-
ation protocol directed against H pylori SS1. Indeed,
dministration of PGE2 during challenge impaired the
accine-induced reduction of bacterial loads (Figure 6A).
he infiltration of leukocytes and CD4 T cells into the
hronic inflammation and epithelial pathology IL-10/ BL/6 mice were
he day of infection (A). Representative Giemsa-stained sections and
ting cell nuclear antigen (PCNA)–positive hyperplasia is depicted in (C).
ges of all mice per group are shown with standard deviations, (D)], and
ion (E); (*not detectable).its c
on t
lifera
averaastric mucosa observed in vaccinated/challenge-infected
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1462 TOLLER ET AL GASTROENTEROLOGY Vol. 138, No. 4ice was largely prevented by administration of PGE2
Figure 6B and C), possibly explaining why PGE2-treated
ice fail to reduce bacterial colonization. In single-cell
LN preparations of individual mice (Figure 6D), PGE2
reatment during the challenge phase clearly abolished
he vaccination-induced increase of IFN-–producing
D4 T cells in the MLN (Figure 6D). Taken to-
ether, our data imply that PGE2 interferes with the
-cell–mediated control of Helicobacter infection, not only
nder standard experimental infection conditions, but
lso during a challenge infection after vaccination, and
igure 5. PGE2 treatment of C57BL/6mice reverses preexisting gastric p
nd treated with PGE2 for the last month as indicated (A). Representative G
uantification of proliferating cell nuclear antigen (PCNA)–positive hyperpla
uantified by myeloperoxidase activity assay. H felis colonization and gasthat this effect is due to T-cell inhibition in vivo. lTo test whether PGE2 directly interferes with IFN- pro-
uction by MLN cells, single-cell suspensions were cultured
n the presence of increasing concentrations of PGE2 (Figure
E). PGE2 treatment reduced the infection-dependent secre-
ion of IFN- into the supernatant by, on average, 43% and
4% at a low and high dose, respectively (Figure 6E). We
onclude that PGE2 efficiently blocks production of IFN-
oth in vitro and in vivo, which may explain why PGE2-
reated mice are protected from IFN-–induced preneoplas-
ic pathology and show impaired bacterial clearance, a find-
ng that is consistent with our previous report of an inverse
sor lesions. C57BL/6micewere infected for a total of 16weekswithH felis
-stained sections and histopathology scores are shown in (A) and (B); the
percent of the corpus area is depicted in (C). (D) Neutrophil infiltration was
erferon- expression are shown in (E) and (F).recur
iemsa
sia inink between colonization and pathology.7
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April 2010 PGE2 PREVENTS PRENEOPLASTIC IMMUNOPATHOLOGY 1463PGE2 Inhibits the Migration, Activation,
and Effector Functions of Wild-Type CD4
T Cells
To test the effects of PGE2 on CD4CD25 T-cell
igration, we utilized a transwell migration assay in
hich calcein-labeled CD4CD25 T cells were allowed
o migrate toward supernatants of H pylori–infected im-
igure 6. PGE2 treatment during challenge infection impairs vaccine-i
ith liveHpyloriSS1; somemice received PGE2 during the challenge ph
ounts are shown as colony-forming unit (CFU)/stomach (A). (B–D) Sin
uninfected, 4 control infected, 4 immunized/challenged, and 4 im
ytometry. Leukocyte (B) and CD4 T-cell (C) infiltration into the stomac
-cell population in the MLNwas quantified by intracellular cytokine stain
E) Single-cell MLN cultures obtained from 5 H felis–infected and 2 contr
r 25 M). IFN- secretion into the supernatants was assessed by enzortalized gastric epithelial cells. Interestingly, the su- pernatants of infected cells attracted T cells more effi-
iently than those of uninfected cells (Figure 7A). The
igration could be blocked by addition of PGE2 (Figure
A). In order to assess the effects of PGE2 on the prolif-
ration and activation of CD4 effector T cells, we stim-
lated CFSE-labeled CD4CD25 T cells with anti-CD3/
nti-CD28 monoclonal antibody–coated beads in the
ed clearance. C57BL/6 mice were vaccinated 4 times and challenged
s indicated. Nonvaccinated infectedmice served as controls (A). Colony
ll suspensions from stomachs (B, C) and MLN (D) were generated for
ed/challenged/PGE2-treated mice and analyzed individually by flow
hown in percent of total stomach cells. (D) The IFN-–producing CD4
verages and standard deviations are shown for every treatment group.
e were cultured overnight in the presence or absence of PGE2 (2.5 M
linked immunosorbent assay (*not detectable).nduc
ase a
gle-ce
muniz
h is s
ing. A
ol micresence or absence of PGE2 (Figure 7B). The activation
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April 2010 PGE2 PREVENTS PRENEOPLASTIC IMMUNOPATHOLOGY 1465nd proliferation of T cells, as assessed by measuring IL-2
eceptor  chain (CD25) expression and CFSE dilution,
as blocked almost completely by PGE2 (Figure 7B). In
ivo pretreatment of 5 donor mice with PGE2 for 1
onth prior to T-cell isolation also strongly reduced
-cell activation and proliferation upon CD3/CD28
ross-linking (compare Figure 7B and C). The secretion of
FN- by CD3/CD28-activated T cells was also blocked
y PGE2, both by the direct addition of the compound to
he cultures and by pretreatment of the donor mice
Figure 7D). These results suggest that PGE2 is an effec-
ive immunosuppressant capable of blocking the activa-
ion and proliferation of CD4 T cells, as well as their
bility to secrete IFN-. CD4 effector T-cell activation
nd proliferation requires an autocrine-positive feedback
oop of IL-2 secretion and IL-2 receptor activation.27 We,
herefore, asked whether the first step in this cascade, the
ranscriptional activation of the IL-2 gene, could be
locked by PGE2. Indeed, PGE2 treatment efficiently in-
ibited IL-2 and IFNG gene expression induced by CD3/
D28 cross-linking (Figure 7E). Therefore, we tested
hether adding recombinant IL-2 would reverse the ef-
ects of PGE2. Indeed, addition of IL-2 was able to com-
letely reverse the effects of PGE2 on T-cell activation,
roliferation, and IFN- secretion (Figure 7C and D).
hese results suggest that PGE2 inhibits T cells, at least in
art, by interfering with their autocrine IL-2–driven pos-
tive feedback loop.
Based on studies reporting that PGE2 may act as an
mmunosuppressant by stimulating the suppressive ac-
ivities of regulatory T cells (Tregs),28 we speculated that
regs might be an additional target of PGE2 in the
ontrol of T-cell–mediated immunopathology in the
elicobacter-infected stomach. To examine this possibi-
ity, we preconditioned immunomagnetically isolated
y5.2CD4CD25 T cells with PGE2 for 6 hours prior
o coculturing them with CFSE-labeled Ly5.1 effector T
ells at various ratios. Indeed, we found that PGE2 pre-
reatment modestly enhanced the suppressive capacity of
regs, albeit only at a ratio of suboptimal suppression
Supplementary Figure 2). This piece of data suggests
™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
igure 7. PGE2 treatment inhibits CD4CD25 T-effector cell migratio
everses the effects of PGE2 in vivo. (A) 1  105 Calcein-labeled splenic
igrate toward supernatants of H pylori–infected or uninfected immorta
igration was quantified spectrophotometrically; data are displayed w
B–E), CD4CD25 cells were isolated from the combined MLN of 5 inf
GE2 in vivo for 1 month (C,D). Cells were labeled with CFSE and stimu
dded where indicated. The CFSE dilution as a measure of proliferatio
upper panels of B,C) were assessed flow-cytometrically. All culture co
D28, PGE2, IL-2 in (B) and (C);  anti-CD3/CD28 with or without P
eadouts of CFSE dilution and of CD25 up-regulation. (D) The anti-C
easured by enzyme-linked immunosorbent assay for the same cultur
emi-quantitative reverse transcription polymerase chain reaction. A rep
ere infected for 1 month with H felis and treated with PGE2 or recombi
nd histopathology scores are shown. No significant differences were obserhat Tregs can indeed respond to PGE2 in vitro and
ecome more suppressive as a result of PGE2 stimulation.
Recombinant IL-2 Reverses the Effects of
PGE2 In Vivo
In order to investigate whether the observed op-
osing effects of IL-2 and PGE2 hold true in vivo, and to
xplore whether T cells are indeed critical targets of PGE2,
e utilized the previously mentioned IL-10/ model
Figure 4). In addition to a group treated with PGE2 only,
e also included groups that received IP doses of recom-
inant IL-2 (4  104 units, 3 times weekly) together with
GE2 or IL-2 alone (Figure 7F). IL-2 administration effi-
iently reversed the protection from gastric pathology
onferred by PGE2 (Figure 7F). This result suggests that
he protective effect of PGE2 on the infected gastric
ucosa is due to the suppression of T-cell effector func-
ions, which are known to directly trigger the atrophic
astritis, hyperplastic, and metaplastic transformation
hat are a hallmark of the infection in mice as well as in
umans.7
Discussion
In this study, we provide experimental evidence
hat COX-2/PGE2-dependent pathways play an impor-
ant immunomodulating role during the early stages of
elicobacter-induced gastric pathogenesis, thereby pre-
enting excessive gastric immunopathology. We show
hat systemic administration of PGE2 prevented, and
OX-2 inhibition exacerbated, Helicobacter-induced atro-
hic gastritis, epithelial hyperplasia, and metaplasia.
hese effects were due to the immunosuppressive effects
f PGE2 on T cells, which failed to proliferate and to
ecrete IL-2 and IFN- when exposed to PGE2 in vitro or
n vivo.
Our data are in line with several previous studies re-
orting exacerbated gastritis in H pylori–infected rodents
nder conditions of COX-1 or -2 inhibition or deletion of
he COX-1 or -2 genes.29–32 Similar effects were observed
n human trials investigating the effects of COX inhibi-
™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
ivation, proliferation, and IFN- secretion in vitro, and recombinant IL-2
CD25 T cells were seeded into transwell chambers and allowed to
gastric epithelial cells in the presence or absence of 25 M PGE2. The
e baseline migration of cells toward unconditioned medium set as 1.
animals (B,D,E) or of 5 infected animals that had been pretreated with
with CD3/28-coated beads; 25 M PGE2 and/or 10 ng/mL IL-2 was
er panels of B,C) and CD25 up-regulation as a measure of activation
ns were analyzed in triplicate; all statistical comparisons [anti-CD3/
pretreatment in vivo] revealed significant differences (P  .05) for the
D28-induced secretion of IFN- into the culture supernatants was
shown in (B) and (C). (E) IL-2 and IFN- expression was assessed by
ntative experiment of 3 (A) and 4 (B–E) is shown. (F) IL10/ BL/6 mice
L-2 or a combination of the 2. Representative Giemsa-stained sections™™™
n, act
CD4
lized
ith th
ected
lated
n (low
nditio
GE2
D3/C
es as
rese
nant Ived between IL-2–treated groups  PGE2.
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1466 TOLLER ET AL GASTROENTEROLOGY Vol. 138, No. 4ion by aspirin in H pylori–infected, asymptomatic indi-
iduals, who suffered significantly more from mucosal
njury and peptic ulcers than their uninfected counter-
arts.33,34
Despite the well-documented side effects of aspirin use
n the gastric mucosa, the long-term, low-level use of
spirin or nonaspirin nonsteroidal anti-inflammatory
rugs prevents development of gastric cancer; this asso-
iation holds true even in a large meta-analysis including
total of 9 studies.14 Similarly, treatment with the COX
nhibitor, nimesulide, prevented a substantial portion of
hemically induced gastric cancers in H pylori–infected
ice.35 The chemopreventive outcome of COX inhibition
n studies examining cancer as the end point is generally
elieved to be due to the powerful effects of tumor-
erived PGE2 on cancer cell survival and invasion, tumor-
ssociated angiogenesis, and on anti-tumor immunosup-
ression, all of which promote cancer progression.15
We demonstrate here that T cells, in particular effector
ubsets of the T-helper compartment, can be targeted by
GE2. We have shown in a previous study that Helicobac-
er-induced gastric preneoplastic lesions result from dif-
use infiltration of CD4, Th1-polarized effector T cells
nto the gastric lamina propria, where T-cell–derived
FN- acts directly on gastric epithelial lineages to pro-
ote their hyperproliferation and their transformation
o intestinal-type cells.7 Effector functions of CD4 T
ells, such as proliferation, IFN- production, and migra-
ion are blocked upon exposure to PGE2 in our models,
ith the underlying mechanism being a block of IL-2
ene transcription. Consequently, administration of re-
ombinant IL-2 was sufficient to override the protective
ffects of synthetic PGE2 in vitro and in vivo. The pro-
ound effect of PGE2 on CD4 T-cell effector functions,
aintained even in explanted T cells restimulated ex vivo,
lso explains why PGE2-treated mice are colonized at
igher levels than untreated counterparts, and show im-
aired vaccine-induced protection. We conclude that
GE2 averts immunopathology in the infected stomach
y T-cell suppression, the necessary consequence of
hich is persistent colonization with Helicobacter. In
eeming contrast to the protective effect of exogenously
dded PGE2, we observe elevated endogenous PGE2 in
ice with established atrophy. We believe that this PGE2,
hich may be COX-1–derived, is secreted by the gastric
ucosa in an effort to repair the mucosal damage,36 but
s insufficient to act on T cells and to prevent further
amage or to reverse preestablished lesions.
Our finding that PGE2 treatment protects IL-10/
ice from gastric pathology argues against Tregs being
he primary target of PGE2-driven immunosuppression
s IL-10/ Tregs are incapable of blocking the Helicobac-
er-associated gastritis induced by adoptive transfer of
ffector T cells into infected Rag-2/ recipients.37 How-
ver, we did observe that Tregs became modestly more
uppressive in vitro upon pretreatment with PGE2, asemonstrated previously by Sharma et al;28 this observa-
ion suggests that the combined effects of PGE2 on ef-
ector and regulatory T cells may together account for the
omplete block in T-cell–driven immunopathology ob-
erved in our wild-type infection models.
An intriguing finding of our study was the observed
herapeutic effect of PGE2 on preexisting lesions, an ob-
ervation that is seemingly incongruent with studies re-
orting the prevention of gastric cancer by COX inhibi-
ion.14,35 However, it has to be stressed that Helicobacter-
ssociated preneoplastic lesions in our mouse models are
enign and can be at least partially reversed upon anti-
iotic eradication of the infection.38 Under these circum-
tances, the beneficial effect of PGE2’s suppression of
athogenic T cells apparently outweighs the potential
ro-carcinogenic effects that PGE2 may have on gastric
pithelial cells themselves.32
In conclusion, our data are consistent with a protective
ole for PGE2 during the early stages of the Helicobacter-
nduced gastric carcinogenesis sequence; at the molecular
evel, PGE2 blocks the autocrine IL-2–driven positive
eedback loop to prevent T-cell effector functions that are
equired for both Helicobacter clearance and induction of
reneoplastic gastric immunopathology.
Supplementary Material
Note: To access the supplementary material
ccompanying this article, visit the online version of
astroenterology at www.gastrojournal.org, and at doi:
0.1053/j.gastro.2009.12.006.
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Assessment of Gastric Histopathology
Paraffin sections were stained with the histologi-
al dyes Giemsa, Alcian Blue, and Periodic acid Schiff, as
ell as an antibody specific for proliferating cell nuclear
ntigen (clone PC10; Zymed Labs) for grading of gastric
istopathology based on the features described in the
pdated Sydney classification.1 We divided each of the 3
ategories of the Sydney system (mild, moderate, and
evere) into 2 subcategories as proposed by Chen et al,2
esulting in a scale of 0–6 (none, 0; mild, 1–2; moderate,
–4; severe, 5–6). The definitions of the 4 histopatholog-
cal parameters scored were the following: chronic in-
ammation: infiltration of the mucosa and submucosa of
he antrum and corpus of the stomach with B- and T-
ymphocytes; atrophy: loss of specialized, terminally dif-
erentiated cells of the gastric mucosa, such as parietal,
hief and mucus-producing cells (evident histologically
s loss of surface staining with the Periodic Acid Schiff
ye); hyperplasia: hyperproliferation of progenitor cells
o compensate for the loss of differentiated gastric cells
therefore, sometimes called compensatory epithelial hy-
erplasia; detected by proliferating cell nuclear antigen
eactivity); acidic mucus-producing metaplasia: appear-
nce of acidic mucus-producing goblet-like cells in the
astric corpus mucosa, for simplicity reasons here re-
erred to as metaplasia (histologically evident due to
lcian Blue positivity).
Quantification of COX-2 Expression and
Enzymatic Activity, and PGE2 Levels in
Gastric Tissues
COX-2 expression was assessed by Western blot-
ing (no. 160106; Cayman Chemicals, Ann Arbor, MI);
OX-2 activity was determined using the COX activity
ssay Kit (no. 760151; Cayman Chemicals) according to
anufacturer’s protocol with addition of COX-1 inhibi-
or. PGE2 was assessed by competitive immunoassay (As-
ay Designs, Ann Arbor, MI) according to manufacturer’s
nstructions.
Pharmacological Treatments (Extended
Version)
For inhibition of COX-2, mice were fed a diet
upplemented with 1500 ppm celecoxib (D04090202) as
escribed by Jacoby et al3 (Research Diets, New Bruns-
ick, NJ) or an identical control diet (AIN 76A D1000)
ithout the active compound. The average daily drug
ose per mouse was determined to be 3.7 mg, based on
he quantification of food intake per cage. For PGE2
reatment in vivo and in vitro, a stock containing 1
g/mL 16,16-dimethyl PGE2 and 1 mg/mL 17-phenyl
rinor PGE2 was prepared in 100% ethanol, as described
y Hansen–Petrik et al.4 To this end, the methyl acetate
n which PGE2 is commercially available had to be vac-
um-evaporated and then reconstituted in ethanol. The ptock solution was diluted to 10 g/100 L in phos-
hate-buffered saline (PBS) and injected twice IP and
nce combined IP/orogastrically per week resulting in a
otal dose of 30 g/week/mouse. Control mice were in-
ected with PBS. For IL-2 treatment (BD Pharmingen;
0069, Lot 06498) in vivo, we administered 4  104 units
er injection as proposed by Chong.5 Recombinant IL-2
as diluted in PBS and administered 3 times weekly IP.
Vaccination of Mice, Challenge Infection, and
Colony Count Assay
For vaccination, mice were gavaged 4 times at
eekly intervals with 1 mg whole-cell sonicate of H pylori
train SS1 together with 10 g cholera toxin as adjuvant
List Biologicals, Campbell, CA) prior to challenge infec-
ion with 108 colony-forming unit H pylori SS1. Mice were
acrificed 2 weeks postchallenge; bacterial colonization
as assessed by plating of increasing volumes (1, 10, and
00 L) of homogenized stomach extract on horse blood
gar plates followed by colony counting after 5 days of
ulture under microaerophilic conditions as described
reviously.6
Determination of IL-2 and IFN- Expression
by Reverse Transcriptase Polymerase Chain
Reaction (RT-PCR) and Real-Time RT-PCR
IL-2 and IFN- expression were analyzed by RT-PCR
sing the following primers: IL-2 forward: 5=GCGCAC-
CACTTCAAGCT 3=; IL-2 reverse: 5=CCTGCTTACAACAC
TAAGGC3=; IFN- forward: 5=GGTGACATGAAA ATC-
TGCAGAGC3=; IFN- reverse: 5= TCAGCAGCGACTC-
TTTTCCGCTT 3=. The quantitative analysis of gastric
FN- expression was performed as described;6 in brief, total
NA was isolated from scraped gastric mucosa using
Neasy Mini columns (Qiagen, Hilden, Germany). The cor-
esponding complementary DNA served as template for
eal-time PCR (LightCycler; Roche, Mannheim, Germany)
sing the LightCycler 480 SYBR Green I master kit (Roche);
lyceraldehyde phosphate dehydrogenase expression was
etermined for normalization.
Preparation of Protein Extracts for COX-2
and PGE2 Quantification
Protein extracts of scraped gastric mucosa were
repared by homogenization in extraction buffer (20 mM
EPES, 0.4 mM NaCl, 25% glycerol, 1 mM EDTA, 1 mM
aF, and 0.1% NP-40, supplemented with protease inhib-
tors); 10 g/mL indomethacin (a COX inhibitor; Sigma,
t Louis, MO) was added to all extracts intended for
GE2 quantification.
Transwell Migration Assay
CD4CD25 T-cells were generated as described
ere and labeled with calcein (BD Pharmingen); 105 lym-
hocytes were seeded onto 96-well format transwell
p
P
c
t
c
1
2
3
4
5
6
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robe, Gaithersburg, MD) and chemoattracted by 30 L
onditioned medium for 2 hours at 37°C. The propor-
ion of migrated cells was quantified spectrophotometri-
ally.
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April 2010 PGE2 PREVENTS PRENEOPLASTIC IMMUNOPATHOLOGY 1467.e4upplementary Figure 2. PGE2 treatment moderately enhances the suppressive activity of CD4CD25 T cells on T-effector cell proliferation.
D4CD25 (Ly5.1BL/6) and CD4CD25(Ly5.2BL/6) T cells were immunomagnetically isolated from the MLN of uninfected mice. 1.5  105
FSE–labeled CD4CD25 cells were stimulated with anti-CD3/CD28-coated beads in the presence or absence of 25 M PGE2 (A) or combined
t increasing ratios with CD4CD25 Treg as indicated (B). PGE2 was either added to combined cultures, or Treg were pretreated for 6 hours with
GE2 and then added to CD4CD25 cells. Proliferation (CFSE dilution) and activation (CD25 expression) of T-effector cells were analyzed after 3
ays by fluorescence-activated cell sorting. In (B), only the cells from the upper left quadrant (CD25, CFSE low) are plotted. All cultures were
nalyzed in triplicate; averages and standard deviations are shown.
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Summary:            The PARP family of enzymes constitute key players of inflammatory 
processes and as guardians of genome stability through their ability to 
post-transcriptionally ADP-ribosylate its targets. We show that the T cell-
driven gastric preneoplastic immunopathology that is observed in 
Helicobacter-infected C57BL/6mice is attenuated by systemic 
administration of PJ34, an NAD+ analogue and inhibitor of ADP- 
ribosylation originally designed to inhibit PARP1. The same treatment 
further efficiently reversed pre-existing lesions, especially when applied in 
combination with Helicobacter eradication therapy. We find that PJ34 
exerts its chemopreventive and therapeutic effects by inhibiting the priming 
and programming of Th-1 polarized T cells in the gut-draining lymph 
nodes. An essential role for ADP-ribosylation during T-cell activation was 
further corroborated in vitro, as the PAR formation, cytokine secretion, and 
proliferation induced by CD3/CD28 crosslinking were blocked by PJ34. In 
conclusion, we propose that targeting ADP-ribosylating enzymes in T cells 
may represent a novel treatment strategy of gastric premalignant lesions in 
patients that are refractory to Helicobacter eradication therapy. 
Therapeutics, Targets, and Chemical Biology
Inhibition of ADP Ribosylation Prevents and Cures
Helicobacter-Induced Gastric Preneoplasia
AU Isabella M. Toller1, Matthias Altmeyer2, Esther Kohler1, Michael O. Hottiger2, and Anne Müller1
Abstract
Gastric adenocarcinoma develops as a consequence of chronic inflammation of the stomach lining that is
causedQ3 by persistent infection with the bacterium Helicobacter pylori. Gastric carcinogenesis progresses
through a sequence of preneoplastic lesions that manifest histologically as atrophic gastritis, intestinal
metaplasia, and dysplasia. We show here in several preclinical models of Helicobacter-induced atrophic gas-
tritis, epithelial hyperplasia, and metaplasia that the inhibition of ADP ribosylation by the small-molecule
inhibitor PJ34 not only prevents the formation of gastric cancer precursor lesions, but also efficiently re-
verses preexisting lesions. PJ34 exerts its chemopreventive and therapeutic effects by impairing Helicobacter-
specific T-cell priming and TH1 polarization in the gut-draining mesenteric lymph nodes. The subsequent
infiltration of pathogenic T cells into the gastric mucosa and the ensuing gastric T cell–driven immunopa-
thology are prevented efficiently by PJ34. Our data indicate that PJ34 directly suppresses T-cell effector
functions by blocking the IFN-γ production of mesenteric lymph node T cells ex vivo. Upon exposure to
PJ34, purified T cells failed to synthesize ADP-ribose polymers and to activate the transcription of genes
encoding IFN-γ, interleukin 2, and the interleukin 2 receptorQ2 α chain in response to stimuli such as CD3/
CD28 cross-linking or phorbol 12-myristate 13-acetate/ionomycin. The immunosuppressive and chemopro-
tective effects of PJ34 therefore result from impaired T-cell activation and TH1 polarization, and lead to the
protection from preneoplastic gastric immunopathology. In conclusion, ADP-ribosylating enzymes constitute
novel targets for the treatment of Helicobacter-associated gastric lesions predisposing infected individuals to
gastric cancer and may also hold promise for the treatment of other T cell–driven chronic inflammatory
conditions and autoimmune pathologies. Cancer Res; 70(14); OF1–11. ©2010 AACR.
Introduction
Epidemiologic and experimental studies have established
unequivocally that chronic inflammatory diseases predispose
to cancers of the liver, cervix, colon, stomach, and several
other organs (1). In the stomach, chronic inflammation
caused by persistent infection with the Gram-negative bacte-
rial pathogen Helicobacter pylori is the most important risk
factor for the development of adenocarcinoma (2–5). In a
high-risk subset of infected individuals, H. pylori causes mul-
tifocal corpus-predominant atrophic gastritis, which fre-
quently progresses to intestinal metaplasia, occasionally to
dysplasia, and rarely to adenocarcinoma (6, 7). We have
shown recently using a C57BL/6 mouse model of Helicobacter
infection that the early stages of this preneoplastic
sequence develop as a result of gastric infiltration by TH1-
polarized, MHC class II–restricted effector T cells (8). This
T-cell subset is, on the one hand, absolutely essential for
the efficient control of infection and, on the other hand
either directly or indirectly induces gastric epithelial transfor-
mation (8). Both phenotypes depend on IFN-γ, which is se-
creted by TH1-polarized effector T cells both locally at the
site of infection and in the gut-draining mesenteric lymph
nodes (MLN). Targeting T cells pharmacologically in the in-
fectious process prevents and even reverses established pre-
malignant lesions, confirming that T cells are crucial
mediators of gastric preneoplasia (9).
Poly(ADP-ribose) (PAR) is synthesized by the PAR poly-
merase (PARP) family of enzymes, which use the substrate
NAD+ to ADP-ribosylate acceptor proteins (10–12). PARP
enzymes have been implicated in the pathogenesis of sev-
eral chronic inflammatory and autoimmune conditions,
and NAD+-mimicking inhibitors of poly(ADP-ribosyl)ation
efficiently block inflammation in rodent models of Crohn's
disease (13) and in allergen-induced airway inflammation
models (14), and protect mice from endotoxic shock (15).
Since the concept of synthetic lethality of PARP inhibitors
in cells with defects in homologous recombination was
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introduced in 2005 (16, 17), PARP inhibitors have entered the
arena of cancer therapy, showing a benefit in breast and
ovarian cancer patients with BRCA1- or BRCA2-deficient
tumors (18–21).
We show here that the T cell–driven gastric preneoplastic
immunopathology observed in Helicobacter-infected C57BL/6
mice is attenuated by systemic administration of PJ34, a
NAD+ analogue and inhibitor of ADP ribosylation originally
designed to inhibit PARP1 (22). The same treatment further
efficiently reversed preexisting lesions, especially when ap-
plied in combination with Helicobacter eradication therapy.
We find that PJ34 exerts its chemopreventive and therapeutic
effects by inhibiting the priming and programming of TH-1
polarized T cells in the gut-draining lymph nodes. An essen-
tial role for ADP ribosylation during T-cell activation was
further corroborated in vitro, as the PAR formation, cytokine
secretion, and proliferation induced by CD3/CD28 cross-
linking were blocked by PJ34. In conclusion, we propose that
ADP-ribosylating enzymes in T cells may represent novel
targets for the treatment of gastric premalignant lesions in pa-
tients that are refractory to Helicobacter eradication therapy.
Materials and Methods
Animal experimentation, Helicobacter strains, and
pharmacologic treatments
Male C57BL/6, interleukin (IL)-10)−/−BL/6, CD4−/−BL/6,
and MyD88−/−BL/6 mice (Charles River Laboratories) as well
as PARP1−/−BL/6 (23) and PARP2−/−BL/6 (a kind gift from
Gilbert de MurciaQ4 ) were maintained in individually ventilated
cages and infected at 5 to 6 weeks of age with two consecu-
tive doses of ∼108 H. felis CS1 (ATCC 49179; ref. 24). All an-
imal experiments were approved by the cantonal veterinary
office. For in vivo inhibition of ADP ribosylation, PJ34 [N-(6-
Oxo-5,6-dihydro-phenanthridin-2-yl)-N,N-dimethylacetamide,
Enzo Life Sciences] was administered in drinking water sup-
plemented with 0.1 mg/mL Aspartame, resulting in a daily
dose of 30 mg/kg of body weight. In cell culture experiments,
PJ34 and DAM-TIQ-A [2-Dimethylaminomethyl-4H-thieno
(2,3-c)isoquinolin-5-one; Enzo Life Sciences] were each used
at 15 μmol/L. Antibiotic eradication therapy was achieved by
2 weeks of daily orogastric treatment with 4.5 mg/mL met-
ronidazole, 10 mg/mL tetracycline hydrochloride (both Sig-
ma-Aldrich), and 1.2 mg/mL bismuth subcitrate (Park-Davis).
Assessment of H. felis colonization, gastric IFN-γ
production, gastric neutrophil and lymphocytic
infiltration, and histopathology
Murine stomachs were dissected longitudinally into equal-
ly sized pieces. For the assessment of H. felis colonization,
total genomic stomach DNA was subjected to quantitative
PCR analysis of the flaB gene, as previously described (8).
The quantitative analysis of gastric IFN-γ expression by
real-time reverse transcription-PCR (RT-PCR) and the quan-
tification of neutrophil infiltration by myeloperoxidase activ-
ity assay were performed as described (8). Gastric lymphocyte
single-cell suspensions were generated by digestion with
0.25 mg/mL collagenase IV (Sigma) and passing through a cell
strainer. PARP1 expression was analyzed by immunoblot-
ting of mucosal extract using rabbit anti-PARP1 antibody
H-250 (Santa Cruz). Gastric histopathology was graded
on Giemsa-stained paraffin sections as described in detail
previously (8, 9). All pictures were taken with a Leica Leitz
DM RB microscope equipped with a Leica DFC 420C cam-
era. Images were acquired at ×20 magnification using the
Leica Application Suite 3.3.0 software. Scale bars indicate
50 μm. The immunomagnetic isolation of lymphocytes
from MLN and spleen, and the assessment of lymphocyte
proliferation as well as IFN-γ and IL-2 expression by real-
time RT-PCR and intracellular staining is described in the
Supplementary Methods.
Statistical analysis
P values were calculated using GraphPad prism 5.0 soft-
ware. The significance of differences in histopathology cate-
gories was calculated by Mann-Whitney test, and the
significance of numerical differences was calculated by Stu-
dent's t test. All in vitro assays were analyzed in triplicate and
are shown with SDs.
Results
Inhibition of ADP ribosylation by PJ34 in vivo
attenuates Helicobacter-induced atrophic gastritis
As ADP-ribosylating enzymes have been implicated in
chronic inflammatory and autoimmune disorders, and also
in the development and progression of certain neoplasms
(13, 14, 16, 17), we hypothesized that blocking ADP ribosyla-
tion in vivo would modulate Helicobacter-induced gastric
(pre) neoplasia. To validate the use of the NAD+ analogue
PJ34, an inhibitor of PARPs and of ADP ribosylation in gen-
eral, we first used the standardized human AGS gastric epi-
thelial cell culture model of H. pylori infection. PAR
formation could be detected in H. pylori–infected AGS cells
as early as 6 hours postinfection ( SF1Supplementary Fig. S1A).
The synthesis of PAR was completely blocked by the addition
of PJ34 (Supplementary Fig. S1B), implying that PJ34 readily
permeates into cultured cells and efficiently blocks all en-
zymes involved in Helicobacter-dependent PAR formation.
Experimental infection of C57BL/6 mice with the close
H. pylori relative H. felis mimics the human host's response
to the bacterium, with gastric lesions manifesting histologi-
cally as chronic atrophic gastritis accompanied by epithelial
hyperplasia and acidic mucus–positive metaplasia (8, 9, 25,
26). The formation of preneoplastic lesions is strongly accel-
erated in IL-10−/− mice, which develop atrophy, hyperplasia,
and metaplasia as early as 4 weeks postinfection ( F1Fig. 1A)
compared with ∼12 weeks postinfection in wild-type (WT)
mice (8). IL-10−/− mice thus constitute a convenient model
for pharmacologic intervention.
IL-10−/− mice were given PJ34 with the drinking water at a
daily dose of 30 mg/kg of body weight. The quantitative anal-
ysis of gastric histopathology revealed that PJ34 treatment
strongly reduced Helicobacter-associated inflammation, atro-
phy, and epithelial hyperplasia and, to a lesser extent, intes-
tinal metaplasia (Fig. 1A). In agreement with the effects of
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PJ34 on gastric histopathology, the mucosal infiltration of
neutrophils as determined by myeloperoxidase activity assay
was reduced in the presence of the inhibitor (Fig. 1B). PJ34
treatment further significantly impaired the clearance of
Helicobacter that is typically observed in IL-10−/− mice (Fig. 1C).
To clarify whether PJ34 exerts its protective effects through
inhibition of PARP1, the target for which PJ34 was originally
designed, we first analyzed PARP1 expression in the gastric
mucosa of infected and uninfected IL-10−/− mice (Fig. 1D).
All infected mice showed higher levels of PARP1 than their
age-matched uninfected counterparts; PARP1 levels were
not influenced by PJ34 (Fig. 1D). To investigate the functional
consequences of Helicobacter-associated PARP1 accumula-
tion in the gastric mucosa, we crossed IL-10−/− mice with
PARP1−/− mice to generate IL-10−/−/PARP1−/− animals. We
assessed the development of gastritis and preneoplastic
lesions in this strain over time compared with the PARP1-
proficient parental strain. Remarkably, no significant differ-
ences could be observed with respect to the onset or the
severity of lesions (5, 14, and 21 dpostinfection; SF2Supplementary
Fig. S2), implying that PJ34 acts through mechanisms not
dependent only on PARP1 to attenuateHelicobacter-associated
gastric pathology in vivo.
Inhibition of ADP ribosylation by PJ34 reverses
preexisting lesions
We next examined a possible therapeutic effect of PJ34;
to this end, we had to abandon the IL-10−/− model, as these
mice clear the infection (Fig. 1C) and spontaneously revert
to normal gastric histology by 6 to 8 weeks postinfection
Figure 1. Inhibition of ADP ribosylation prevents Helicobacter-induced gastritis and precancerous lesions. IL-10−/− mice were infected for 4 wk with
Helicobacter felis or remained uninfected. One infected group received PJ34 (30 mg/kg/d) during the last 2 wk of infection. A, a schematic treatment
overview, representative Giemsa-stained sections, and histopathology scores are shown for all mice. Gastric histopathology was assessed with respect
toQ8 chronic inflammation, atrophy, metaplasia, and compensatory epithelial hyperplasia; scores were assigned on a scale of 0 to 6. Horizontal columns,
mean values. Scale bars, 50 μm. B, neutrophil infiltration into the stomach was assessed by myeloperoxidase activity assay; columns, means; bars,
SD. C, Helicobacter colonization was analyzed by quantification of the flaB gene copy number by real-time PCR of gastric genomic DNA. Ns, not
significantQ5 . D, gastric PARP1 expression was analyzed for three to four mice per group by immunoblotting. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) levels are shown as loading controls.
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(data not shown). For therapeutic studies, we used CD4−/−
mice that develop premalignant lesions more consistently
than C57BL/6 WT mice by 3 months postinfection, creating
a therapeutic window for pharmacologic intervention be-
tween 3 and 4 months postinfection (F2 Fig. 2). The increased
susceptibility of CD4−/− mice is presumably due to their
lack of a CD4+ regulatory T-cell population that could con-
trol the immunopathology induced by “pathogenic” effector
T cells, which are CD8+ in the absence of CD4+ T cells (27).
CD4−/− mice were infected with H. felis for 3 months, and
the development of premalignant pathology was confirmed
in a small control group (data not shown). The remaining
mice either received PJ34 in the 4th month postinfection or
remained nontreated. The treatment with PJ34 efficiently re-
duced all parameters of gastric histopathology (Fig. 2A). The
regression of lesions was accompanied by a significant reduc-
tion of gastric IFN-γ production and neutrophil infiltration
(Fig. 2B and C). In line with our previous observations
(8, 9), the reduction of IFN-γ and mucosal neutrophils was
associated with an increase in Helicobacter colonization
(Fig. 2D), which is indicative of a reversal to normal gastric
mucosal architecture and physiology.
The regression of preneoplastic lesions is not sustained
under conditions of ongoing Helicobacter colonization
To confirm these results in an independent model, we took
advantage of a mouse strain that lacks the gene encoding the
adaptor protein MyD88. MyD88−/− mice develop severe pre-
neoplastic lesions as early as 1 month postinfection ( SF3Supple-
mentary Fig. S3A), presumably due to a defect in immune
counter-regulation. FN13 However, in contrast to CD4−/− and IL-
10−/− mice, which efficiently reduce H. felis colonization or
even clear the infection, respectively (Figs. 1 and 2), MyD88−/−
3 A. Sayi, I. Toller, A. Mueller, unpublished observations Q6.
Figure 2. Inhibition of ADP ribosylation reverses preexisting gastritis and precancerous lesions. CD4−/− mice were infected with H. felis for 3 mo and either
received PJ34 in the 4th month postinfection or remained nontreated. A group of three mice served as uninfected age-matched controls. A, schematic
overview, representative Giemsa-stained sections, and histopathology scores. Horizontal columns, mean values. B, IFN-γ transcript levels as quantified
byQ8 real-time RT-PCR analysis of gastric total RNA. C, neutrophil infiltration as quantified by myeloperoxidase activity assay. D, H. felis colonization as
analyzed by quantification of the flaB gene copy number by real-time PCR of gastric genomic DNA.
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mice are colonized heavily for at least 3 months postinfection
(F3 Fig. 3). We used the therapeutic window between 1 and 3
months postinfection to test whether the reversal of preneo-
plastic lesions by PJ34 treatment would be sustained after
termination of the treatment, despite ongoing H. felis coloni-
zation, or would require the concomitant eradication of the
infection (Fig. 3).
MyD88−/− mice were infected for 1 month, and the devel-
opment of pathology was verified in a small control group
(Supplementary Fig. S3A and D). The remaining mice either
received PJ34 for the subsequent month, were subjected to
eradication therapy in weeks 5 and 6 postinfection, or re-
ceived both treatments. At 2 months postinfection, the rever-
sal of preexisting lesions and the efficiency of eradication
therapy were verified in additional control groups (Supple-
mentary Fig. S3B and D). All remaining mice were main-
tained for a 3rd month and then analyzed with respect to
their colonization and histopathology. Mice that had been
continuously colonized throughout the 3-month time course
had all developed severe pathology (Fig. 3A). The regression
Figure 3. The regression of
preneoplastic lesions is stable
under conditions of simultaneous
PJ34 treatment and Helicobacter
eradication. MyD88−/− mice were
infected for 3 mo and received
PJ34 in the 2nd month with or
without eradication therapy in
weeks 5 and 6 postinfection.
Additional mice served as infected
or uninfected age-matched
controls. Control groups were
sacrificed after 1, 2, and 3 mo to
verify the success of the respective
treatments (see Supplementary
Fig. S3). A, schematic overview,
representative Giemsa-stained
sections, and histopathology
scores;Q8 horizontal columns,
means. B, neutrophil infiltration
into the gastric mucosa as
quantified by myeloperoxidase
assay. C, H. felis colonization as
quantified by real-time PCR of the
flaB gene.
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of preneoplastic lesions induced by PJ34 treatment during
the second month was transient, as the mice relapsed once
the treatment was discontinued (Fig. 3A). In contrast, mice
that had been cured of their infection while receiving PJ34
showed sustained regression of their lesions, i.e., the effect
of the treatment was stable in this group (Fig. 3A). As re-
ported previously (28), eradication therapy by itself was also
effective at reversing existing lesions (Supplementary Fig.
S3C and D), indicating that Helicobacter eradication and
the inhibition of ADP ribosylation have comparable effects
in mice. In contrast, eradication therapy typically fails to cure
the human counterpart lesions (29), suggesting that the con-
secutive treatment with antibiotics and ADP ribosylation in-
hibitors would have a beneficial effect over eradication
therapy alone in humans.
The effects on gastric histopathology were reflected in the
levels of neutrophil infiltration, which decreased more dra-
matically in the group that was subjected to both PJ34 treat-
ment and eradication therapy than in the group that received
PJ34 only (Fig. 3B). Helicobacter levels were not significantly
different between the two infected groups with or without
PJ34 treatment; only background levels of Helicobacter-
specific PCR products were detectable upon eradication
therapy (Fig. 3C). In conclusion, the pharmacologic inhibition
of ADP ribosylation for therapeutic purposes is temporarily
successful in reversing preexisting lesions, but is sustained
only if the underlying infection is eradicated.
Inhibition of ADP ribosylation prevents T-cell
priming in MLNs
We have reported previously that gastric IFN-γ responses
to Helicobacter infection correlate with the level of gastric
T-cell infiltration and preneoplastic pathology (8, 9). This
association was again confirmed in this study (Figs. 1 and
2). The proportion of T cells producing IFN-γ (i.e., TH-1–
polarized effector T cells) in the MLN is a reliable indicator
of Helicobacter-specific T-cell responses and a good predictor
of gastric pathology (9). To assess whether inhibition of ADP
ribosylation modulates gastric histopathology by interfering
with T-cell priming, we infected 10 WT C57BL/6 mice with
H. felis and treated one half of the group with PJ34 for
1 month. The rest remained nontreated; additional mice
served as uninfected, nontreated controls. IFN-γ–positive
T cells were quantified in single-cell MLN preparations of in-
dividual mice by intracellular staining for IFN-γ combined
with surface staining for CD4 (F4 Fig. 4A). The proportion of
IFN-γ+ cells increased in the CD4+ and CD4− fractions as a
result of the infection; this increase was suppressed by PJ34
treatment (Fig. 4A). As a consequence of impaired T-cell
priming in the MLN due to PJ34 treatment, fewer leukocytes
were present in single-cell preparations of the corresponding
stomachs (Fig. 4B, top), and fewer of these gastric leukocytes
stained positive for CD4 (Fig. 4B, bottom). To test whether
the inhibition of TH-1 polarization was due to a direct effect
of PJ34 on IFN-γ production, we cultured single-cell prepara-
tions from five additional H. felis–infected WT mice for 3 days
in the presence or absence of PJ34. All treated cultures re-
vealed a reduction of IFN-γ expression compared with the
respective controls (Fig. 4C); the simultaneous visualization
of PAR showed that PJ34 indeed significantly reduced PAR
formation under these circumstances (Fig. 4C). Finally, we
pulsed immunomagnetically isolated MLN-derived dendritic
cells with Helicobacter sonicate and cocultured them with
splenic CD4+ T cells isolated from uninfected or infected
donors (Fig. 4D); the infection-dependent IFN-γ response
of the T cells was significantly reduced by PJ34 treatment,
as were the background levels of T-cell activation (Fig. 4D).
In conclusion, the T-cell priming, TH-1 polarization, and
IFN-γ production that are a prerequisite for the development
of gastric Helicobacter-associated pathology are blocked by
PJ34, suggesting that T cells represent the key target of
PJ34 in this scenario.
T-cell activation is impaired by inhibition of
ADP ribosylation
T-cell activation requires two external signals, an antigen-
specific signal that is transmitted through the TCR/CD3
complex and a costimulatory signal received by activation
of CD28 (30). Primary T cells are induced to proliferate, to
express the activation marker CD25, and to produce and
secrete IFN-γ upon CD3/CD28 cross-linking or treatment
with phorbol 12-myristate 13-acetate (PMA) and ionomycin
( F5Fig. 5). We isolated splenic CD4+CD25− T cells and stimulated
them with anti-CD3/anti-CD28 monoclonal antibody–coated
beads or PMA/ionomycin in the presence or absence of
either PJ34 or an alternative inhibitor of ADP ribosylation,
DAM-TIQ-A. Both treatments induced proliferation of the
T cells as assessed by carboxyfluorescein diacetate succini-
midyl ester (CFSE) dilution, and proliferation was blocked
by both compounds (Fig. 5A). PJ34 was more active than
DAM-TIQ-A at the same final concentration. The concomi-
tant upregulation of CD25 was reduced as well (data not
shown; F6Fig. 6B), as was IFN-γ production (Fig. 5C). We
conclude that inhibition of ADP ribosylation by either PJ34
or DAM-TIQ-A significantly blocks CD4+CD25− T-cell activa-
tion triggered by two alternative stimuli.
To investigate whether the effect of blocking ADP ribosy-
lation was attributable to either PARP1 or PARP2, we stimu-
lated parallel preparations of immunomagnetically isolated
WT, PARP1−/−, and PARP2−/− CD4+CD25− T cells by CD3/
CD28 cross-linking in the absence or presence of PJ34 and
quantified their proliferation ( SF4Supplementary Fig. S4). T cells
of all three genotypes responded equally well to CD3/CD28
cross-linking; no differences were detected with respect to
proliferation (Supplementary Fig. S4), CD25 upregulation,
or IFN-γ production (data not shown). Furthermore, we
found that PJ34 had similarly suppressive effects on all three
genotypes (Supplementary Fig. S4), suggesting that neither
PARP1 nor PARP2 are the sole targets of PJ34 in T cells.
To test whether T-cell inhibition by PJ34 is restricted to
CD4+ T cells or is a common feature shared by other T-cell
subsets, we immunomagnetically isolated splenic CD8+ T
cells, subjected them to CD3/CD28 cross-linking, and mea-
sured their proliferation ( SF5Supplementary Fig. S5). PJ34 treat-
ment indeed blocked the proliferation of CD8+ T cells as
efficiently as that of CD4+ T cells, implying that PJ34 has
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Figure 4. Inhibition of ADP ribosylation impairs T-cell priming and TH-1 differentiation in the MLNs. A and B, C57BL/6 mice were infected for 1 mo with
H. felis or remained uninfected; of the infected mice, a subset received PJ34 during the entire course of infection. Single-cell suspensions were
generated from the MLN (A) and stomachs (B) of all five mice per group and analyzed individually by flow cytometry. Representative dot plots of CD4 and
intracellular IFN-γ signals and averages of all MLN cultures are shown (A). Similarly, representative dot plots and group averages are shown for the
percentage of leukocytes and CD4+ T cells per total stomach cells (B, top and bottom). C, additional MLN cultures from five infected mice (numbered
1–5)Q8 were cultured for 3 d in the presence or absence of 15 μmol/L PJ34 before intracellular staining for IFN-γ and ADP-ribose polymers.
D, immunomagnetically isolated MLN-derived dendritic cells from uninfected donors were pulsed with Helicobacter sonicate for 16 h and cocultured with
splenic CD4+ T cells from uninfected or infected donors before staining of CD4 and intracellular IFN-γ. All events in the CD4+ gate are plotted; representative
dot plots and group averages are shown. P values were calculated by unpaired (A, B, and D) and paired (C) Student's t test.
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broad T-cell immunosuppressive capacity. Interestingly,
splenic CD4+ T cells isolated from PJ34-treated mice at
the time of sacrifice were as responsive to CD3/CD28 cross-
linking–induced activation as cells from nontreated donors
(data not shown), suggesting that the effects of PJ34 in vivo
are transient and do not permanently silence this important
branch of the immune system. In conclusion, PJ34 acts as an
efficient T-cell immunosuppressant in vitro, suggesting that
it may target T cells in a similar manner also in vivo.
Inhibition of ADP ribosylation blocks il-2 and ifng
gene transcription
Activated T cells require IL-2 for growth (31); therefore,
some of the earliest markers of T-cell activation are the up-
regulation of the high-affinity α-chain of the IL-2 receptor
(CD25; Fig. 5B) and the production of IL-2. IL-2 acts on the
producing T cell and its neighbors to sustain their prolifera-
tion in an auto and paracrine manner (31). To monitor PAR
formation during early stages of T-cell activation upon CD3/
CD28 cross-linking, we stained intracellular ADP-ribose poly-
mers after 2, 6, and 16 hours with an antibody that recog-
nizes polymers >16 units in length. PAR formation
gradually increased in this time frame and was blocked effi-
ciently by PJ34 (Fig. 6A). Transcription of the il-2 and ifng
genes was detectable as early as 2 hours after CD3/CD28
cross-linking (Fig. 6B and C) and remained high after 6 and
16 hours (data not shown). The induction of il-2 and ifng
transcripts could be prevented by PJ34, but was independent
of PARP1 and PARP2 (Fig. 6B and C), suggesting that the two
PARP family members are redundant or that additional PJ34-
sensitive ADP-ribosylating enzymes function in the transcrip-
tional activation of T cells. The results indicate that PJ34
blocks T-cell activity by interfering with the autocrine, IL-
2–driven positive feedback loop required for sustained T-cell
proliferation, and suggest that ADP ribosylation is required
for the initiation of the transcriptional program activating
T-cell effector functions.
Discussion
Inhibitors of ADP-ribosylating enzymes have attracted at-
tention lately as new compounds for cancer therapy (16, 17,
19, 20), and for the treatment of chronic inflammatory diseases
and autoimmune pathologies (13–15, 32). We show here that
a broad range inhibitor of ADP ribosylation, PJ34, is capable
of preventing and also of curing the Helicobacter-associated,
T cell–driven immunopathology that precedes gastric can-
cer development. Several pieces of evidence indicate that
pathogenic T cells, and not Helicobacter-infected epithelial
cells (which also upregulate PAR in the infectious process),
are the key targets of PJ34 inhibition in our preclinical model:
(a) The gastric expression of IFN-γ, which is produced
Figure 5. Inhibition of ADP ribosylation prevents T-cell activation by CD3/CD28 cross-linking or treatment with PMA/ionomycin. CD4+CD25− cells were
isolated from single cell preparations of the combined MLN of five mice. The cells were labeled with CFSE and stimulated for 3 d with αCD3/28-coated
beads or PMA/ionomycin; 15 μmol/L PJ34 or 15 μmol/L DAM-TIQ-A was added where indicated. A, CFSE dilution as a measure of proliferation was
assessedQ8 flow cytometrically. Representative histograms (left) as well as the averages of triplicate cultures (right) are shown. B, CD25 expression was
assessed by surface staining. Representative dot plots and averages of triplicate cultures are shown. C, the αCD3/CD28-induced secretion of IFN-γ into the
culture supernatants was measured by ELISA for the same cultures as shown in B.
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exclusively by infiltrating CD4+ T cells, is strongly reduced
in vivo; (b) the priming and polarization of TH1 T cells in
the gut-draining lymph nodes is impaired both in vivo and
ex vivo in cocultures of T cells with Helicobacter antigen–
pulsed MLN-derived dendritic cells; (c) IFN-γ secretion by
explanted MLN cells from infected mice cultured ex vivo is
blocked, and (d) these effects are presumably due to the
PJ34 sensitivity of il-2 gene transcription as shown in an
ex vivo model of T-cell stimulation.
ADP-ribose polymers are detectable in T cells only hours
after their activation by CD3/CD28 cross-linking; the time
frame of PAR formation suggests a role for PAR in the tran-
scriptional activation of genes encoding IL-2, IFN-γ, and the
IL-2 receptor α-chain. In line with this observation, the inhi-
bition of ADP ribosylation in T cells by PJ34 blocks il-2 and
ifng gene transcription and, presumably as a consequence of
these early effects, prevents T-cell proliferation in response
to CD3/CD28 cross-linking– and PMA/ionomycin-induced
activation. Our ex vivo results suggest that PARP1, PARP2,
and possibly other PJ34-sensitive PARP family members have
redundant roles during T-cell activation. Our finding that IL-
10−/−/PARP1−/− mice develop gastritis and epithelial pathol-
ogy with similar kinetics as the parental IL-10−/− PARP1+
strain argues in favor of a redundant role of PARP enzymes
also in vivo. We conclude from the combined results that
ADP ribosylation by PJ34-sensitive enzymes is an essential
step in the activation and/or TH1 polarization of pathogenic
T cells, which directly cause the gastric pathology preceding
gastric neoplasia.
The concept of treating T cell–driven diseases such as
chronic inflammatory disorders or autoimmune diseases
with inhibitors of ADP-ribosylating enzymes is not new.
PARP inhibitors have for instance been successfully used
in preclinical models of asthma and colitis (13, 14, 33–35).
PARP inhibition and PARP1 gene deletion were shown to
protect mice from ovalbumin-induced allergic airway inflam-
mation (14). In rodent models of Crohn's disease–like colitis,
the inhibition of ADP ribosylation was sufficient to prevent
disease (13, 33–35). Protection was accompanied by de-
creased levels of inflammatory and T cell–derived cytokines
Figure 6. CD3/CD28 cross-linking–induced PAR formation and il-2 and ifng gene transcription are blocked by PJ34. A, PAR formation in CD4+CD25− T
cells upon CD3/CD28 cross-linking was analyzed by intracellular staining; cells were stimulated with anti-CD3/CD28–coated beads in the presence or
absenceQ8 of 15 μmol/L PJ34 for 2, 6, and 16 h as indicated. Representative dot plots (top) as well as the averages of triplicate cultures (bottom) are shown.
B and C, parallel cultures treated for 2 h as described in A were subjected to RNA isolation and quantitative RT-PCR analysis of il-2 (B) and ifng (C)
gene expression. Parallel CD4+CD25− T-cell cultures from PARP1−/− and PARP2−/− mice were included as well. Transcript levels of il-2 and ifng were
normalized to rps12 levels. Columns, mean; bars, SD.
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and a restoration of colonic barrier functions (13, 33–35).
Overall, substantial preclinical evidence is available to sup-
port a role for ADP ribosylation also in other T cell–driven
immune and autoimmune pathologies, suggesting a more
general mechanism and a broad applicability of ADP ribosy-
lation inhibitors to these indications.
One of the least anticipated findings of our study was the
almost complete reversion of preexisting Helicobacter-
induced gastric lesions by PJ34 treatment. This result indi-
cates that inhibitors of ADP ribosylation, for which safety
data are now available due to their extensive testing in
trials of metastatic breast and other cancers (19, 20), might
be useful compounds for the treatment of symptomatic
H. pylori–infected patients. Most patients presenting with
atrophic gastritis, metaplasia, or dysplasia are routinely
subjected to eradication therapy targeting the underlying
infection; however, eradication is only partly efficient in re-
versing atrophy and fails in the treatment of metaplasia and
dysplasia (29). As patients with any of these conditions have
an at least 10-fold increased risk of developing gastric can-
cer compared with histologically unapparent infected indi-
viduals, and are currently subjected to an unsatisfactory
watch-and-wait strategy, there is a clear unmet need for
new treatment options for this patient group. We conclude
based on the results obtained by our combined treatment
with PJ34 and antibiotics that this inhibitor, or other com-
pounds mimicking NAD+, may successfully reverse gastric
preneoplastic lesions in humans if administered together with
or after eradication therapy. In summary, we provide evidence
that ADP ribosylation is required for T-cell activation, and
that inhibition of ADP-ribosylating enzymes efficiently im-
pairs the TH-1–polarized T-effector cell responses and the as-
sociated gastric immunopathology that are a hallmark of
chronic Helicobacter infection.
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Supplemental Figure 1 
 
 
 
 
Supplemental Figure 1: The NAD+ analog PJ34 prevents H. pylori-induced PAR synthesis 
in gastric epithelial cells. 
(A) Human gastric epithelial cells (AGS; purchased from ATCC, CRL 1739) were infected with 
H. pylori strain G27 for 0, 3, 6, 12 and 24 hours. PAR formation was detected by immunoblotting. 
(B) AGS cells were infected with H. pylori for 24 hours in the presence or absence of 15μM 
PJ34. PAR formation was analyzed by immunoblotting. 
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Supplemental Figure 2: PARP1 does not contribute to H. felis-induced gastric pathology 
in vivo. IL10-/- and IL10-/-/PARP1-/- mice were infected with H. felis for 5, 14 and 21 days. Gastric 
histopathology was assessed with respect to chronic inflammation, atrophy, metaplasia and 
compensatory epithelial hyperplasia; scores were assigned to every mouse on a scale ranging 
from 0-6. The horizontal bars represent mean values.  Representative Giemsa-stained sections 
are shown in the left panels.  
 
 
 
 
 
 
 
 
                                                 Toller et al., Cancer Res. 2010 – Supplemental Figures 
Supplemental Figure 3 
 
 
 
Supplemental Figure 3: Gastric histopathology of H. felis-infected MyD88-/- mice that have 
received PJ34 treatment or eradication therapy. (A) Two Myd88-/- mice were infected for one 
month and compared to two age-matched uninfected controls with respect to gastric 
histopathology. (B) Seven additional infected mice were analyzed two months p.i.; of these, 
three were treated with PJ34 (30mg/kg per day) for the second month of infection, whereas two 
remained untreated and two more received eradication therapy during weeks 5 and 6 p.i. (C) 
Four additional mice were analyzed three months p.i.; all four had received eradication therapy 
in weeks 5 and 6 p.i., but had not received PJ34. Giemsa-stained sections of representative 
animals are shown in A-C. (D) Gastric histopathology scores for all mice included in A-C.  
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Supplemental Figure 4: T-cell proliferation upon CD3/CD28 crosslinking does not depend 
on PARP1 or PARP2. 
CD4+CD25- cells were immunomagnetically isolated from WT, PARP1-/- and PARP2-/-  spleens. 
The cells were labeled with CFSE and stimulated with αCD3/28 coated beads for three days; 
15μM PJ34 was added where indicated. The CFSE dilution was assessed flow-cytometrically; 
numbers indicate the percentages of CFSElow (proliferating) cells. Representative histograms as 
well as the averages of triplicate cultures are shown.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 Toller et al., Cancer Res. 2010 – Supplemental Figures 
Supplemental Figure 5 
 
 
 
Supplemental Figure 5: CD8+ T-cell proliferation upon CD3/CD28 crosslinking is blocked 
by PJ34. CD8+ T-cells were immunomagnetically isolated from the combined MLN of five 
infected animals, labeled with CFSE and stimulated with αCD3/28 coated beads; 15μM PJ34 
was added where indicated. CFSE dilution was quantified as a measure of proliferation. 
Representative histograms as well as the averages of triplicate cultures are shown.  
 
 
 
2. Supplemental Methods:  
Lymphocyte proliferation assays and flow cytometry 
CD4+CD25- and CD8+ T-cells were immunomagnetically purified from single cell suspensions of 
spleens, mesenteric lymph nodes or stomach tissue (R&D Systems, Minneapolis, USA). Cells 
were labelled with 5μM carboxyfluorescein succinimidyl ester (CFSE) and stimulated with either 
anti-CD3/CD28-coated beads (Invitrogen) or PMA (50ng/ml) and ionomycin (0.5mg/ml) (both 
from Sigma). The CFSE dilution was assessed flow cytometrically. IFN-γ secretion was 
measured by ELISA (BD Biosciences, San Diego, CA, USA). IL-2 and IFN-γ expression was 
determined by real time RT-PCR using primers specified previously for IFN-γ (9) and using the 
following primers for IL-2: 5’-GCGCACCCACTTCAAGCT -3’; reverse: 5’-
CCTGCTTACAACACATAAGGC-3’. For the immunomagnetic isolation of dendritic cells, single 
cell MLN preparations were labeled with a biotinylated CD11c-specific antibody (clone HL3, BD 
Biosciences) followed by magnetic isolation with streptavidin-coated beads (R&D Systems). DC 
were pulsed for 16 h with 10μg/ml Helicobacter sonicate prior to co-culturing for 4 days with 
CD4+ T-cells. For staining of intracellular IFN-γ, cultures were stained for CD4 (clone RM4-5, 
eBioscience, San Diego, USA) and/or CD25 (clone PC-61.5, R&D Systems) prior to fixation, 
permabilization and IFN- staining XMG1.2, BD Biosciences). Poly(ADP-ribose) was detected 
using a polyclonal anti-PAR antibody (no. 551813, BD Biosciences). FACS analyses were 
performed on a Cyan9 instrument (Beckman Coulter).  
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Summary:            Helicobacter-associated chronic inflammation is a well known risk 
factor for gastric cancer development due to genotoxic byproducts 
secreted by inflammatory cells, e.g. reactive oxygen species by neutrophils 
and IFN-γ by immune cells and subsequent acquisition of tumor-promoting 
mutations. Helicobacter-induced carcinogenesis occurs in sequence of 
precancerous lesions which manifest histologically as atrophic gastritis, 
intestinal metaplasia and dysplasia. During this process, various genetic 
aberrations occur including mutations in TP53 and other guardians of the 
genome. In this study we report that Helicobacter infection of various cell 
lines leads to DNA double strand breaks (DSB) and DNA damage 
dependent signalling represented by 53BP1 and MDC1 foci formation. This 
process occurs in an infection dose-dependent manner, requires cell 
contact with live bacteria and is largely independent of Helicobacter-
induced reactive oxygen and the H. pylori virulence determinants VacA 
and the Cag pathogenicity island (CagPAI). We further show, that 
Helicobacter-associated DSB induction is reversible but requires prior 
bacterial killing. In conclusion, we provide evidence that Helicobacter 
infection directly contributes to gastric carcinogenesis by harming the host 
cellular DNA, providing a mechanistic explanation for the carcinogenic 
properties of this bacterial pathogen. 
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Abstract 
    Helicobacter-associated chronic inflammation is a well known risk factor for gastric 
cancer development. Helicobacter-induced carcinogenesis occurs in a sequence of 
precancerous lesions which manifest histologically as atrophic gastritis, intestinal metaplasia 
and dysplasia. During this process, various genetic aberrations occur including mutations in 
TP53, E-cadherin and the p16 tumor suppressor genes that support tumor development. In 
this study we report that Helicobacter infection of various cell lines and primary gastric 
epithelial cells leads to DNA double strand breaks (DSB) and activation of DNA damage 
signalling pathways indicated by 53BP1 and MDC1 foci formation. This process occurs in an 
infection dose-dependent manner, requires cell contact with live bacteria and is largely 
independent of Helicobacter-induced reactive oxygen species and the H. pylori virulence 
determinants VacA and the Cag pathogenicity island. We further show that Helicobacter-
associated DSB induction is reversible upon bacterial elimination. In conclusion, we provide 
evidence that Helicobacter infection directly contributes to gastric carcinogenesis by 
damaging the host DNA, providing an explanation for the carcinogenic properties of this 
bacterial pathogen. 
 
Introduction 
Chronic infection with the human bacterial pathogen Helicobacter pylori causes 
gastritis and peptic ulceration1 and increases the carriers’ risk of developing gastric cancer2, 3 
or gastric mucosa-associated lymphoid tissue (MALT) lymphoma.4, 5 The epidemiological 
association between H. pylori infection and gastric adenocarcinoma has been confirmed 
experimentally in rodent models using Mongolian gerbils6 and C57BL/6 mice.7-10 Both 
epidemiological and experimental data suggest that bacterial virulence determinants, host 
genetic factors and environmental influences determine whether or not Helicobacter-induced 
gastritis will progress to gastric cancer.9, 11 In particular, H. pylori‘s Cag pathogenicity island, 
certain pro-inflammatory cytokine promoter polymorphisms and a high salt diet have been 
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identified as co-factors affecting gastric cancer risk.2, 6, 7, 12 The Lauren classification 
describes two main histological types of gastric cancer,13 both of which have been linked to 
H. pylori infection.3, 14 The diffuse type is often diagnosed in younger patients, has a 
hereditary component and arises directly in the chronically inflamed stomach without the 
involvement of histologically defined precursor lesions.15 In contrast, the intestinal type 
mostly affects older individuals and is preceded by a sequence of precursor lesions such as 
chronic atrophic gastritis, epithelial hyperplasia, intestinal metaplasia and dysplasia, each of 
which have independently been linked to H. pylori infection and to an increased gastric 
cancer risk.14, 15 
We have shown previously that the atrophic gastritis, hyperplasia and metaplasia 
associated with H. felis or H. pylori infection in C57BL/6 mice is predominantly an 
immunopathological response to the infection driven by Th1-polarized, IFN-γ-producing CD4+ 
T-cells.16, 17 Mice lacking functional α+β+T-cells or the V(D)J recombination activation gene 
(Rag1-/-) are protected from precancerous lesions. Moreover, the adoptive transfer of 
CD4+CD25- effector T-cells from infected donors immunosuppressed recipients is sufficient 
to cause the development of precancerous lesions.16 Furthermore we have shown that 
pharmacological suppression of T-cell activation and Th1 differentiation in the draining 
mesenteric lymph nodes prevents and even reverses gastric preneoplasia, implying that 
targeting T-cells during the infectious process may prevent the progression to gastric 
cancer.17 
In addition to the pathological effects of the Helicobacter-specific immune response 
on the gastric mucosa, several lines of evidence indicate that the bacteria promote gastric 
carcinogenesis by jeopardizing the integrity and stability of their host’s genome in multiple 
ways.18  For example, TP53 mutations are detected in more than 60% of advanced gastric 
cancers, as well as in gastric cancer precursor lesions: intestinal metaplasia (38%) and 
gastric dysplasia (60%).19, 20 In addition, gastric cancers frequently show epigenetic silencing 
by promoter hypermethylation of genes involved in the maintenance of genetic stability: 
mismatch repair protein MLH-121, 22, E-cadherin23 and the p16 INK4A tumour suppressor 
gene.24 Furthermore, gastric carcinogenesis may be supported by the fact, that the 
Helicobacter-infection leads to the reversible down-regulation of the mismatch repair (MMR) 
proteins MLH1, PMS1, PMS2, MSH2 and MSH6.25,26 Furthermore, recent studies have 
reported elevated levels of 8-oxo-7,8 dihydroguanine (8-oxoG) in gastric cancer precursor 
lesions and gastric cancer.27,28 8-oxoG is an abundant DNA lesions causing G:C to T:A 
transversions that potentially lead to genome instability.29 Izotti et al. also provide evidence 
for increased oxygen-induced damage in cancerous tissue. They show that the homozygous 
Ser326Cys polymorphism in the 8-oxoguanosine-glycosylase1 (OGG1) gene, encoding the 
enzyme removing 8-oxo-dG from DNA, leads to a significant increase in the occurrence of 
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oxidative DNA damage in H.pylori infected patients.27  However, the exact mechanism of 
Helicobacter-induced carcinogenesis is poorly understood. 
To maintain genome integrity, a variety of redundant pathways alerts the cell to the 
presence of DNA damage and coordinates an appropriate response. 30 DSB-induced signal 
transduction pathways include the DNA-dependent protein kinase (DNA-PK) and 
phosphatidylinositol 3-kinase related kinases (PIKKs) – ataxia telangiectasia mutated (ATM) 
and ataxia telangiectasia and Rad3-related (ATR). The main DSB repair pathways are DNA 
non-homologous end joining (NHEJ) and homologous recombination (HR). The primary 
sensor of DSB is the MRE11-RAD50-NBS1 complex (MRN) which recruits ATM to the DSB, 
and is furthermore involved in the initiation of the feed back loop required for functional DNA 
damage repair (DDR).31 Activated ATM or DNAP-PK in turn phosphorylate H2A histone 
family member X (H2AX) (γH2AX).32 H2AX phosphorylation spans megabase-pair regions 
surrounding the lesion allowing their visualization as microscopically detectable foci.33  
γH2AX mediates the recruitment and retention of mediator proteins such as p53 binding 
protein-1 (53BP1), mediator of DNA damage checkpoint 1 (MDC1), breast cancer 1 (BRCA1) 
and the MRN complex at the site of DSB.34 The second DSB-induced pathway, the ATR-
dependent signal transduction pathway is activated in the process of DSB resection. In the 
absence of DSB, ATR is activated by single stranded regions of DNA that arise as a result of 
replication-fork stalling, or during repair of bulky lesions.35 
In the present study, we examined the possibility that H. pylori infection directly leads 
to host DNA damage. We found that DNA double strand breaks (DSB) accumulate in various 
cell lines and in primary gastric epithelial cells upon infection with H. pylori. The 
fragmentation of host nuclear DNA requires infection with live bacteria that are in direct 
contact with their host cells. However the DSB occurred independently of the two 
Helicobacter-virulence factors VacA and the Cag pathogenicity island (CagPAI). We further 
observed that Helicobacter-induced DNA fragmentation triggers aDNA damage signaling 
response such as the phosphorylation of histone H2AX (γH2AX), and the recruitment of 
53BP1 and MDC1 to sites of damage. Finally our data show that efficient DSB repair is only 
achieved upon bacterial eradication. The results obtained in this study indicate that 
Helicobacter drives tumorigenesis not only by causing an environment of chronic 
inflammation, but that Helicobacter per se possesses carcinogenic properties.  
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Results 
H. pylori infection of cultured cells induces double strand breaks (DSB) in nuclear 
DNA that trigger a DNA damage signaling 
To assess a possible effect of H. pylori infection on the integrity of host cellular DNA, 
we subjected infected cell lines to pulse field gel electrophoresis (PFGE). Hanada et al. 
adapted this technique to visualize fragmented DNA resulting from DSB.36 The 
electrophoresis conditions were set as such that intact, high molecular weight genomic DNA 
could be separated from fragmented DNA. DNA fragments with sizes ranging from 0.5 to 2.5 
megabases (Mb) are compacted in a single band which allows the detection and 
quantification of differentially sized and low abundant DNA fragments.36 Infection of gastric 
adenocarcinoma cells (AGS) with H. pylori for 6h resulted in dose-dependent fragmentation 
of host cell DNA (Figure 1A) that persisted for at least 48 hours post infection (Supplemental 
Figure 1).  The amount of H. pylori-induced DSB exceeded the DNA fragmentation resulting 
from 16h treatment with hydroxyurea (HU), a replication inhibitor that depletes cellular dNTP 
pools by blocking ribonucleotide reductase and was used here as a positive control (Figure 
1A). Similar results were obtained in infected non-cancerous immortalized gastric epithelial 
cells (IMPGE) (Supplemental Figure 1). The massive DSB caused by the infection lead to 
complete inhibition of cell proliferation after 16h of infection, shown by blocked incorporation 
of the thymidine analogue, EdU (Supplemental Figure 2B).37 We also tested the effect of 
Helicobacter infection in U2OS cells, an osteosarcoma cell line frequently used to study DNA 
damage signaling (Supplemental Figure 2A). Surprisingly, H. pylori adheres very well to 
these cells (Supplemental Figure 2C) rendering U2OS a suitable model to study H.pylori 
induced cellular DNA damage responses. 
To assess the cellular response of infected cells to DSB, we monitored the cellular 
distribution of the 53BP1 and MDC1 upon infection. After phosphorylation of the H2A histone 
(H2AX), 53BP1 localizes to DSB, which is one of the earliest events of DSB processing and 
required for the activation of the ATM kinase.38 Likewise, MDC1 is readily recruited to DSB 
where it binds to phosphorylated H2AX (γH2AX) and directs further recruitment of DNA 
damage response and repair factors to damaged chromatin.39 The localization of 53BP1 and 
MDC1 at DSB is microscopically evident as foci. Indeed, H.pylori infection of AGS cells 
(Figure 1B, left panel) and U2OS cells (Figure 1B, right panel) leads to increased numbers of 
53BP1 foci when compared to uninfected controls. All cells were positive for 53BP1 after 
10Gy γ-irradiation (IR), and H.pylori infection leads to a 2-3-fold increase of 53PB1-positive 
cells (≥ 5 foci/cell). To assess whether this effect is restricted to cancer cells or if DSB also 
occur in primary gastric epithelial cells, we generated single cell suspensions of murine 
gastric epithelial cells. The cells were cultured on collagen-coated cover slips for two days 
and infected with H. pylori for 6h. Indeed, the number of 53BP1 positive cells was increased 
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also in primary cells upon H.pylori infection (Figure 1C).  In addition to 53BP1 recruitment to 
DSB, we found that endogenous MDC1 also forms foci upon infection of U2OS cells (Figure 
1E).  The utility of U2OS cells as in vitro H. pylori infection model allowed us to confirm the 
above presented results but also to determine the kinetics of DSB foci formation in U2OS 
cells that stably express MDC1 as an eGFP fusion protein; eGFP-MDC1 was rapidly 
recruited to sites of DSB (Figure 1F) and the cells continued to show foci for at least 16h as 
determined by time lapse video microscopy (Supplemental Figure 1C). However, due to the 
long incubation and the motility of the cells, we could not determine if the same foci persisted 
or if the cell constantly acquired new DSB.  
To rule out that the “fragmented DNA” detected by PFGE is of bacterial origin, we 
performed Southern Blot analysis of a pulse field gel comparing the signals on the PFG 
derived from bacterial concentrates with the signal intensities obtained from infected AGS 
cells. For that, we used a probe hybridizing to the H. pylori ribosomal 16S subunit 
(Supplemental Figure 2A). The r16S Southern Blot revealed that concentrated bacterial 
pellets showed a strong signal. In contrast, the band derived from infected cells, did not show 
a positive r16S signal (Supplemental Figure 2A). The results confirm that the band observed 
on the PFG in Helicobacter-infected cells is indeed fragmented host DNA and not of bacterial 
origin.  
Since the process of apoptosis also leads to DNA fragmentation, we assessed the 
viability of the infected cells by immunoblotting for activated caspase-3 and cleaved PARP-1, 
as well as by flow cytometric analysis of hypodiploid cells and subG1 accumulation 
(Supplemental Figure 3B,C). No indication of apoptotic cell death was observed at 6, 16 and 
54h post infection confirming that the infected cells are viable throughout the time of infection 
(Supplemental Figure 3B,C and data not shown). In conclusion, the presented data suggest 
that H. pylori efficiently causes DSB in various primary and transformed epithelial cells that 
leads to prompt recruitment of DNA damage response proteins to Helicobacter-associated 
DSB. 
 
H. pylori-induced DSB depend on direct host-pathogen contact, but not on the Cag 
pathogenicity island and VacA virulence factors 
To test whether DSB induction is specific to live H. pylori, we compared the potential 
of live and ethanol-killed bacteria to induce DSB. Furthermore, we infected cells also with the 
E. coli DH10B strain at high multiplicity of initial infection. Only live H. pylori efficiently 
induced DSB in AGS cells, whereas dead bacteria and E. coli caused no discernible effect 
on DNA integrity(Figure 2A). DSB induction by H. pylori further required a direct interaction 
between the bacteria and their host cells, as separation of the bacteria by a transwell filter 
abolished DSB induction (Figure 2B). We also assessed the potential of preconditioned 
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medium to induce DSB in untreated cells. Supernatants obtained from 16h infected AGS 
cells did not induce DSB in untreated cells, thus excluding the possibility that host or 
bacterial secreted substances account for DSB induction (Figure 2B). Finally we sought to 
determine whether well-known H. pylori virulence factors such as the CagPAI or VacA 
contribute to DSB induction. Isogenic mutants of G27 lacking the entire pathogenicity island 
or the gene encoding VacA induced DSB and 53BP1 foci to a similar extent as wild type 
bacteria (Figure 2C,D), suggesting that neither VacA nor the PAI-encoded type IV secretion 
system of H. pylori is essential for DSB induction. In summary, H. pylori, but not E. coli 
DH10B infection induces DSB in a contact dependent, but VacA- and CagPAI-independent 
manner.  
 
Inhibition of ADP-ribosylation sensitizes cells to H. pylori-induced DSB 
We have shown earlier that H. pylori infection induces poly-ADP-ribosylation of host 
cellular proteins.40 Poly(ADP-ribose) polymerases (PARPs), are involved in the repair of 
various types of DNA damage41, 42  by recruiting DNA repair proteins to the site of damage or 
by facilitating the access of the repair machinery to damaged DNA.41,43 We have recently 
shown that PARP inhibitors such as PJ34 block H. pylori-induced PARP formation in vitro 
and prevent Helicobacter-associated gastric cancer precursor lesions in vivo.40 PAR 
synthesis induced by H. pylori infection in vitro is dependent almost exclusively on PARP1, 
with a minor contribution of PARP2.40 Both the formation of PAR and the induction of DSB 
are first detectable in infected cells between 3 and 6h p.i..40  To assess whether ADP-
ribosylation also plays a role in H.pylori associated DSB induction, we treated infected cell 
cultures with the small molecule inhibitor PJ34. Interestingly, PJ34 sensitized the cells to H. 
pylori-induced DSB at low multiplicities of infection (Figure 3B). This effect was further 
confirmed using other inhibitors of ADP-ribosylation (data not shown). The results suggest 
that PJ34 treatment possibly interferes with the ongoing DNA repair and thereby amplifies 
H.pylori induced DNA fragmentation at low MOIs.  
 
H. pylori-induced DSB occur largely independently of reactive oxygen and nitrogen 
species 
It has been postulated that Helicobacter-induced reactive oxygen species are 
important drivers of carcinogenesis. In line with this hypothesis, mutations detected in 
chronically H. pylori-infected patients are predominantly ‘AT to CG’ and ‘GC to TA’ type 
transversions, and serve as indicators of oxidative DNA damage.44 H. pylori induces reactive 
oxygen and nitrogen species (RONS) in AGS cells at MOIs which also trigger DSB (Figure 
4A). To determine whether H. pylori-associated DSB induction is dependent on RONS, we 
utilized three complementary approaches in which the production of RONS was minimized 
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by growth under hypoxic conditions, pharmacological scavenging of RONS, or the combined 
targeted deletion of the genes encoding inducible nitric oxide synthase (iNOS) and NADPH 
oxidase (NOX2). AGS cells grown for 6 hours at 1% oxygen acquired more, rather than less, 
DSB upon infection with H. pylori. This observation suggests that the reactive oxygen is not 
the main mediator of H. pylori-induced DSB (Figure 4B). Similarly, addition of the RONS 
scavenger N-acetyl-cysteine (NA) to infected cells enhanced H. pylori-induced DSB rather 
than prevented them (Figure 4C); this result was particularly compelling as the same 
scavenger concentrations efficiently reduced H2O2-induced DSB (Figure 4C). Finally, 
infection of primary gastric epithelial cells isolated from iNOS/NOX2-/- mice and grown as 
described above (Figure 1C), induced 53BP1 foci (Figure 4D) and DSB (Figure 4E) to a 
similar extent as infection of wild type primary gastric epithelial cells, suggesting that the 
RONS produced through the combined activity of both enzymes are not essential for DSB 
induction. In summary, the results suggest that the RONS produced by gastric epithelial cells 
upon H. pylori infection are not mechanistically involved in DSB induction despite a temporal 
correlation of RONS and DSB induction.     
 
The repair of H. pylori-induced DSB requires prior killing of H. pylori 
Our data suggest that Helicobacter-infected continuously damages its host cell DNA and 
induces the activation of DNA damage signaling pathways as long as the bacteria are 
present. To test whether the cells are capable of initiating DSB repair upon killing of the 
bacteria, we infected AGS cells for 6h prior to 2 days of bacterial eradication therapy (ET). 
The efficient induction of DSB was verified after 6h of infection, as well as after 54h of 
continuous infection (Figure 5A). ET resulted in the efficient repair of DSB as judged by the 
disappearance of the band corresponding to broken DNA in the PF gel (Figure 5A) as well as 
the loss of repair-related 53BP1 and MDC1 foci (Figure 5B), indicating that H. pylori-induced 
DSB can be repaired by the affected cells, but only after H. pylori is inactivated. 
 
Discussion 
We show here that H. pylori efficiently induces DNA double strand breaks in primary 
gastric epithelial cells and various cancer cell lines. DSB formation depends on viable 
bacteria and direct bacterial contact with the host cells, but is independent of the Cag 
pathogenicity island and VacA, and also largely independent of host cellular ROS and RNS 
production. H. pylori-induced DSB can be repaired efficiently by the cells, but only upon 
elimination of bacteria. This observation may indicate a continuous induction of DSB by the 
bacteria and a subsequently lagging DSB repair process.  
Very few reports are available on bacterially induced DNA damage of host cell DNA. 
Interestingly, of the few bacterial species suggested to possess genotoxic potential, all are 
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gastro-intestinal colonizers. Examples include E. coli which is commonly associated with 
gastrointestinal infections and Campylobacter jejuni, the most frequent bacterial cause of 
diarrhea in humans45 have been associated with DSB induction. Recently, it has been shown 
that E. coli expresses a so-called peptide–polyketide compound (colibactin) that is essential 
for the induction DSB and subsequent ATM/H2AX activation.46 The Cytolethal distending 
toxin (CDT) is another potential genotoxin found in Campylobacter jejuni and other bacteria 
(Thelestam, 2005) that is able to induce DSB in mammalian cells  by the DNase activity of a 
CDT subunit (CdtB).47 CDT is also expressed by Helicobacter hepaticus and other 
enteropathogenic bacteria. In murine H. hepaticus infection models, CDT is required for 
colonization,48 mimics inflammatory bowel disease in humans by triggering a chronic 
intestinal inflammation,49 and promotes hepatocellular dysplasia.50 However, there is no 
evidence for CDT-dependent DSB induction in H. hepaticus, and H. pylori does not encode 
for a CDT-like protein. We suspect that H. pylori derived nucleases may take over the role of 
the CDT-DNase activity.   
Furthermore we tested the effect of Helicobacter-induced reactive oxygen species on 
DSB induction. We show that DSB occurred also under low oxygen conditions and also in 
primary epithelial cells deficient for iNOS/NOX-2. The nitric oxide synthase (iNOS) and 
NADPH oxidase (NOX2) are important mediators of the pro-infalammatory response, 
microbial elimination and cancer development.51, 52 Thus, inhibitors of those enzymes have 
been proposed for cancer therapy.53 However, our results suggest that Helicobacter-induced 
ROS are not the only cause for DSB in the host cell DNA.  
Quite surprisingly, we find that live bacteria not only induce DSB, but that the DSB 
persist as observed by PFGE and activation of DNA-damage signaling proteins. This 
observation may be explained in two different ways. It is possible, that the DNA repair 
machinery is either not functioning or not efficient enough to continuously repair newly 
established DSB.  A second explanation includes that the Helicobacter caused arrest of cell 
proliferation may result in an impaired efficiency to synthesize DNA repair proteins required 
for DSB resolution.  This finding extends previous reports showing that H. pylori down-
regulates the components of the host’s mismatch repair machinery, MSH2, MSH6, MLH1 
and PMS2, both at the protein and RNA levels.54 Follow-up work by Machado et al. showed 
that this down-regulation indeed results in a decreased repair efficiency of infected compared 
to uninfected AGS cell extracts of 2bp loop heteroduplex substrates.55 The same authors 
also reported increased genetic instability of three loci carrying CA repeats in mice 
chronically infected with H. pylori;55 this finding may be relevant as microsatellite instability is 
a common feature of sporadic gastric cancer 56 and MMR levels tend to recover in patients 
treated for the infection by antibiotic eradication therapy 25. Similarly, certain components of 
the BER machinery, such as APE2, were found to be downregulated upon infection of gastric 
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epithelial cells55 and this may correlate with an increased susceptibility of BER-deficient mice 
lacking the enzyme alkyladenine DNA glycosylase to Helicobacter-induced gastric cancer 
precursor lesions.57 Whether the persistence of DSB benefits the bacteria in terms of 
colonization or persistence remains to be clarified. Important to note is that H.pylori-induced 
DSB only occur at very high infection doses and even then, only approximately thirty percent 
of the cells show signs of DSB-induced DNA damage signaling.  
However, when bacteria are eradicated, the cells are able to repair the DSB caused 
by the infection. Interestingly, this process requires 48 hours to be observed by PFGE, 
suggesting that Helicobacter-induced DSB are of rather high complexity or that intracellular 
bacterial factors have a long half life. The above presented data suggest that Helicobacter-
induced DSB can be resolved by the host DNA repair machinery, however.  
In conclusion, we propose that persistent H. pylori infection causes DSB induction in 
the infected host cells, thereby contributing to the genetic instability and frequent 
chromosomal aberrations and cancer development.  
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Figures 1-5 and Supplemental Figures 1-3 
 
Figure 1 
 
Figure 1. H. pylori infection of cultured cells induces DNA double strand breaks (DSB) 
followed by the activation of DNA damage response pathways 
A, AGS cells were infected with H. pylori for 6h at multiplicities of infection (MOI) of 10 and 
200. 5mM Hydroxyurea (HU) treatment for 16h served as positive control. DNA integrity was 
assessed by pulse field gel electrophoresis (PFGE). Fragmented DNA accumulates in the 
band comprising fragments from 0.5-2.5Mb. B, AGS cells were infected with H. pylori for 6h 
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and stained for 53BP1, an early marker of DSB; Cells irradiated with 10Gy served as positive 
control. In C, explanted primary gastric epithelial cells from wild-type C57BL/6 mice and in 
U2OS cells (D) were infected for 6h with H. pylori and immunostained for 53BP1; Cells 
irradiated with 10Gy served as positive control. Cells with more than 5 foci per nucleus were 
graded as positive and are represented in percentages of total cells counted 
(53BP1+/number of DAPI+ cells). In D, AGS cells were infected with H. pylori for 6h and 
stained for MDC1. E, eGPF-MDC1-expressing U2OS cells were infected and eGFP-MDC1 
foci formation was quantified. 
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Figure 2  
 
Figure 2:  DSB are H. pylori-specific and depend on living bacteria and direct bacterial 
contact with the host cells.  
A, AGS cell were co-cultured with live H. pylori (MOI 200), dead bacteria (MOI 200) or E. coli 
DH10B (MOI 1000) or left uninfected. DNA fragmentation was assessed by PFGE. B, DNA 
fragmentation was assessed by PFGE of: AGS cells that were left uninfected or were 
infected with H. pylori for 6h at MOI 200 (lanes 1-3). In lanes 4 and 5, cells were treated with 
sterile-filtered cell culture supernatants obtained from 16h control- or H. pylori-infected (MOI 
200) AGS cells.  In lanes 6-8, trans-well membranes were used to physically separate AGS 
cells from a concentrated over-night H. pylori culture supernatant (lane 6), or living bacteria 
at MOIs 10 (lane 7) and 200 (lane 8). In C+D, AGS cells were infected with wild-type H. pylori 
or isogenic mutants lacking the Cag pathogenicity island (ΔPAI) or the vacuolating cytotoxin 
A (ΔvacA). DNA fragmentation was assessed by PFGE (C) and 53BP1 immunostainings (D). 
Cells with more than 5 foci per nucleus were graded as positive and are represented in % of 
total cells counted (53BP1+/number of DAPI+ cells).  
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Figure 3 
 
 
 
Figure 3. Inhibition of ADP-ribosylation leads to hypersensitivity of infected cells to 
DSB 
A, AGS cells were left untreated, were infected with H. pylori at an MOI 200 or were infected 
and treated with 15μM PJ34. PJ34 treatment started either at the time of infection (24h) or 1h 
prior to harvesting (1h). Immunoblots against PAR and PARP1 are shown. B, AGS cells were 
infected with H. pylori at the indicated MOIs for 6h or were infected and treated with 15μM 
PJ34 during the entire time of the infection. DNA fragmentation upon infection is visualized 
by PFGE.  
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Figure 4 
 
Figure 4. H. pylori-associated DSB occur largely independently of reactive oxygen 
species.  
A, AGS cells were left untreated, were treated with 5mM N-acetyl-cysteine (NA), a radical 
scavenger and/or were infected with H.pylori at MOIs 10 and 200. The relative induction of 
reactive oxygen species (ROS) was assessed by oxidation of 2,7-Dichlorofluorescein 
Diacetate (DCF-DA) to fluorescent  DCF (emission at 530nm) and was quantified in a 
microplate reader.  B, AGS cells were infected with H. pylori for 6h at the indicated MOIs at 
20% (normoxia) and 1% (hypoxia) oxygen in a gas-controlled glove box. DNA fragmentation 
is visualized by PFGE. C, AGS cells were left untreated, were treated with 5mM NA and/or 
were infected with H.pylori at MOIs 10 and 200. Cells treated with 50 and 200mM H2O2 
served as positive controls. DNA fragmentation was assessed by PFGE. D, AGS cells were 
infected at the indicated MOIs for 6h. In addition, NA was added at 1 and 5mM where 
indicated. Hydrogen peroxide (H2O2) treatment for one hour with or without NA treatment 
served as positive control. DNA fragmentation is visualized by PFGE. D, Primary gastric 
epithelial cells explanted from wild-type C57BL/6 mice and mice lacking iNOS (iNOS-/-) and 
NADPH peroxidase 2 (NOX2-/-) (iNOS-/- NOX2-/-) were infected with H. pylori for 6h. Cells 
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were immunostained with 53BP1. Cells with more than 5 foci per nucleus were graded as 
positive and are represented in % of total cells counted (53BP1+/number of DAPI+ cells). E, 
Primary gastric epithelial cells explanted from iNOS-/- /NOX2-/- mice were infected for 6h with 
H. pylori at the indicated MOI. DNA fragmentation upon infection is visualized by PFGE.  
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Figure 5 
 
 
Figure 5.  H. pylori-induced breaks are repaired only after bacterial killing 
A, AGS cell were infected with H. pylori at MOI 200 for 6h. Cells were washed and the 
remaining bacteria were killed with 4.5μg/mL metronidazole, 10μg/mL tetracycline 
hydrochloride and 1.2μg/mL bismuth subcitrate (eradication therapy, ET) and grown in full 
medium containing penicillin/streptomycin for 48 hours to allow DNA repair to occur. On the 
second day, ET treatment was repeated. After 54h hours of infection and/or 48h ET 
treatment, cells were harvested and subjected to PFGE. B shows 53BP1 immunostaining of 
the cells described in A.  Cells with more than 5 foci per nucleus were graded as positive and 
are represented in % of total cells counted (53BP1+/number of DAPI+ cells).  
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Supplemental Figure 1 
 
Supplemental Figure 1: H. pylori induces persistent DSB also in primary immortalized 
gastric epithelial cells  
A, Immortalized gastric epithelial cells (IMPGE) and AGS cells were infected for 16 and 48 
hours with H. pylori at the indicated MOIs. 16h 5mM Hydroxyurea (HU) treatment served as 
positive control. DNA fragmentation was visualized by PFGE.  
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Supplemental Figure 2 
 
 
Supplemental Figure 2: U2OS cells can be used as a model for H. pylori-induced DSB 
A, U2OS (osteosarcoma) cells were infected with H. pylori for 6h at the indicated MOIs. DNA 
fragmentation was assessed by PFGE. B, U2OS cells were infected with H.pylori for 16h. 
Proliferating cells were pulse-labelled with EdU for 20min. EdU positive cells were quantified 
by FACS. C, U2OS cells were infected with H. pylori for 6h. Immunofluorescence images 
showing H. pylori (red), Phalloidin (green) and nuclei (blue) are presented. D, U2OS-eGFP-
MDC1 cells were infected with H. pylori and MDC1-foci formation was monitored over a 
period of 16h. Pictures of single cells were taken at 1h, 6h and 16h post infection.  
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Supplemental Figure 3 
 
Supplemental Figure 3: Fragmented DNA indicates DSB and neither corresponds to 
bacterial DNA nor to apoptotic DNA damage 
A, AGS cells were infected with H. pylori for 6h at the indicated MOIs. In addition, bacterial 
pellets corresponding to MOI 200, 20000 and 10000 were loaded. Fragmented DNA and 
bacterial DNA were visualized by PFGE (upper panel). The DNA was transferred to a Zeta 
membrane, UV-cross-linked and probed for H. pylori using a dCTP α32-P labeled 16S rRNA 
probe (lower panel). B, AGS cells were infected with H. pylori for 16h or were treated for 6 
and 16h with 5μM staurosporine, a global tyrosine kinase inhibitor known to induce 
apoptosis. Immunoblots are shown for the cleavage products of PARP1 and Caspase-3. 
Tubulin served as loading control. C, AGS cells were infected with H. pylori for 16 and 54h. 
Cell cycle distribution was assessed by propidium iodide (PI) staining. The percentage of 
cells in the respective cell cycle phases is indicated.  
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Materials and Methods 
Mice, bacteria, cell lines and infections 
C57BL/6, (Charles River Laboratories, Sulzfeld, Germany) and iNOS-/-/NOX2-/- mice were 
used to generate primary gastric epithelial cell cultures. H. pylori  was grown on solid 
medium on horse blood agar containing 4% Columbia agar base (Oxoid; Basingstoke), 5% 
defibrinated horse blood (HemoStatLabs), 0.2% β-cyclodextrin, 5μg/ml trimethoprim, 8 μg/ml 
amphotericin B, 10μg/ml vancomycin, 5μg/ml cefsulodin, and 2.5 U/ml polymyxin B sulfate 
(all from Sigma-Aldrich) at 37°C for 2 days under microaerophilic conditions. For liquid 
culture, H. pylori was grown in Brucella broth (Difco) containing 10% FBS (Life Technologies) 
with shaking in a microaerobic atmosphere at 37°C. AGS cells (ATCC CRL 1739; human 
gastric adenocarcinoma epithelial cell line) and U2OS cells and U2OS-EGF-MDC1 and 
primary immortalized gastric epithelial cells (IMPGE) (Sayi , 2009) and were infected with H. 
pylori strains G27 or isogenic mutants lacking the Cag pathogenicity island (PAI), G27ΔPAI 58 
or the vacuolating toxinA (VacA) G27ΔVacA 59 for 6h to 54 hours with indicated multiplicities 
of infection (MOI). Primary gastric epithelial cells were generated as follows: stomach was 
excised, washed in PBS and digested for 7min in 20mM ETDA/Hanks Balanced Salt 
Solution. Stomach was grinded between two glass plates and cell suspension seeded into 
rat-tail collagen (50 µg/ml; C3867 Sigma) coated cell culture dishes in 1:1 Ham’s F12/DMEM 
medium containing Penicillin/Streptomycin and FBS (Life Technologies).  The DH10B E.coli 
strain was used at MOI 1000. Experiments under hypoxic conditions (1% oxygen) were 
performed in a gas-controlled glove box (InVivO2 400, Ruskinn Technologies, Leeds, UK).  
 
Immunostainings and Immunoblots 
For immunostainings, cells were fixed in methanol and stained with 53BP1 (H300: sc-22760, 
Santa Cruz; 1/500), MDC1 (3835; 1/200; courtesy of PD Dr. M. Stucki, Zurich)60, γH2AX 
(Upstate: 05-636; 1/500), anti-Helicobacter Pylori (polyclonal; Dako; 1/200), Phalloidin-Alexa 
488 (Molecular Probes) and mounted with vectashield (Vector Laboratories). Cells were 
imaged in a Leica Leitz DM RB microscope equipped with a Leica DFC 360 FX camera. 
Images were taken at 60 to 100x magnification using the Leica Application Suite 3.3.0 
software. At least 100 nuclei were assessed and graded positive if more than 5 foci were 
detected per nucleus. PARP1 and PAR expression was analyzed by immunoblotting of cell 
extracts using rabbit anti-PARP1antibody H-250 (Santa Cruz) and anti-PAR antibody (no. 
551813, BD Biosciences) respectively. As markers of apoptosis, PARP1 (sc7150) and 
Caspase-3 were used.  
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si/shRNAs 
The following proprietary Qiagen siRNAs were used: PARP1 mouse: Mm_Parp1_4 HP 
siRNA (NM_007415); PARP1 human Hs_PARP1_6 (NM_001618); PARP2 mous: 
Mm_Parp2_6 HP siRNA (NM_009632); PARP2 human: Hs_PARP2_6 HP (NM_001042618, 
NM_005484) E 
 
Detection of ROS with 2,7 Dichlorofluorescein Diacetate 
Cells were washed and 5μM 2,7 Dichlorofluorescein Diacetate (DCF-DA, Sigma) in PBS was 
added to the cells and incubated for 30min at 37°C protected from light. Oxidation-induced 
de-esterified fluorescent DCF was detected at 530nm.  
 
Cell cycle analysis 
For cell cycle analysis, cells were fixed in 70%ethanol followed by a 100ug/ml RNase 
treatment and staining with 25ug/ml propidium iodide. Cell-cycle distribution was measured 
by flow cytometry in a Cyan9 instrument (Beckman Coulter) and analyzed using the Summit 
Software (Beckman Coulter).  
 
Transwell-Assay, pharmacologic treatments with PJ34 and scavengers 
0.4um cell culture inserts (Falcon 353493) were used to separate bacteria or supernatants 
from cells. PJ34 was added as PJ34 (N-(6-Oxo-5,6-dihydro-phenanthridin-2- 
yl)-N,N-dimethylacetamide, Enzo Life Sciences) was used at 15uM in cell culture and 
Hydroxy Urea (H8627, Sigma) was used at 5mM, N-acetyl cysteine (Sigma) was used at 1 
and 5mM and staurosporine at 5uM (S5921, Sigma). Bacteria were killed with 
penicillin/streptomycin combined with  with 4.5 mg/mL metronidazole, 10 mg/mL tetracycline 
hydrochloride (both Sigma-Aldrich), and 1.2 mg/mL bismuth subcitrate (Park-Davis). 
 
Pulse Field Gel Electrophoresis 
This protocol was  adapted from Hanada et al., 2007.36 Briefly, cells were infected with 
H.pylori, trypsinized and immobilized in a 2% agarose plug (5x105 cells/plug). Plugs were 
incubated in lysis buffer (100 mM EDTA, 1% (w/v) sodium lauryl sarcosyne, 0.2% (w/v) 
sodium deoxycholate, 1 mg ml–1 proteinase K) at 37 °C for 48 h and then washed them in 
TE buffer (10 mM Tris-HCl (pH 8.0), 100 mM EDTA) before loading them onto an 0.9% 
agarose gel. Electrophoresis was performed for 23 h at 14°C in 250 mM Tris-borate with 
EDTA (TBE) using a Biometra Rotaphor apparatus with the following parameters: voltage 
180–120 V log; angle from 120° to 110° linear; interval 30 s to 5 s log. Gel was stained with 
EtBr and analyzed using an Alpha Innotech Imager.  
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Southern Blot analysis 
Anti-Helicobacter spp.-specific16S probe was generated using primers previously published 
by Harper et al.: C97 forward: GCTATGACGGGTATCC; C05 reverse: 
ACTTCACCCCAGTCGCTG resulting in a 1200 bp fragment.61 Pulse Field Gel 
electrophoresis was performed as described above. Gel was stained and UV cross-linked  
with 150mJ, probes transferred to Zeta-Probe GT nylon membrane for 12hours and probed 
with dCTP α32-P labbleled 16S probe (Roche #11004760001) followed by exposure in a 
Typhoon 9400 PhosphoImager.   
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Summary:          This manuscript provides evidence that excessive Helicobacter-
induced Th-1 driven gastric immunopathology is restricted by cooperating 
‘regulatory’ B- and T-cells. Using mouse strains with defined defects in 
either of the two populations, we found that B-cells, upon their MyD88-
dependent activation by Helicobacter TLR-2 ligands, are able to efficiently 
induce IL-10-dependent suppressive activity in conventional CD4+ T-cells, 
converting these into T regulatory-1 (Tr-1)-like cells. The cooperative 
activity of ‘regulatory’ B-cells and Tr-1 cells prevents the development of 
gastric premalignant lesions, thus providing evidence that B-cells can have 
important immunomodulatory function during immune responses to 
persistent bacterial infections. 
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4. Discussion   
  Gastric cancer is among the leading causes of cancer-related deaths worldwide due 
in large part to the inefficient diagnosis and therapy of premalignant lesions.262 In this study 
we provide strong evidence that targeting the CD4+ T-cell mediated immune response by 
inhibiting COX-2 and PARP enzymatic activities prevents and sustainably cures 
Helicobacter-induced gastric pre-neoplastic lesions in the murine stomach. We show that the 
protective effect is procured by blocking the effector functions of pathogenic CD4+IFNγ+ T-
cells. Furthermore we show that Helicobacter infection leads to DNA fragmentation and 
triggers DNA damage signal transduction pathways characteristic of DNA double strand 
breaks (DSB), suggesting a direct role of Helicobacter in cancer development.  
  In the following section, the importance of pathogenic CD4+CD25- effector T-cells will 
be discussed in the light of recent findings from our and other laboratories on the effects of 
vaccination and tolerance induction on gastric preneoplastic pathology. This section will be 
followed by an illustraton of the results obtained in this study and put into perspective with 
known concepts combined with future prospects and therapeutic implications.  
 
4.1  Pathogenic CD4+CD25- T-cells Mediate Helicobacter-Associated Disease 
in the CD57BL/6 Mouse Model 
Patient data as well as mouse and gerbil models have impressively shown that 
Helicobacter-induced chronic inflammation is an essential prerequisite for developing gastric 
cancer.36, 57, 58, 70, 71, 263 Infection of C57BL/6 mice with Helicobacter pylori and the close 
relative Helicobacter felis results in a strong pro-inflammatory and adaptive immune 
response that is reminiscent of the human setting.17, 264  
  The Helicobacter-induced inflammation is mediated by T helper (Th) cells. Th 
responses have either predominant Th1 (mainly cell mediated) or Th2 (mainly antibody 
dependent; humoral) character. Typical Th1 cytokines are IFN-γ, TNF-α, IL-12 and IL-2; Th2 
cells predominantly secrete IL-4 and IL-5.  Helicobacter infection triggers both  responses, 
although gastric mucosal cytokine profiles show an over-representation of Th1 type 
cytokines.17, 265, 266 Those cells are closely associated with the development of Helicobacter-
induced gastric pathogenesis.  
 As a counter balance to inflammation-promoting effector T-cells, immunosuppressive 
regulatory T-cells (Treg) play a crucial role during Helicobacter infection. Tregs mediate their 
regulatory effects by secreting the immunosuppressive cytokines IL-10 and TGFβ.267 Tregs 
function to avoid exaggerated immune responses to the infection, but thereby also facilitate a 
state of chronic infection. The importance of Tregs is reflected by our and other laboratories’ 
data showing that Helicobacter induces more severe pre-neoplastic lesions and  fails to 
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persistently colonize IL-10-deficient mice or mice lacking CD4+CD25+ Treg268 or 
CD25+FOXP3+ Treg.269 
  Our hypothesis that Helicobacter-associated disease is indeed the result of an 
immunopathological response of the gastric mucosa is corroborated by the fact that 
Helicobacter-infected mice lacking cellular immune responses, e.g. RAG-1-/- (B- and T-cell-
deficient) or TCR-β-/- (T cell-deficient) mice, are highly colonized but do not develop gastric 
pathology.270 This phenotype can be rescued by the adoptive transfer of CD4+IFN-γ+ effector 
T-cells, which results in severe gastritis in H. pylori-infected recipients. Conversely, co-
transfer of Tregs antagonizes the T-effector functions and blocks the development of gastric 
cancer precursors.271, 272  
IFN-γ is an important mediator of inflammatory diseases and is critically involved in 
anti-microbial responses. This is underscored by observations that IFN-γ deficient/inhibited 
mice develop less severe symptoms of inflammation and epithelial atrophy.18, 273-275 We have 
shown previously that IFN-γ expression significantly correlates with the appearance of 
epithelial atrophy and hyperplasia.18 Furthermore, we noted an inverse relationship between 
IFN-γ expression and the number of colonizing bacteria in the stomach. Interestingly and in 
accordance with these results , IFN-γ-/- fail to reduce the bacterial burden and can not resolve 
bacterial colonization as efficiently as wild-type mice in a vaccination model.18 The effect of 
IFN- γ on bacterial reduction is most likely of indirect nature, since IFN-γ has been shown to 
potentiate the leukocyte/macrophage-mediated uptake and killing of various bacterial 
strains.276-278  
We could further demonstrate that CD4+ T-cells are the prime source of pathogenic 
IFN-γ in our model, since adoptive transfer of CD4+CD25- from IFN-γ-/- mice did not cause 
epithelial pathology in Helicobacter-infected immunodeficient mice (TCRβ-/- and Rag2-/-).18 
Our data support a dual role of IFN-γ during Helicobacter infection. As a pro-inflammatory 
cytokine it fights bacterial colonization, but its prolonged expression is also strongly 
correlated with increased severity of epithelial atrophy in infected mice. A role of IFN-γ in the 
progression of pre-neoplastic conditions is supported by the observation that recombinant 
IFN-γ treatment of gastric epithelial cells results in mucous neck cell hypertrophy.75  Another 
study observed that a rare progenitor cell type of the antral gland that possesses multilineage 
potential multiplies in response to IFN-γ and thus may contribute to preneoplasia.279  
Another important cytokine during Helicobacter infection is the Th1 suppressing 
interleukin IL-10. A mentioned above, IL-10 is secreted by Treg, but also other immune cells 
such as dentritic cells (DCs).280 Helicobacter infection of IL-10-deficient mice leads to rapid 
induction of gastric preneoplasia and efficient bacterial clearance. Data generated in our lab 
further show that IL-10 proficiency is important for the regulatory function of T-cells, since 
mice with a CD4+ T-cell specific deletion of the il-10 gene display accelerated development of 
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epithelial pathology and lower bacterial colonization as compared to IL-10-proficient control 
mice.272 In a very recent study conducted in our lab, we show that a Treg-biased 
Treg/Teffector ratio confers peripheral immune tolerance in neonatally Helicobacter-infected 
mice that is characterized by high bacterial colonization but absence of epithelial pathology 
compared to mice that were infected as adults.281  Neonatally infected mice fail to upregulate 
Th1 cytokines (e.g. IFN-γ, IFN-γ inducible protein 10 (IP10) and MIP2) despite normal T-
effector development. However, if Treg are depleted by various means or are not able to 
respond to TGFβ signalling, neonatally infected mice fail to mount and/or maintain 
tolerance.281 IL-10-deficient mice can be tolerized initially, but do not stably maintain 
neonatally-induced tolerance to Helicobacter infection.281 
CD4+ T-cells are not restricted to hyperplastic and metaplastic lesions preceding 
gastric adenocarcinoma but also play important roles in the development and maintenance of 
another type of Helicobacter-associated gastric malignancy, i.e. mucosa-associated 
lymphoid tissue (MALT) lymphoma. We have recently shown that tumor-derived CD4+ T-cells 
strongly stimulate tumor B-cell proliferation, supporting their essential contribution to MALT 
lymphomagenesis.282 The importance of T-cells in inducing and/or maintaining MALT 
lymphomas is underlined by the observation that CD4+ T-cell and CD4+CD25+ Treg depletion 
led to tumor regression.282 In addition, we observed CCL17/22-dependent recruitment of 
highly suppressive Treg (CD4+CD25+FOXP3+) to these B-cell tumors. This implies an 
essential role of Helicobacter-induced T cells in MALT lymphomagenesis and its 
maintenance. This observation together with the beneficial effect of bacterial eradication in 
MALT lymphoma highlights the antigen dependency of this B-cell malignancy.282 In other 
words, effector and regulatory CD4+ T-cells regulate not only the intestinal type of gastric 
cancer initiation and progression, but are also master regulators of MALT lymphomagenesis. 
Targeting this cell population at early stages of gastric carcinogenesis may offer the 
possibility to treat and prevent progression from benign gastric cancer precursors to 
malignant lesions.  
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4.2  Activation of COX-2/PGE2-Dependent Pathways Prevents and Cures 
Helicobacter-induced Gastric Preneoplastic Lesions 
COX-2/PGE2-dependent pathways play central roles in the host’s response to 
inflammatory stimuli and critically shape cellular immune responses.1 Moreover, COX-2 is 
also implicated in malignant transformation of cells by promoting proliferation, migration and 
invasion and by inhibiting apoptosis.283 We provide experimental evidence that COX-2/PGE2 
dependent signalling plays an essential immunosuppressive role during early stages of 
Helicobacter-associated disease by inhibiting pathogenic Th1 immune responses. We show 
that activation of this pathway by administration of exogenous, synthetic PGE2 prevents, and 
COX-2 inhibition exacerbates, Helicobacter-induced atrophic gastritis, epithelial hyperplasia 
and metaplasia.  Data obtained from in vitro studies strongly suggest that PGE2 exerts an 
immunosuppressive effect on T-cells, especially CD4+IFN-y+ cells, which fail to migrate to the 
stomach and to prime other T-cells in the mesenteric lymph nodes. PGE2 treatment of anti-
CD3/28 stimulated T cells further resulted in a complete block of IL-2 and IFN-γ expression 
and thus proliferation, and inhibited up-regulation of the high-affinity IL-2 receptor α chain.   
The contribution of Helicobacter infection to gastric cancer development is a proven 
concept and bacterial eradication therapy (ET) has been associated with beneficial effects, 
for example in patients with gastric atrophy.262 However, increasing recent evidence 
contradicts the efficacy of ET in the reversal of intestinal metaplasia and the prevention of 
cancer progression,262, 284, 285 and highlights the need for alternative treatment options. PGE2 
treatment may constitute a suitable new therapeutic alternative to prevent and reverse 
Helicobacter-induced pre-existing lesions.  
We and others show that Helicobacter infection leads to up-regulated COX-2 and 
PGE2 expression in infected cell lines and in the stomach of infected mice.88, 118 However, the 
role of COX-2/PGE2 signalling in precancerous lesions has only poorly been described to 
date. Therefore we assessed the effects of inhibition of COX-2 enzymatic activity during 
H.felis infection using the COX-2 inhibitor Celecoxib. COX-2 inhibitors have been known to 
efficiently prevent the occurrence of sporadic colon cancer and other cancers of the 
gastrointestinal tract (GI) for some decades5, 139, 140, 143 by abolishing the immunosuppressive 
role of PGE2 and thereby rendering the tumor accessible to the host’s immune defence.135, 286  
However, COX-2 inhibition during early stages of inflammation-induced maligancies 
shows inverse effects. COX-2 inhibition at very early time points of infection led to 
significantly aggravated inflammation and epithelial atrophy in treated compared to untreated 
mice. In accordance with this observation, activation of COX-2 dependent signalling by 
exogenous PGE2 treatment during infection resulted in abrogated inflammation and absence 
of epithelial atrophy. This notion suggests that the absence of PGE2’s immunosuppressive 
function during acute inflammation leads to uncontrolled immune cell proliferation and 
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accelerated development of Helicobacter associated epithelial atrophy. Our results are 
supported by various previous studies reporting exacerbated gastritis in H. pylori-infected 
rodents under conditions of COX inhibition or deletion of COX genes.82, 287-290 Furthermore, 
an experimental 45-day treatment of Helicobacter-infected individuals with aspirin, a non-
steroidal anti-inflammatory drug (NSAID) and unspecific COX inhibitor, resulted in 
significantly elevated gastric epithelial atrophy compared to uninfected counterparts.291 
However, conventional NSAIDs target all COX isoforms and are known to cause adverse 
gastrointestinal and renal complications that occur irrespective of Helicobacter infection.292  
The COXibs, a new generation of anti-inflammatory drugs that specifically target 
COX-2 have shown significantly less gastrotoxicity in clinical trials than conventional 
NSAIDs. Several of these new compounds later had to be withdrawn from the market due to 
increased cardiovascular toxicity observed in clinical trials with refecoxib and celecoxib.293, 294 
Thus, the chemopreventive usage of COXibs is questionable, and further down-stream 
targets probably constitute safer target candidates.295  
In this study we show that COX-2 inhibition results in two inversely related effects in 
the context of Helicobacter-associated carcinogenesis. At initial stages of the infection, when 
superficial and atrophic gastritis are the predominant precancerous lesions, the inhibition of 
COX-2 signalling results in the block of COX-2/PGE2-mediated immunosuppressive and thus 
protective effects on the gastric mucosa. Impaired COX-2/PGE2 functions thus lead to an 
uncontrolled pro-inflammatory response and hence more severe disease symptoms. By 
contrast, abrogated immunosuppression in a tumor restores a tumor-specific immune 
response and subsequent  tumor regression.1, 142 It would be interesting to test in our model if 
COX-2 inhibtion supports cancer progression if administered once precancerous lesions 
have formed.  
Strikingly and in accordance with the above presented data, we have proven that 
exogenous PGE2 has beneficial effects in infected mice.  We could show that PGE2 
treatment not only prevented Helicobacter-induced development of atrophic gastritis but also 
therapeutically reversed pre-existing precancerous lesions. This effect was accompanied by 
reduced numbers of proliferating (hyperplastic) cells in infected mice and resulted in restored 
mucosal architecture. We further provide evidence that PGE2 mediates its effect on CD4+ T-
cells by the transcriptional suppression of IL-2 and its receptor IL-2Rα. IL-2Rα is expressed 
upon initial encounter of T cells with a specific antigen resulting in IL-2 expression and later 
upregulation of IL-2Rβ and γ, forming the high-affinity trimeric IL-2R. Activated T cells 
proliferate rapidly upon IL-2 stimulation, which also acts as a survival factor. Thus, removal of 
IL-2 leads to T cell anergy and cell death.296  This notion not only explains the prophylactic 
effect of PGE2 treatment but also the therapeutic effect we observe with PGE2.  
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We further confirmed this hypothesis by co-administering PGE2 with recombinant IL-2 
(rIL-2) during the infection. Indeed, rIL-2 neutralized the beneficial effects of PGE2 on the 
development of Helicobacter-associated epithelial atrophy, further underlining the importance 
of IL-2-driven pathogenic T cell responses in our model. Interesting to note in this context is 
the fact that the immunosuppressive effect of PGE2 on CD4+ T-cells was maintained even 
after explantation from in vivo treated mice. We found that CD4+ T-cells from in vivo PGE2 
treated mice proliferated less upon anti-CD3/28 stimulation than T-cells derived from 
untreated mice. Furthermore, PGE2 treatment of anti-CD3/28 stimulated CD4+ and CD8+ T-
cells completely abolished proliferation and cytokine secretion. These results suggest that 
PGE2 treatment interferes with antigen-induced T-cell activation and thereby renders T-cells 
unresponsive to Helicobacter infection.   
Our data support a model in which PGE2 directly inhibits the induction or maintenance 
of the T-effector mediated immune response towards the infection. Previous reports have 
suggested that tumor-derived PGE2 induced the activity of regulatory T-cell (Treg) 
populations by upregulating FOXP3, a Treg-specific transcription factor.297 Mahic et al. 
showed that in vitro-induced Treg themselves produce PGE2 and are able to suppress 
effector T-cell functions.128 We tested this hypothesis but observed only a marginally 
increased regulatory activity of Tregs. This question was addressed by co-culturing various 
ratios of Treg and Teffectors in the presence of anti-CD3/28, in a setting in which Tregs were 
pre-treated with PGE2. PGE2-pretreated Treg showed a slightly increased potential to 
suppress Teffector proliferation and IFN-γ secretion. Based on these results, we exclude a 
major contribution of PGE2-activated Treg in our model.  
Data obtained in our lab showed earlier that CD4+ IFN-γ+ T cells are key mediators of 
Helicobacter-associated disease, including MALT lymphoma,282 neonatal Helicobacter-
tolerance and of vaccine-induced protection against H. pylori challenge infection.18 Here we 
further extend this model and provide evidence that PGE2’s protective effect is due to 
inhibited CD4+IFN-γ+ mediated responses, indirectly by inhibition of the IL-2 feed-back loop.  
PGE2 treatment of infected mice showed significantly lower proportions of CD4+ T-cells and 
IFNG gene expression in the gastric mucosa as well as lower numbers of CD4+IFNγ+ cells in 
the mesenteric lymph nodes, the site of T cell priming. 
Taken together we propose that PGE2-mediated repression of pathogenic T-cells in 
Helicobacter-associated disease may reinforce conventional ET-induced therapy and could 
show beneficial effects in patients with established intestinal metaplasia.   
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4.3  Inhibition of Poly(ADP-ribosyl)ation Inhibits and Sustainably Cures 
Helicobacter-Associated Gastric Preneoplastic Lesions 
 Poly(ADP-ribosyl)ation (PARylation) of PARP1 and other acceptor molecules 
represents a powerful posttranscriptional modification involved in a variety of physiological 
and pathophysiological conditions including inflammation and possibly also cancer 
development (reviewed in Hassa, 2006).6 Inhibitors of ADP-ribosylation have shown disease-
relieving effects in a multitude of chronic inflammation-associated diseases, but have also 
been effective in rendering BRCA1- and BRCA2-deficient breast cancer cells susceptible to 
accumulation of genomic instability, cell cycle arrest and apoptosis.225  
 In this study we provide strong evidence that inhibition of PARylation with the NAD+ 
analogue PJ34 suppresses and even cures Helicobacter-induced gastritis and epithelial 
pathology. We show that PJ34 accomplishes this beneficial effect by targeting pathogenic 
Th1 polarized immune responses. PJ34 treated mice show significantly reduced numbers of 
stomach-infiltrating neutrophils and pathogenic CD4+ T-cells. This effect was accompanied 
by suppressed IFNG gene transcription in the stomach mucosa. Furthermore, T-cell priming 
was suppressed as indicated by reduced numbers of CD4+IFN-γ+ T-cells in the mesenteric 
lymph nodes of PJ34-treated compared to untreated mice. 
Our data are in line with previous studies reporting beneficial effects of PARylation 
inhibitors in models of chronic inflammation such as inflammatory bowel disease,209 allergen-
induced airway inflammation198 and endotoxin-induced septic shock.210 Beneficial effects 
correlated with defective NF-κB induction, suppressed transcription and activation of IL-6, 
ICAM-1, E-selectin, TNF-α and IFN-γ mediated responses,212-214, 298, 299 overall resulting in 
defective immune responses to the respective antigens.   
The beneficial effect of PJ34 treatment in Helicobacter-associated disease, which is 
mainly driven by pathogenic Th1 responses, is illustrated by the following observations: we 
show that anti-CD3/28 activated CD4+ T-cells produce large amounts of PAR and that this 
induction is significantly suppressed by PJ34 treatment. The involvement of PAR synthesis in 
chromatin replication, by modification of histones is a widely accepted concept.300 Recent 
data investigating the function of PAR in T-cells suggest that PARylation modifies and 
positively regulates nuclear factor of activated T-cell (NFAT)-dependent gene 
transcription.202, 203 NFAT exerts a critical function in regulating IL-2 transcription.301, 302 Our 
data are in agreement with this concept, since PJ34 treatment of anti-CD3/28 stimulated 
cells lead to drastically suppressed il-2 (and IFNG) gene transcription and a subsequent 
block of CD4+ and CD8+ proliferation and activation. This observation was further confirmed 
with the alternative PARP inhibitor, DAM-TIQ-A.  
PAR synthesis in T cells seems to be independent of PARP1 or PARP2 (but rather 
depends on PARP1 AND PARP2), since antiCD3/28 stimulation induced PARylation also in 
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PARP1-/- and PARP2-/- T-cells. This observation points towards a redundant function of 
PARP1 and 2 for PAR formation in T cells. Due to embryonic lethality of PARP1/2 double-
knock out animals, we could not assess if either PARP reconstitutes PARylation in PARP1- 
or 2-deficient T-cells. The redundant functions of PARP1 and 2 proteins in catalyzing 
PARylation provides a possible explanation for why we did not find any difference in infected 
IL-10-/--deficient compared to IL-10-/-/PARP1-/- mice regarding gastritis, epithelial atrophy and 
intestinal metaplasia at 5 to 21 days post infection. However, it remains to be clarified if PJ34 
treatment is efficient also in a PARP1 or 2-deficient genetic background.  
In addition to blocking CD4+ T-cell migration to the stomach we further show evidence 
that PJ34 additionally interferes with the T-cell priming in the mesenteric lymph nodes, since 
PJ34 treatment blocked IFN-γ secretion by MLN cells. Altoghether our data indicate that 
PJ34 treatment suppresses the Helicobacter-specific immune response in the stomach and 
thus prevents epithelial immunopathology and facilitates bacterial colonization.   
Interestingly, we found that PJ34 treatment not only suppresses Helicobacter-induced 
epithelial immunopathology but also successfully cures severe precancerous lesions. 
However, sustainable restoration of the gastric mucosa was only achieved by combination 
with bacterial eradication therapy (ET). PJ34 treatment of mice with pre-existing lesions 
resulted in a significant regression of metaplastic lesions. In contrast to the human situation, 
ET in mice leads to a significant regression of disease symptoms, though only if administered 
at early time points after infection303 (this study). Extended meta-analyses evaluating the 
long-term benefit of ET in humans concluded that ET had a favourable effect only on gastric 
atrophy, but did not prevent re-occurrence of metaplastic lesions nor cancer progression,262 
271, 272 emphasizing the need for treatment options other than sole ET. 
The majority of PARylation inhibitors have been designed to inhibit the activity of 
Poly(ADP-ribose)polymerases (PARPs) by mimicking its substrate NAD+,304  and competing 
for binding to the catalytic domain.162, 305 Due to the ubiquitous usage of NAD+ as coenzyme, 
NAD+ analogues may target other NAD+ dependent enzyme classes as well. Another major 
concern is that the long-term effects of PARP inhibitiors have not yet been assessed, but 
require careful consideration.  
In summary, we provide evidence that inhibition of PARylation by PJ34 holds promise 
in preventing and treating Helicobacter-associated gastric cancer precursor lesions.  
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4.4  Therapeutic Implication of PGE2 and PJ34 Treatments in Related Disease   
            Entities 
  The above presented results show unambiguously that inhibitors of pathogenic Th1 
responses represented by CD4+IFN-γ+ cells prevent and even resolve Helicobacter-induced 
immunopathology in the stomachs of infected mice.  
  PGE2 and PJ34 target effector T-cell populations and render them inert to external 
stimuli, thereby blocking their proliferation, migration to the site of infection and secretion of 
effector cytokines. Of the two compounds, PGE2 showed more pronounced effects in all 
readouts and seems to have a long-lasting suppressive effect that is sustained also after 
explantation and in vitro re-stimulation. While in vivo PGE2 treatment completely abolished 
anti-CD3/28-induced IL-2R expression on T-cells, PJ34 treated cells only showed a partial 
impairment of IL-2R up-regulation and thus retained residual stimulation potential.  
   Furthermore, addition of rIL-2 to treated CD4+T-cell cultures only rescued the 
suppressive effect of PGE2, suggesting that PJ34 regulates T-cell proliferation also by other 
means. Interestingly, PGE2 and PJ34 exert similarly suppressive and enduring effects on 
IFNG and Il-2 transcription that were already observable after a two hour treatment.  
  The general observation that both PGE2 and PJ34 possess T-cell suppressing 
characteristics is not only interesting for Helicobacter-associated diseases, but may also 
have relevance for related T-cell driven diseases.  First of all, PGE2 and PJ34 might be 
beneficial also in T-cell dependent B-cell tumors such as in MALT lymphoma. A study 
performed in our laboratory revealed that CD4+T-cells significantly contribute to 
tumorigenesis, since CD4+T-cell depletion in BALB/c mice by an anti-CD4 antibody resulted 
in tumor regression.282 Therefore, inhibition of CD4+T-cell functions using a pharmacological 
approach may result in the same outcome and might even circumvent adverse effects of 
immunotherapies. Furthermore, targeting and neutralizing the activation of T cells may also 
have beneficial effects in other T-cell driven diseases such as T-cell lymphomas and 
inflammatory skin diseases such as psoriasis.306 Other wide-spread diseases with as yet 
limited treatment options and pathogenic T-cell involvement include specific autoimmune 
diseases such as multiple sclerosis (triggered by T-cell responses against myelin in the 
central nervous system), diabetes (destruction of insulin-producing β-cells of the pancreas) 
and others. Another possible indication for PGE2 or PJ34 treatment in the GI tract would be 
Crohn’s disease, a risk factor for colon carcinogenesis.296 Interestingly, PARP inhibitors and 
genetic models have already been tested in models of IBD and have shown encouraging 
results.209, 307 Based on our findings, PGE2 treatment holds great potential to be at least as 
effective as previously used PARP inhibitors since it resulted in even more drastic relief of 
disease symptoms in our model. However, PGE2 as well as PJ34 are robust 
immunosuppressive compounds and adverse effect may be expected with regard to 
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enhanced tumor immune escape and enhanced susceptibility to severe infections and their 
complications.  
Helicobacter pylori & DSB - Discussion 
 
4.5  Helicobacter pylori causes potentially genotoxic DNA double strand 
breaks in infected cells  
 Carcinogen-induced DNA damage constitutes an important driving force of 
carcinogenesis by causing alterations in tumor suppressor genes and oncogenes. Mutations 
frequently observed in gastric cancers comprise the TP53 gene at relatively early stages of 
infection, whereas mutations in RAS and ‘deleted in colorectal cancer’ (DCC) are more 
commonly reported in metaplastic, dysplastic and cancerous lesions.7  
 We show in this study that H. pylori infection efficiently causes DNA double strand 
breaks (DSB) in primary gastric epithelial cells and various cancer cell lines. DSB breaks are 
induced in an infection-dose dependent manner and require contact of host cells and live H. 
pylori. We further show that this feature is Helicobacter-specific, since E.coli DH10B infection 
does not cause DSB, even at multiplicities of infection (MOI) corresponding to roughly 10000. 
Interestingly, infected cells are able to repair the H. pylori-induced DSB breaks, yet only upon 
bacterial killing with metronidazole, tetracycline hydrochloride, bismuth subcitrate. This result 
implies that H. pylori continuously assaults the eukaryotic DNA. On the one end, his 
hypothesis is supported by the persistence of eGFP-MDC1 foci in the very same cell for at 
least 15 hours, but also by the fact that DNA fragmentation is still observed 54 hours post 
infection.   
Another important point to consider is the Helicobacter-induced inhibition of cell 
proliferation in vitro. So far we have no indication that protein synthesis of DNA repair genes 
is inhibited as well. Looking at the kinetics, however, it is conspicuous that DNA fragments 
are observed as early as 1-3 hours post infection. In contrast, PARP activation, generally 
considered a very early event upon single strand break (SSB) induction,308  is not induced 
until 6 hours post H. pylori infection. This delayed response to DNA damage may be 
explained by the absence of single strand breaks (SSB) in H. pylori-infected cells or by the 
not yet initiated DSB repair (which includes SSB formation prior to repair). Another rather 
speculative possibility includes H. pylori-mediated inhibition of the DNA damage repair 
process downstream of 53BP1 and MDC1.  
 The rapid induction of DSB as observed by PFGE suggests host-independent 
induction of DNA damage. Several studies have reported the existence of bacterial genotoxic 
factors. For example, enteropathogenic bacteria encode a variety of toxins that specifically 
interfere with eukaryotic host cell signalling and thus possess putative genotoxic potential 
(genotoxin). Pathogenic and commensal E.coli have been reported to express a peptide–
polyketide compound, termed colibactin, which causes DBS and subsequent ATM/H2AX 
activation.248 The cytolethal distending toxin (CDT) is another potential genotoxin found in 
Campylobacter jejuni and Helicobacter hepaticus,309 that is able to induce DSB in
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mammalian cells by the DNase activity of a CDT subunit (CdtB).310 In murine H. hepaticus 
infection models, CDT is required for colonization,311 causes chronic intestinal 
inflammation,312 and promotes hepatocellular dysplasia.313 However, there is no evidence for 
CDT-dependent DSB induction in H. hepaticus infection models. Moreover, sequence 
comparisons reveal that H. pylori does not encode a CDT-like protein. We suspect that H. 
pylori derived nucleases may assume the role of the CDT’s DNase activity and thereby 
damage host DNA.   
 To test the possible involvement of bacterial factors in DNA fragmentation, we plan to 
perform a comprehensive screen by testing transposon-generated bacterial mutants.314 The 
efficiency of the mutants to trigger DNA damage signaling, using a eGPF-MDC1 cell line, will 
serve as readout and be quantified by light microscopy. The mutant library comprises 5363 
independent transposon mutants. 344 of 1500 genes could not be mutated; thus the genome 
coverage is roughly 3-fold.315 This approach will enable us to test in parallel a large number 
of mutants for their ability to induce DSB in the host cell.  
 Another question that has not been resolved so far is the importance of H. pylori DSB 
in vivo. So far, we do not have strong evidence for H. pylori-induced DSB in the stomachs of 
infected mice bearing various kinds of cancer precursors. Bartkova et al. reported that ATM-
dependent pathways are activated in certain types of cancer precursor lesions (of the urinary 
bladder, breast, lung and colon) which may delay or even prevent cancer development.255 
However, these authors did not provide data for gastric cancer precursors. A recent study 
revealed, however, that γH2AX staining was not significantly associated with the Lauren's 
classification, depth of invasion, lymph node metastasis or TNM stage in patients exposed to 
atomic-bomb derived radiation.316 Taken these reports and our data together, it seems that 
Helicobacter infection does not cause massive amounts of DSB in vivo. This observation is 
not thoroughly surprising taken the fact that Helicobacter-associated carcinogenesis 
develops over decades,317 suggesting that the mutagenic events are relatively infrequent. In 
addition it should be considered that the MOIs used in our study exceed the number of 
bacteria present in the stomach; infections with low MOI indeed only caused insignificant 
amounts of breaks and DSB-specific responses in the cell. 
To further clarify the role of damaged DNA in Helicobacter-associated disease and its 
progression we have collected a series of human biopsies in collaboration with Dr.med. S. 
Cogliatti of the Institute of Pathology, Cantonal Hospital of Skt. Gallen. The selected human 
biopsies display different grades of Helicobacter-associated disease, ranging from superficial 
gastritis to adenocarcinoma. This sample collection will serve as a valuable tool to monitor 
changes in the host DNA integrity during the progression of Helicobacter-associated gastric 
disease.  
Conclusion 
 
A few reports have investigated the correlations between Helicobacter infection, DNA 
integrity and DNA damage response signalling in order to explain the development of gastric 
cancer. There is evidence for Helicobacter-induced down regulation of proteins involved in 
mismatch repair (MMR) processes, such as MLH1, PMS1, PMS2, MSH2 and MSH6.235, 236 
Other reports investigated the presence of  8-oxoG in cancerous tissues, a marker of 
oxidized DNA and correlate of increased DNA damage.238, 245 These studies suggest that a 
direct contribution of oxidative damage (derived from ROS generated by infiltrating immune 
cells) and deficiency of DNA repair account for gastric carcinogenesis. However, there is no 
profound study addressing the direct contribution of the bacteria to carcinogenesis. 
Another interesting preliminary observation is that the degree of epithelial atrophy 
may be reflected even after explantation. To test this notion, primary gastric epithelial cells 
were explanted from wild-type mice bearing different grades of epithelial pathology. 
Interestingly, cells derived from mice with predominantly hyperplastic lesions showed slightly 
increased numbers of 53BP1 foci upon explantation if compared to cells derived from 
uninfected mice or mice only showing signs of minor gastritis. This result may reflect the fact 
that hyperplastic cells activate DSB signalling pathways in vivo.   
 In conclusion, our data provide evidence that Helicobacter infection reversibly causes 
severe DNA lesions in the infected host cells in vitro and that this feature may provide a 
mechanism of carcinogenesis attributed to these stomach-colonizing bacteria. 
 
4.6  Conclusion 
The studies presented in this thesis provide experimental proof that the development 
of Helicobacter-associated gastric pre-cancerous lesions can be prevented and pre-existing 
lesions can be cured by the administration of PGE2 and PJ34. The beneficial effect of PGE2 
and PJ34 treatments is achieved by the inhibition of CD4+IFN-γ+ effector T-cell functions. 
This T-cell population is essential for the development of Helicobacter-associated disease 
and is thus also termed ‘pathogenic’. We show that PGE2 and PJ34 treatments lead to 
suppressed CD4+ T-cell proliferation and migration to the infected gastric mucosa, which is 
accompanied by impaired secretion of T-cell signature cytokines. The therapeutic efficacy of 
PGE2 and PJ34 is achieved by abolished IL-2 expression and the subsequent lack of T-cell-
dependent immune responses. These findings offer important insights for the development of 
future therapeutics for patients refractory to antibiotic eradication therapy and patients 
bearing incurable stages of gastric cancer precursor lesions.  Furthermore, we also show 
that living Helicobacter bacteria per se damage the host cell DNA in various cell culture 
models in vitro. This observation suggests an intrinsic genotoxic potential of Helicobacter 
pylori that may contribute to gastric cancer development in infected individuals. 
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53BP1 p53 binding protein 1 
ADP Adenosine diphosphate 
AID  activation-induced deaminase 
AIF  apoptosis inducing factor 
ATM Ataxia telangiectasia mutated 
bp  base pair 
BRCA1 breast cancer type I susceptibility factor 
CFSE carboxyfluorescein succinimidylester; 
COX  cyclooxygenase 
DNA  desoxyribonucleic acid 
DSB  DNA double strand break 
H2AX H2A histone 
IFN interferon 
IL interleukin 
IMPGE  immortalized primary gastric epithelial cells 
IP intraperitoneal 
LPS  Lipopolysachharide 
MDC1  Mediator of DNA damage checkpoint protein 
MLN mesenteric lymph node 
MOI multiplicity of infection 
NAD  nicotinamide adenine dinucleotide 
NFAT  nuclear factor of activated T-cells 
NF-KB  nuclear factor-kappa B 
PAI pathogenicity island 
PARG  Poly(ADP-ribose)glycohydrolase 
PFGE  Pulse Field Gel Electrophoresis 
PGE2 prostaglandin E2 
PJ34 N-(6-Oxo-5,6-dihydro-phenanthridin-2-yl)-N,N-
dimethylacetamide 
TGF tumor growth factor 
Th1 T-helper 1 cell 
TNF tumor necrosis factor 
Teffector effector T cell (CD4+CD25-) 
Treg regulatory T cell (CD4+CD25+) 
γH2AX phosphorylated H2AX 
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Abstract 
B-cells regulate autoimmune pathologies and chronic inflammatory conditions such as 
autoimmune encephalomyelitis and inflammatory bowel disease. The potential counter-
regulatory role of B-cells in balancing pathogen-specific immune responses and excessive 
immunopathology is much less understood due to the lack of appropriate persistent infection 
models. We show here that B-cells have the ability to negatively regulate adaptive immune 
responses to bacterial pathogens. Using mouse models of infection with Helicobacter felis, a 
close relative of the human gastrointestinal pathogen H. pylori, we found that B-cells activated 
by Helicobacter TLR-2 ligands induce IL-10-producing CD4+CD25+ T regulatory-1 (Tr-1)-like 
cells in vitro and in vivo. Tr-1 conversion depends on TCR signalling and a direct T-/B-interaction 
through CD40/CD40L and CD80/CD28. B-cell-induced Tr-1 cells acquire suppressive activity in 
vitro and suppress excessive gastric Helicobacter-associated immunopathology in vivo. Adoptive 
co-transfer of MyD88-proficient B-cells and Tr-1 cells restores a normal gastric mucosal 
architecture in MyD88-/- and IL-10-/- mice in a manner that depends on T-cellular, but not B-
cellular IL-10 production. Our findings describe a novel mechanism of B-cell dependent Tr-1 cell 
generation and function in a clinically relevant disease model. In conclusion, we demonstrate 
here that the B-cell/Tr-1 cell axis is essential for balancing the control of Helicobacter infection 
with the prevention of excessive Th1-driven gastric immunopathology, promoting gastric 
mucosal homeostasis on the one hand and facilitating Helicobacter persistence on the other. 
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Introduction 
B-cells have emerged in recent years as important regulators of T-cell-driven autoimmune 
pathologies and of excessive immune responses to the indigenous microbiota (1-4). The first 
evidence for a regulatory role of B-cells was described in mouse models of experimental 
autoimmune encephalomyelitis (EAE) (5). More recently, B-cells were shown to also suppress 
excessive inflammation in models of collagen-induced arthritis (4, 6), type I diabetes (7), contact 
hypersensitivity (8) and inflammatory bowel disease (9, 10). The proposed mechanisms of B-
cell-driven immunoregulation include the production of IL-10 (9, 11, 12) and the activation of 
CD4+CD25+ or CD8a+ T regulatory cells (Treg) via a direct interaction (10, 13).  
In contrast to Treg, which represent phenotypically and developmentally distinct lineages, B-cells 
with regulatory properties (sometimes termed ‘Breg’) remain ill defined with respect to their 
immunophenotype, preferred anatomical location and ontogeny. All B-cells can in principle 
produce IL-10 upon TLR-2, -4 or -9 stimulation or T-cell-dependent activation (14, 15), with 
particularly strong production being attributed to CD5+ peritoneal B-1a cells (16), intestinal 
CD19+CD1dhi cells (9) and splenic CD1dhiCD5+ ‘B10’ cells (8). Other B-cell subsets with reported 
IL-10-dependent regulatory activity include splenic CD21hiCD23+IgM+ transitional 2 marginal 
zone precursor cells (6) and CD21hiCD23lo marginal zone B-cells (10).  
Little information is available regarding ‘regulatory’ B-cell activity in bacterial infectious diseases, 
possibly due to the fact that most bacterial infections take an acute rather than chronic course in 
humans and the respective experimental models (17).  Exceptions include Mycobacterium 
tuberculosis and the widespread bacterial pathogen Helicobacter pylori, a gram-negative 
colonizer of the human gastric mucosa (17). Helicobacter infections are acquired during 
childhood and, despite triggering strong local and systemic immune responses, typically persist 
for life. Whereas a majority of infected individuals remain asymptomatic, ~20% develop one or 
more Helicobacter-associated severe gastric and duodenal disease manifestations; these 
include chronic active gastritis, ulcers, gastric B-cell lymphoma and, rarely, gastric 
adenocarcinoma (18-21). While the bacterial virulence factors, host genetic traits and 
environmental parameters predisposing to Helicobacter-associated disease have been the 
subject of intense investigation, much less is known about the protective mechanisms that 
operate in the majority of infected individuals not developing disease symptoms (22-26).  
We have reported recently using a mouse model of Helicobacter felis-induced gastric 
preneoplasia that C57BL/6 mice recapitulate the human scenario, as even closely related 
animals differ substantially with respect to disease susceptibility (27). A subset of infected mice 
displayed the histopathological changes indicative of early gastric carcinogenesis, i.e. the 
appearance of a chronic inflammatory infiltrate, the loss of specialized gastric lineages (a 
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process termed ‘atrophy’ or ‘atrophic gastritis’), the compensatory hyperproliferation of 
undifferentiated progenitor cells (‘hyperplasia’) and the development of intestinal metaplasia. In 
contrast, their less susceptible littermates were largely protected from the development of such 
lesions (27). We further showed that Th-1-polarized T-cells and their signature cytokine IFN-γ 
cause preneoplastic gastric transformation in susceptible animals, and that these cells are 
essential for control of the infection (27). Additional evidence for this model came from our 
recent observation that the pharmacological targeting of Th-1 cells efficiently prevents and even 
reverts preneoplastic gastric pathology (28). 
Here we show that excessive Helicobacter-induced Th-1 driven gastric immunopathology is 
restricted by cooperating ‘regulatory’ B- and T-cells. Using mouse strains with defined defects in 
either of the two populations, we found that B-cells, upon their MyD88-dependent activation by 
Helicobacter TLR-2 ligands, are able to efficiently induce IL-10-dependent suppressive activity in 
conventional CD4+ T-cells, converting these into T regulatory-1 (Tr-1)-like cells. The cooperative 
activity of ‘regulatory’ B-cells and Tr-1 cells prevents the development of gastric premalignant 
lesions, thus providing evidence that B-cells can have important immunomodulatory function 
during immune responses to persistent bacterial infections. 
 
Materials and Methods 
Animal experimentation 
C57BL/6, TCR-β-/-BL/6, Rag-1-/-BL/6, IL-10-/-BL/6, MyD88-/-BL/6, TLR-2-/-BL/6 and Ly5.1BL/6 
mice were purchased from Charles River Laboratories (Sulzfeld, Germany). IL-10-GFP reporter 
mice (‘TIGER’) were described previously (29). Mice with a B-cell-specific or CD4+/CD8+ T-cell-
specific inactivation of IL10 were generated by crossing CD19-Cre or CD4-Cre mice with 
IL10flox/flox mice (30, 31). All mice were bred at a University of Zurich SPF facility and maintained 
in individually ventilated cages. All animal experiments were approved by the cantonal veterinary 
office.  Mice were infected at 5-6 weeks of age with two consecutive orogastric doses of H. felis, 
which was grown as described (27). For adoptive transfer experiments, immunomagnetically 
sorted splenic CD4+CD25- T-cells from H. felis infected donors were injected into the tail veins of 
recipient mice, either alone or in combination with equal numbers of CD4+CD25+ Treg. In vivo 
depletion of regulatory T-cells was achieved by weekly i.p. injections of 1x100μg and 3x50μg of 
anti-CD25 antibody (clone PC-61.5). Recombinant IL-10 (BD Pharmingen) was administered i.p. 
thrice weekly at 270ng/dose. 
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Assessment of H. felis colonization, IFN-γ expression and gastric histopathology 
Stomachs were retrieved and dissected longitudinally into several equally sized pieces. For the 
qPCR-based assessment of H. felis colonization, genomic DNA was isolated using the DNeasy 
blood and tissue kit (Qiagen, Hilden, Germany) and subjected to qPCR analysis of the flaB gene 
as described (27). For the quantitative analysis of gastric IFN-γ expression, total gastric RNA 
was subjected to real time RT-PCR using primers and conditions specified previously (27). For 
the quantitative assessment of gastric histopathology, Giemsa-stained paraffin-embedded 
stomach sections were scored on a scale of 0-6 for the parameters chronic inflammation, 
atrophy, epithelial hyperplasia and metaplasia as described in detail previously (27). All pictures 
were taken with a 20x magnification on a Leica Leitz DM RB microscope equipped with a DFC 
420C camera. Images were acquired using the Leica Application Suite 3.3.0 software. Scale 
bars indicate 50μm.     
 
Cell culture and flow cytometry 
Gastric lymphocyte and mesenteric lymph node single cell suspensions were generated by 
digestion with 0.25mg/ml collagenase IV (Sigma) and passing through a cell strainer. 
CD4+CD25- T-cells and B-cells were purified from single cell suspensions of freshly isolated 
spleens or mesenteric lymph nodes by immunomagnetic sorting (R&D Systems, Minneapolis, 
USA), according to the manufacturer’s instructions. IL-10 secretion was measured by ELISA (BD 
Biosciences, San Diego, CA, USA).  Directly coupled antibodies for the following markers were 
used for flow cytometry: CD4 (clone RM4-5, eBioscience, San Diego, USA), CD25 (clone PC-
61.5, R&D Systems), CD19 (clone 6D5, Abcam, Cambridge, UK), CD80 (clone 16-10A1, 
Biolegend), CD86 (clone GL1, BP Pharmingen), IgM (polyclonal goat serum, Southern Biotech), 
CD21 (clone 7G6, BD Pharmingen), CD23 (clone B3B4, Biolegend), CD5 (clone 53-7.3 BD 
Pharmingen), CD1d (clone 1B1, BD Pharmingen), CD45 (clone 30-F11, Biolegend), B220 (clone 
RA3-6B2, BD Pharmingen), Ly5.1/CD45.1 (clone A20, Biolegend). All FACS analyses were 
performed on a CyanADP instrument (Dako, Glostrup, Denmark). FACS sorting was performed 
on a FACS Aria cell sorter (BD Biosciences).  For B-/T-cell co-cultures, immunomagnetically 
sorted B-cells and CD4+CD25− T cells were cultured at a 1:1 ratio in 96 well round bottom plates 
(Nunc, Roskilde, Denmark) at 2× 105 cells/well in the presence of 1µg/ml anti-CD3 (clone 145-
2C11; Bio X Cell) and 10ng/ml recombinant IL-2 (R&D Systems). Blocking antibodies to CD40L 
(clone MR1, BD Biosciences) and CTLA-4 (clone 4F10) or agonistic anti-CD28 antibody (clone 
37.51, Biolegend) were added where appropriate. Cells were separated by transwell filters as 
indicated. After four days, cells were harvested, stained and analyzed by flow cytometry or used 
for adoptive transfer experiments. For in vitro suppression assays, Ly5.1+CD4+CD25− T cells 
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were labelled with 5M carboxyfluorescein succinimidyl ester (CFSE) and stimulated with anti-
CD3/CD28-coated Dynabeads (Invitrogen, Carlsbad, CA, USA) in the presence or absence of 
equal numbers of FACS-sorted CD4+CD25+il-10-GFP+ or CD4+CD25+il-10-GFP- T cells. Cells 
were harvested after five days and the CFSE signal of Ly5.1+ lymphocytes was analyzed by flow 
cytometry. 
 
Statistical analysis 
All p-values were calculated using Graph Pad prism 5.0 or R software. The significance of 
categorical differences in histopathology scores was calculated by Mann-Whitney or unpaired 
Wilcox test and the significance of numerical differences was calculated by Student’s t-test. In all 
graphs showing colonization data and histopathology scores, the medians are indicated by 
horizontal bars. In column bar graphs, standard errors of the mean are indicated by vertical bars. 
n.a. denotes ‘not applicable’, and n.s. stands for ‘not significant’.  
 
Results 
Regulatory T-cells restrict Helicobacter-induced gastric preneoplastic immunopathology  
Immunodeficient mouse strains lacking either T-cells (TCR- β -/-) or T- and B-cells (Rag-1-/-) are 
protected from the gastric histopathology observed in H. felis-infected wild type C57BL/6 mice 
(27). The adoptive transfer of pure populations of splenic CD4+CD25- effector T-cells from H. 
felis-infected donors into hosts of both immunodeficient backgrounds causes severe gastric 
mucosal inflammation and the rapid development of preneoplastic lesions within only four weeks 
of infection (Figure 1A,B,E,F). The lesions are histologically evident as chronic atrophic gastritis, 
epithelial hyperplasia and intestinal metaplasia (Figure 1A,B,E,F). The gastric 
immunopathological response to the infection is accompanied by a strong increase in local IFN-γ 
levels (Figure 1C,G) and a concomitant reduction in Helicobacter burden (Figure 1D,H). The co-
transfer of equal numbers of spleen-derived CD4+CD25+ regulatory T-cells with the effector cells 
prevented gastric IFN-γ production, Helicobacter clearance and the development of gastric 
lesions in the TCR-β-/- background (Figure 1A-D), but not in the Rag-1-/- background (Figure 1E-
H). We deduce from this observation that the suppressive activity of co-transferred Treg on 
CD4+ effector T-cells depends on a cell type that is present in the TCR- β -/-, but not the Rag-1-/- 
strain.  
To verify the importance of CD4+CD25+ Treg in controlling excessive gastric immunopathology 
in H. felis-infected wild type mice, we depleted Treg systemically by twice-weekly injections of 
anti-CD25 antibody during the entire four week time course of infection (supplemental Figure 1). 
This treatment resulted in the strikingly accelerated development of atrophy and hyperplasia and 
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a significantly reduced bacterial burden (supplemental Figure 1A-C). In conclusion, the data 
suggest that Treg effectively limit excessive gastric immunopathology and, at the same time, 
prevent Helicobacter clearance. The failure of Treg to function in the Rag-1-/- background further 
argues that additional cell types are required for optimal suppressive activity of Treg in this 
scenario; possible candidate cell types include B-cells.  
 
B-cells produce IL-10 and up-regulate CD80 in a MyD88-dependent manner upon exposure to 
Helicobacter-derived TLR-2 ligands  
Hypothesizing that B-cells might have an important role in (co-) regulating Helicobacter-specific 
T-cell responses and gastric immunopathology, we analyzed the response of B-cells to 
Helicobacter sonicate. We examined expression of the activation markers CD80 and CD86 as 
well as IL-10 production; we focused on this cytokine because IL-10-/- mice develop more severe 
preneoplastic gastric pathology upon H. felis infection than wild type mice infected for the same 
time frame (supplemental Figure 2). To analyze IL-10 expression at the single cell level, we took 
advantage of a reporter mouse that was generated by insertion of a GFP element in front of the 
polyadenylation site of the il-10 gene (29). Treatment of immunomagnetically purified splenic il-
10-GFP knock-in B-cells with Helicobacter sonicate revealed a robust il-10-GFP+ population that 
strongly expressed CD19 (Figure 2A), IgM, CD21 and CD23 (Figure 2B). The CD21+CD23+ 
phenotype is characteristic of the transitional 2 marginal zone precursor cell lineage that was 
recently reported to be an important source of B-cellular IL-10 (6). The TLR-2 and -4 ligands 
PAM3Cys and E. coli LPS also strongly induced il-10-GFP (Figure 2A); this was further 
confirmed by IL-10 ELISA of the culture supernatants (Figure 2C). A comparison of the 
responsiveness of B-cells from various anatomical locations and lymphoid organs to 
Helicobacter sonicate revealed that all B-cells, independent of whether they had been isolated 
from the spleen, peritoneum, mesenteric lymph nodes or Peyer’s patches, could be stimulated to 
express IL-10 upon exposure to Helicobacter, albeit at variable levels (supplemental Figure 3).  
IL-10 secretion by purified B-cells absolutely required MyD88 signaling and TLR-2 as B-cells 
isolated from the respective MyD88-/- and TLR-2-/- animals failed to respond to Helicobacter 
extract or PAM3Cys (Figure 2C); in contrast, TLR-4-/- and TLR-9-/- B-cells showed normal IL-10 
production upon Helicobacter exposure (data not shown). The treatment of B-cells with 
Helicobacter sonicate further strongly induced the surface expression of CD80 (Figure 2D) and 
CD86 (supplemental Figure 4), and IL-10 production was detected in CD80+, but not CD80- B-
cells (Figure 2D). The up-regulation of surface CD80 on B-cells was entirely dependent on 
MyD88 and TLR-2, as B-cell preparations from the respective k/o animals failed to induce CD80 
upon stimulation with Helicobacter sonicate (Figure 2E, supplemental Figure 4). In contrast, the 
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up-regulation of CD86 appeared to be only partially MyD88- and TLR-2-dependent 
(supplemental Figure 4). Interestingly, CD80+ cells also expressed higher levels of CD40, with 
mean fluorescence intensities of CD40 being more than twice as high in CD80+ than in CD80- 
cells (MFI=70 vs. 156; Figure 2E). In conclusion, the results suggest that B-cells sense 
Helicobacter in a TLR-2- and MyD88-dependent manner, and respond to Helicobacter-derived 
TLR-2 ligands by up-regulating CD40, CD80 and CD86 and by secreting IL-10.  
 
Co-transfer of B-cells and Treg or regular doses of recombinant IL-10 alleviate excessive 
inflammation and Helicobacter-associated immunopathology in MyD88-/- mice  
As the B-cell-specific induction of IL-10 and CD40/CD80 expression requires MyD88 signaling, 
we hypothesized that MyD88-/- mice would show enhanced susceptibility to Helicobacter 
infection. Indeed, MyD88-/- mice displayed strongly accelerated Helicobacter-induced gastric 
histopathology, developing severe atrophy, hyperplasia and metaplasia as early as one month 
post infection (Figure 3A,B). The phenotype of MyD88-/- mice is therefore reminiscent of IL-10-/- 
animals.  However, in contrast to IL-10-/- mice, which consistently clear the infection before one 
month p.i. (supplemental Figure 2) (32), MyD88-/- mice are colonized as densely as wild type 
animals at this time point (Figure 3C).  
To test whether the elevated susceptibility of MyD88-/- mice is due to their defect in IL-10 
production, a group of infected MyD88-/- mice received thrice-weekly intraperitoneal injections of 
recombinant murine IL-10 for the four week duration of the experiment (Figure 3A-C). 
Interestingly, the IL-10 treatment significantly reduced the severity of all parameters of gastric 
histopathology (Figure 3A-C), indicating that IL-10 deficiency is the likely cause of the high 
susceptibility of MyD88-/- mice to Helicobacter-induced gastric preneoplastic changes. 
Having identified TLR-2 as the relevant receptor for Helicobacter-derived PAMPs in purified B-
cells (Figure 2), we asked whether TLR-2-/- mice would show a similarly enhanced susceptibility 
to Helicobacter infection as MyD88-/- animals. Indeed, TLR-2-/- mice developed more severe 
pathology than wild type controls and, in contrast to MyD88-/- mice, were able to reduce the 
bacterial burden significantly (supplemental Figure 5). TLR-4-/- and TLR-9-/- mice did not differ 
from wild type animals in terms of their colonization levels and gastric histopathology (data not 
shown), indicating that TLR-2 is the predominant receptor sensing Helicobacter in vivo.   
In order to assess whether wild type B-cells are able to prevent the accelerated gastric 
histopathology characteristic of MyD88-/- mice, we adoptively transferred purified splenic B-cells 
to MyD88-/- mice at the time of experimental infection. No difference in the severity of gastric 
lesions could be detected between the recipient group and infected MyD88-/- mice that had not 
received B-cells (Figure 3D,E). Similarly, adoptive transfer of purified splenic CD4+CD25+ Treg 
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also failed to prevent gastric pathology (Figure 3D,E). In contrast, the co-transfer of both cell 
types significantly reduced all parameters of gastric histopathology in recipient mice (Figure 
3D,E), suggesting that B-cells and Treg cooperate in the control of excessive 
immunopathological responses to Helicobacter.   
 
Helicobacter-activated B-cells induce Tr-1-like cells with suppressive activity in a TLR-2, MyD88- 
and contact-dependent manner 
B-cells respond to Helicobacter with the MyD88- and TLR-2-dependent production of IL-10 and 
up-regulation of CD80 and CD40 (Figure 2); however, adoptively transferred B-cells prevent 
Helicobacter-induced pathology in MyD88-/- animals only in the presence of co-transferred T-
cells (Figure 3D,E). We speculated that Helicobacter-exposed B-cells might trigger a 
suppressive phenotype in conventional T-cells and/or enhance the suppressor functions of Treg. 
To address these possibilities, we co-cultured immunomagnetically purified splenic B- and 
CD4+CD25- T-cell populations in the presence of crosslinking anti-CD3 antibody and IL-2, with or 
without prior exposure of the B-cells to Helicobacter sonicate, PAM3Cys or LPS. While naïve B-
cells were largely incapable of inducing GFP expression in il-10-GFP knock-in CD4+CD25- T-
cells, a brief pretreatment of the B-cells with either Helicobacter sonicate, PAM3Cys or LPS prior 
to co-culturing efficiently triggered the B-cells’ ability to induce il-10-GFP expression and IL-10 
secretion by T-cells as determined by FACS and ELISA (Figure 4A-C). Il-10-GFP+ T-cells 
expressed high levels of CD25 (Figure 4A), and were FoxP3-negative (data not shown), 
suggesting that the interaction with B-cells had converted conventional T-cells to a T-regulatory-
1 (Tr-1)-like phenotype. Interestingly, T-cellular IL-10 expression was dependent on a direct 
interaction between both cell types, as their physical separation by transwell filters prevented T-
cellular il-10-GFP and IL-10 expression (Figure 4A-C). Addition of a blocking antibody to CD40L, 
but not CTLA-4, prevented il-10-GFP/IL-10 expression (Figure 4A-C). B-cell-induced il-10-
GFP/IL-10 production by T-cells depended on MyD88 signaling and TLR-2, but not on IL-10 
proficiency on the part of the B-cell (Figure 4D,E). This observation is in line with our finding that 
the induction of CD40 and CD80 on B-cells by Helicobacter sonicate, PAM or LPS depends on 
MyD88 and TLR-2 (Figure 2E). Interestingly, addition of an agonistic anti-CD28 antibody to the 
co-cultures strongly enhanced the induction of il-10-GFP+CD25+ cells, both by naïve and by 
Helicobacter-pretreated B-cells (Figure 4F), indicating that the TLR-2- and MyD88-dependent 
up-regulation of CD80/CD86 on B-cells provides a co-stimulatory signal for the generation of Tr-
1-like cells. In summary, exposure to Helicobacter TLR-2 ligands converts B-cells into efficient 
inducers of IL-10-producing CD25+ Tr-1-like cells, and this process depends on a direct 
Sayi, Kohler, Toller et al., manuscript submitted                                                               Appendix 
 
interaction of the two cell types via CD40/CD40L, a TCR stimulus (αCD3) and a co-stimulatory 
signal (αCD28).  
To determine whether B-cell-induced Tr-1-like T-cell populations have acquired suppressive 
activity, we measured the CFSE dilution of CD4+CD25-Ly5.1+ T-cells activated by anti-
CD3/CD28 crosslinking in the presence or absence of FACS-sorted CD4+CD25+il-10-GFP+ and 
CD4+CD25+il-10-GFP- populations (Figure 4G). CD25+ il-10-GFP+ T-cells suppressed Ly5.1+ T-
cell proliferation more effectively than their CD25+ il-10-GFP- counterparts (Figure 4G), indicating 
that B-cell-induced Tr-1-like populations have indeed acquired suppressive properties. 
 
Tr-1-like cells are generated in vivo and recruited to the Helicobacter-infected gastric mucosa  
To determine whether Tr-1-like cells and other IL-10-producing immune cells are generated in 
vivo upon infection with Helicobacter, we infected IL-10-GFP knock-in mice with H. felis for three 
months and analyzed the GFP expression of various hematopoietic lineages in the stomach and 
in several lymphoid organs -the spleen, MLN and Peyer’s patches- in comparison to an 
uninfected control group. IL-10-GFP+ cells were readily detectable in all organs due to their 
robust signal intensity. No significant changes in IL-10-GFP+ cell numbers could be detected in 
the Peyer’s patches and spleens of infected vs. uninfected mice with regard to the B-cell-, T-cell, 
macrophage and DC lineages (using the markers CD4, CD19, F4/80 and CD11c; data not 
shown). In contrast, stomach and MLN preparations revealed clear infection-associated changes 
in the IL-10-GFP+ population, especially in the CD4+ T-cell compartment (Figure 5A,B). In the 
MLN, the fraction of IL-10-GFP+ cells in the CD4+ population increased from on average 3.2 to 
6.2% due to infection (Figure 5A); the majority of IL-10-GFP+ cells were CD25-positive (Figure 
5A). The overall CD25+ fraction increased as well, from 25% to 35% of the total CD4+ population 
(Figure 5A, lower panel). In the stomach, the number of infiltrating CD4+ T-cells was on average 
five times higher in the infected compared to the uninfected mice (Figure 5B); strikingly, the 
number of CD4+IL-10-GFP+ T-cells increased 13 fold due to infection, suggesting that Tr-1-like 
cells are either preferentially recruited to the stomach or directly generated there (Figure 5B). 
Consistent with their Tr-1-like phenotype, most CD4+IL-10-GFP+ cells in the stomach stained 
positive for CD25 (Figure 5B).  
As exposure to Helicobacter TLR ligands induces IL-10 expression and CD80 up-regulation on 
B-cells in vitro, we quantified the IL-10-GFP+ and CD80+ subpopulations of CD19+ B-cells. In the 
MLN, the fraction of IL-10-GFP+ B-cells doubled from 0.7 to 1.5% due to infection (Figure 5C). 
Consistent with the induction of CD80 and IL-10 expression in B-cells in vitro by Helicobacter 
ligands (Figure 2D), all IL-10-GFP+ B-cells in the MLN stained positive for CD80 (data not 
shown). The overall fraction of CD80+ B-cells was also significantly greater in the MLN of 
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infected vs. uninfected mice (14 vs. 10%; Figure 6C), indicating that MLN B-cells respond to 
Helicobacter infection in the stomach in a readily detectable manner. In the gastric mucosa, B-
cells were six times more abundant in infected compared to uninfected animals (Figure 5D). 
However, the absolute number of stomach-infiltrating CD19+IL-10-GFP+ cells was comparable in 
both groups (Figure 5D), indicating that the infected gastric mucosa is targeted preferentially by 
non-IL-10-expressing B-cells. All stomach-infiltrating IL-10-GFP+ B-cells were CD5+CD1d+, 
independent of the infection status of the mouse (data not shown), indicating that they belong to 
the recently described ‘B10’ subset of B-cells with regulatory function (8). Interestingly, roughly 
half of all stomach-infiltrating CD19+ B-cells were CD80-positive, compared to only 8-13% of B-
cells in the lymphoid organs analyzed (data not shown). In summary, large numbers of activated 
CD80+ B-cells infiltrate the stomach in response to Helicobacter infection, yet only a minor 
fraction of these stomach-infiltrating B-cells produce IL-10. Overall, the results obtained in the IL-
10-GFP knock-in mouse imply that, whereas both IL-10-GFP+ T- and B-cells are generated in 
the gut-draining lymph nodes as a result of Helicobacter infection, only IL-10-GFP+ T-cells are 
recruited to the infected stomach with high efficiency.  
 
The control of gastric preneoplastic pathology requires IL-10 expression by T-, but not B-cells  
B-cells constitute a direct source of IL-10, and also trigger IL-10 production by CD4+ T-cells upon 
activation by Helicobacter-derived TLR-2 ligands both in vitro and in vivo (Figures 2, 4, 5).  To 
clarify in vivo whether either one or both cell types require IL-10 for the efficient suppression of 
Helicobacter-induced gastric immunopathology, we took advantage of mouse strains with a 
conditional deletion of the IL-10 gene in the T-cell- (31) or B-cell compartments (30). Infection of 
IL-10fl/flCD4-Cre mice with Helicobacter felis resulted in the significantly accelerated 
development of gastric pathology compared to IL-10fl/fl mice (Figure 6A,B). In contrast, the 
CD19+ B-cell-specific loss of IL-10 did not render the mice more susceptible to Helicobacter-
induced pathology (Figure 6A,B). Consistent with their rapid development of immunopathological 
changes, IL-10fl/flCD4-Cre mice were colonized at significantly lower levels than either IL-10fl/fl or 
IL-10fl/flCD19-Cre mice (Figure 6C) and produced significantly higher levels of gastric IFN-γ 
(Figure 6D). All three read-outs combined indicate that T-cell-derived IL-10 is essential, but B-
cell-derived IL-10 is dispensable, for immune counter-regulation of Th-1-driven 
immunopathology in our model of Helicobacter-associated gastric preneoplasia.  
 
B- and T-cells co-operate in vivo to suppress Helicobacter-induced gastric immunopathology in 
MyD88-/- and IL-10-/- mice 
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Having demonstrated that the co-transfer of splenic B-cells and CD4+CD25+ T-cells into MyD88-/- 
recipients alleviates the pathology characteristic of this strain (Figure 3D,E), and that B-cell-
induced Tr-1-like cells possess suppressive activity in vitro (Figure 4G), we asked whether B-
cells and B-cell-induced Tr-1 cells would synergize to prevent excessive infection-associated 
pathology in MyD88-/- and IL-10-/- mice. To address this question, we adoptively transferred B-/T-
cell co-cultures that were grown under conditions leading to Tr-1 conversion (as described in 
Figure 4A) into recipients of both genetic backgrounds. Interestingly, the transfer of co-cultures 
consisting of wild type B- and T-cells completely inhibited the accelerated pathology of MyD88-/- 
mice (Figure 7A,B). IL-10 proficiency of T-cells, but not B-cells, was essential for conferring 
protection (Figure 7A,B), an observation that is in line with the phenotypes of the respective 
conditional IL-10-/- mice (Figure 6). A total of 250.000 transferred cells were sufficient to prevent 
gastric pathology in MyD88-/- mice; the transfer of pure B-cell or T-cell populations did not alter 
the severity of the lesions (data not shown).  
Finally, we utilized IL-10-/- recipients to test whether MyD88 proficiency is required on the part of 
the B-cells for prevention of the gastric pathology characteristic of this strain. Interestingly, 
protection was conferred in this background only by co-cultures of wild type T- and B-cells 
(Figure 7C,D); MyD88-/- B-cells, which are incapable of inducing Tr-1 cells upon exposure to 
Helicobacter (Figure 4D,E), did not alleviate the gastric pathology of IL-10-/- recipients if co-
transferred with WT T-cells (Figure 7C,D). The clearance of Helicobacter typically observed in 
IL-10-/- mice was prevented in the recipients of WT B-cell/WT T-cell co-cultures, but not the 
recipients of MyD88-/- B-cell/WT T-cell co-cultures (Figure 7E). Finally, the induction of gastric 
IFN-γ which typically accompanies clearance (Figures 1, 6), was suppressed by the transfer of 
WT B-cell/WT T-cell co-cultures, but not MyD88-/- B-cell/WT T-cell co-cultures (Figure 7F). In 
summary, we conclude that B-cells and B-cell-induced Tr-1 cells synergize to prevent excessive 
Helicobacter-associated inflammation and immunopathology in vivo, and that B-cells require 
MyD88 signaling for co-operative counter-immune regulation.  
 
Discussion 
We show here using mouse models of Helicobacter-induced gastric premalignant pathology that 
B-cells have an important role in fine-tuning the adaptive Th-1-driven immune response to the 
infection and in thereby limiting excessive gastric immunopathology. This regulatory function of 
B-cells depends on their ability to sense and respond to Helicobacter via TLR-2 and MyD88 and 
to directly interact with naïve T-cells, which are efficiently converted to Tr-1-like, CD4+CD25+IL-
10+ cells in a CD40L and CD28-dependent manner. B-cell-induced Tr-1 cells acquire 
suppressive activity in vitro and -in collaboration with B-cells- block gastric histopathological 
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changes in vivo in genetic backgrounds that are particularly susceptible to Helicobacter-
associated pathology. Our findings provide a plausible mechanistic explanation for 
epidemiological and experimental data showing that the majority of chronically Helicobacter-
infected individuals and experimentally infected animals remain asymptomatic despite being 
colonized with virulent H. pylori strains and despite harboring high bacterial loads (27, 33, 34).  
B-cells have been shown to possess regulatory activity in several mouse models of chronic 
inflammatory conditions or autoimmune diseases, including models of multiple sclerosis (EAE) 
(5, 11, 13, 15, 35), collagen-induced arthritis (6, 12), contact hypersensitivity (8), type I diabetes 
(7) and inflammatory bowel disease (9, 10). The prevailing mechanistic model of B-cell immune 
counter-regulation postulates that specific subsets of IL-10-producing B-cells possess regulatory 
function. Several studies have shown a strict dependence of B-cell regulatory activity on IL-10 
production by the B-cells themselves (6-8, 11, 12, 30, 35); other proposed mechanisms of B-cell-
mediated immune regulation include the contact-dependent induction or activation of 
CD4+CD25+ or CD8a+ Treg (10, 13, 36).  We show here that, although exposure to Helicobacter-
derived TLR-2 ligands induces IL-10 production in B-cells in a MyD88-dependent manner, IL-10 
is not required on the part of the B-cell for suppression of Helicobacter-induced pathology. 
Rather, Helicobacter-activated B-cells acquire the ability to efficiently induce Tr-1-like cells, an 
abundant population of intraepithelial lymphocytes in the small intestine known to suppress 
excessive intestinal inflammation (29). Therefore, while IL-10 induction in the B-cells coincides 
with their TLR-2- and MyD88-dependent activation and their acquisition of T-cell-converting 
capabilities, the cytokine itself is clearly not required for Tr-1 cell generation. Evidence that IL-10 
production by Tr-1 cells, but not B-cells, is crucial for protection from Helicobacter-induced 
preneoplasia came from the analysis of mouse strains with either a T-cell- or B-cell-specific 
ablation of the il-10 gene. IL-10fl/flCD4-Cre animals displayed significantly accelerated gastric 
pathology upon infection compared to wild type mice; in fact, their phenotype was 
indistinguishable from the phenotype of a complete IL-10-/- strain. In contrast, IL-10fl/flCD19-Cre 
mice did not exhibit increased susceptibility to gastric immunopathology. In line with these 
findings, only IL-10-producing T-cells, but not IL-10-producing B-cells, were found to be recruited 
to the gastric mucosa upon infection, indicating that IL-10+ T-cells cells might be acting locally in 
the gastric mucosa to inhibit pathogenic T-cell responses. Whether Helicobacter-activated 
CD80+ IL-10- B-cells (which, in contrast to IL-10+ B-cells, migrate to the gastric mucosa in large 
numbers) generate Tr-1 cells in the MLN or directly in the gastric mucosa is currently not known. 
We and others have shown previously that chronic Helicobacter infection induces mucosa-
associated lymphoid tissue (MALT) in the gastric mucosa of humans and experimentally infected 
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mice (24, 27, 37). In MALT, T- and B-cells form organized structures mimicking reactive 
lymphoid follicles, which could potentially serve as the sites of Tr-1 cell priming.   
At least one other mechanism has been described through which B-cells can efficiently induce 
Treg with suppressive activity (36). Using co-culture models as well as contact hypersensitivity 
and allogeneic transplant models, Reichardt and colleagues showed that naïve B-cells can 
prime CD4+CD25+ regulatory T cells, which in turn potently suppress T-cell responses in vitro 
and in vivo (36).  
The requirement for TLR-2 expression and MyD88 signaling for a regulatory activity of B-cells 
and for Tr-1 cell generation is consistent with the greatly enhanced susceptibility of TLR-2-/- and 
MyD88-/- animals to Helicobacter-induced gastric histopathology. The phenotypes of both strains 
suggest that TLR-2 is required for priming of the regulatory, but not the effector branches of the 
adaptive immune response to Helicobacter infection. Indeed, effector T-cell activation is not 
impaired in the TLR-2-/- strain, which controls bacterial colonization more efficiently than the wild 
type strain. Our data is consistent with a recent report by Rad et al., who identified TLR-2, and to 
a lesser extent TLR-4 and -9 as essential for the recognition of Helicobacter by dendritic cells in 
vitro (38).  
In conclusion, we show here that B-cells play an essential role in the suppression of excessive 
immunopathology driven by Helicobacter infection in murine models. We provide evidence for a 
novel IL-10-independent, but MyD88-dependent, mechanism of immune counter-regulation by 
B-cells, which generates IL-10-secreting Treg with suppressive activity in vitro and in vivo.  Our 
data have implications for vaccine development against Helicobacter, which must attempt to 
override immune counter-regulation to achieve sterilizing immunity upon challenge infection (39).  
The cooperative B-/T-cell-mediated suppression of immunopathological gastric responses to 
Helicobacter infection provides a possible explanation for why a majority of Helicobacter-infected 
individuals never develop overt disease symptoms but are protected from long-term 
manifestations of Helicobacter infection.  
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Figures and Figure legends 
 
Figure 1 
 
 
Figure 1: Regulatory T-cells block the gastric histopathology induced by co-transferred 
effector T-cells in the TCR-β-/-, but not the Rag-1-/- background. TCR-β-/- mice (A-D) and 
Rag-1-/- mice (E-H) received either 250.000 immunomagnetically isolated CD4+CD25- effector T-
cells and 250.000 CD4+CD25+ Treg (‘Teff+Treg’) or effector cells only (‘Teff’) and were infected with 
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H. felis on the same day. A control group was infected but did not receive cells (‘inf’). All mice 
were sacrificed four weeks p.i. A,E, Representative micrographs of Giemsa-stained sections. 
The scale bar indicates 50 μm. B,F, Histopathology scores assigned to every mouse for all 
indicated parameters on a scale of 0-6. Horizontal bars indicate the means. C,G, Gastric IFN-γ 
production as assessed by quantitative real time RT-PCR. IFN-γ expression is normalized to 
GAPDH expression. D,H, H. felis colonization as assessed by quantitative PCR of the flaB gene 
using total gastric genomic DNA as template. Vertical bars indicate SEM; asterisks designate 
values below the detection limit.  
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Figure 2 
 
 
Figure 2:  B-cells produce IL-10 and up-regulate CD80 in a MyD88- and TLR-2-dependent 
manner upon exposure to Helicobacter sonicate. B-cells were immunomagnetically isolated 
from the spleens of il-10-GFP knock-in reporter mice (A,B,D,E), or wild type, MyD88-/- and TLR-
2-/- mice (C) and treated for 48 hours with 10μg/ml Helicobacter sonicate (‘H.f.’), 5μg/ml 
Pam3Cys or 10μg/ml LPS. The cultures were stained for expression of the indicated surface 
markers (CD19, IgM, CD21, CD23, CD80, CD40) and analyzed for induction of il-10-GFP 
expression. A, Il-10-GFP expression in the CD19+ B-cell population. Representative dot plots 
and the averages of triplicate cultures are shown in the left and right panels. Values indicate 
CD19+ il-10-GFP+/- cells in %; vertical bars indicate SEM. B, IgM, CD21 and CD23 expression of 
the same cultures as shown in A, gated on the CD19+ population. C, IL-10 expression as 
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determined by ELISA of wild type, MyD88-/- and TLR-2-/- B-cells treated as indicated. Averages 
+/- SEM are shown. Asterisks indicate values below the detection limit. D, Il-10-GFP+ B-cells 
induced by exposure to H. felis extract are CD80+. Representative dot plots and averages of 
triplicate cultures are shown. E, Helicobacter sonicate induces CD80 and CD40 up-regulation in 
wild type, but not MyD88-/- and TLR-2-/- B-cells. Representative dot plots and averages of 
triplicate cultures are shown. MFI stands for mean fluorescence intensity of the CD40 signal in 
the CD80+ and CD80- populations. 
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Figure 3 
 
 
Figure 3: The accelerated gastric histopathology of MyD88-/- mice can be prevented by 
administration of recombinant IL-10 or by adoptive co-transfer of wild type B-cells and 
CD4+CD25+ splenic Treg. A,B,C, Wild type and MyD88-/- mice were infected for one month with 
H. felis. A group of infected MyD88-/- animals further received thrice-weekly intraperitoneal doses 
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of recombinant murine IL-10 during the entire month. A, Representative micrographs of Giemsa-
stained sections of one mouse per group. The scale bar indicates 50 μm. B, Histopathology 
scores assigned as described in Figure 1. C, H. felis colonization as determined by quantitative 
PCR of the flaB gene. D,E, MyD88-/- mice were infected for one month with H. felis, and received 
250.000 immunomagnetically isolated, splenic B-cells and/or an equal number of splenic 
CD4+CD25+ Treg as indicated. D, Representative micrographs. E, Histopathology scores of all 
mice included in the four treatment groups. Horizontal bars indicate mean values. 
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Figure 4 
 
 
Figure 4: Helicobacter extract-pretreated B-cells induce IL-10 expression in conventional 
CD4+ T-cells in a manner depending on MyD88 and TLR-2 on the part of the B-cell, and on 
TCR- and CD28 signaling on the part of the T-cell. A-C, Wild type splenic B-cells were treated 
for four hours with 10μg/ml Helicobacter sonicate (‘H.f.’), 5μg/ml Pam3Cys or 10μg/ml LPS prior 
to co-culturing for four days with il-10-GFP knock-in CD4+CD25- T-cells in the presence of anti-
CD3 crosslinking antibody and IL-2. Where indicated, the two populations were separated by a 
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transwell filter, or anti-CD40L and/or anti-CTLA-4 blocking antibody was added at 10μg/ml final 
concentration. The co-cultures were stained for CD4 and CD25; all events in the CD4+ gate are 
plotted. A, Representative dot plots of CD4+ T-cells expressing il-10-GFP and stained for CD25. 
The co-culture conditions are indicated above the plots. Values in quadrants indicate il-10-GFP+ 
CD25+ and il-10-GFP- CD25+ cells in % of all CD4+ cells. B, Averages +/- SEM of il-10-GFP+ 
CD25+ T-cells of triplicate cultures as shown in A. C, IL-10 secretion into the culture 
supernatants as determined by ELISA of the cultures shown in A and B. D,E, Wild type, MyD88-/-
,TLR-2-/- and IL-10-/- splenic B-cells were treated for four hours with 10g/ml Helicobacter 
sonicate (‘H.f.’), 1μg/ml Pam3Cys or 10g/ml LPS prior to co-culturing for four days with il-10-
GFP knock-in CD4+CD25- T-cells in the presence of anti-CD3 crosslinking antibody and IL-2. Il-
10-GFP and CD25 expression were analyzed as described in A and B. D, Averages +/- SEM of 
il-10-GFP+ CD25+ cells in % of all CD4+ T-cells of triplicate cultures. E, IL-10 production of the 
cultures shown in D. F, B- and T-cells were co-cultured as described in A; a CD28-crosslinking 
antibody was added where indicated at a final concentration of 1μg/ml. G, FACS-sorted 
CD4+CD25+ il-10-GFP+ and CD4+CD25+ il-10-GFP- T-cells were added to CFSE-labeled 
Ly5.1+CD4+CD25- effector T-cells at a 1:1 ratio. The effector cells were stimulated by CD3/CD28 
crosslinking, and their proliferation was determined by CFSE dilution. The values indicate 
CFSEdim cells in % of all Ly5.1+ cells. Representative dot plots are shown in the left panels; 
averages +/- SEM of CFSEdim cells in % of all Ly5.1+ T-cells are shown in the right panel. 
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Figure 5 
 
 
Figure 5: Il-10-GFP+ T-cells, but not B-cells, are recruited to the H. felis-infected gastric 
mucosa. Eight il-10-GFP knock-in mice were infected for three months and compared to five 
uninfected controls with respect to il-10-GFP expression in the CD4+CD25+ T-cell  (A,B) and 
CD19+ B-cell (C,D) compartments in the MLN and stomach. A,B, MLN (A) and stomach (B) 
single cell preparations of every mouse were stained for CD4 and CD25 and analyzed with 
regard to il-10-GFP expression. C,D, The same single cell preparation as described in A and B 
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were stained for CD19 and CD80 and analyzed with regard to il-10-GFP expression. CD80 
expression data are only available for a subgroup of three uninfected and five infected mice. In 
all panels, dot plots of representative mice are shown (upper panels) along with the 
quantification for all five uninfected and eight infected mice per group (lower panel). 
 
 
Sayi, Kohler, Toller et al., manuscript submitted                                                               Appendix 
 
Figure 6 
 
 
Figure 6: T-cellular, but not B-cellular IL-10 expression is required for suppression of 
Helicobacter-associated gastric histopathology. IL-10fl/fl, IL-10fl/flCD4-Cre and IL-10fl/flCD19-
Cre mice were infected for one month with H. felis and analyzed with respect to gastric 
histopathology, H. felis colonization and gastric IFN-γ expression. A, Representative 
micrographs of Giemsa-stained sections of one mouse per group. The scale bar indicates 50 
µm. B, Histopathology scores assigned as described in Figure 1. C, H. felis colonization as 
determined by quantitative PCR of the flaB gene. D, Gastric INF-γ expression as assessed by 
real time RT-PCR analysis. IFN-γ levels are normalized to GAPDH expression.  
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Figure 7 
 
 
 
Figure 7: Suppression of gastric pathology in MyD88-/- and IL-10-/- mice requires B-cellular 
MyD88 signaling and T-cellular IL-10 expression. MyD88-/- (A,B) and IL-10-/- (C-E) mice were 
infected with H. felis for one month and three weeks, respectively. On the day of infection, the 
mice received i.v. injections of 250.000 B- and Tr-1 cells (wild type, IL-10-/- or MyD88-/-), that 
were co-cultured for four days at a ratio of 1:1 prior to injection. A,C, Representative 
micrographs of Giemsa-stained sections of one mouse per group. The scale bar indicates 50 
µm. B,D, Histopathology scores assigned as described in Figure 1. E, H. felis colonization as 
determined by quantitative PCR of the flaB gene. 
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Supplemental Figures 1-4  
Supplemental Figure 1 
 
 
Supplemental Figure 1: CD4+CD25+ Treg are essential for the prevention of excessive 
gastric Helicobacter-associated immunopathology. 
(A-C) Wild type mice were infected for one month with H. felis and received weekly injections of 
anti-CD25 antibody; a control group was infected, but left untreated. All mice were assessed with 
respect to gastric histopathology and colonization; representative Giemsa-stained sections are 
shown in A and histopathology scores are shown in B. The scale bar indicates 50μm. 
Colonization as determined by flaB-specific quantitative PCR on total gastric genomic DNA is 
shown in C.  
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Supplemental Figure 2 
 
 
 
 
 
Supplemental Figure 2: IL-10-/- mice develop greatly accelerated gastric preneoplastic 
pathology and efficiently clear H. felis infection. 
(A,B) Wild type and IL-10-/- mice were infected for one month with H. felis and analyzed with 
respect to gastric histopathology (A) and colonization (B). Representative Giemsa-stained 
sections and histopathology scores are shown in A; colonization levels as determined by flaB-
specific quantitative PCR on total gastric genomic DNA are shown in B. The scale bar indicates 
50μm. 
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Supplemental Figure 3 
 
 
 
 
 
 
Supplemental Figure 3:  B-cells from various organs can be induced to express IL-10 by 
treatment with H. felis extract. 
(A,B) B-cells were immunomagnetically purified from single cell suspensions of pooled spleens, 
MLN, Peyer’s patches and peritoneum of three mice. The B-cells were treated with Helicobacter 
extract for 72 hours (‘H.f.’) or left untreated (‘C’), and were stained for expression of B220. 
Representative dot plots of il-10-GFP production in the B220+ population are shown in A and 
averages of triplicate cultures are shown in B.  
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Supplemental Figure 4 
 
 
 
 
 
 
Supplemental Figure 4: The Helicobacter-induced up-regulation of CD80 and, to a lesser 
extent, of CD86 on B-cells depends on MyD88 and TLR-2. 
(A,B) Splenic B-cells were immunomagnetically purified from wild type, MyD88-/- and TLR-2-/- 
mice, treated with Helicobacter extract for 24 hours (‘H.f.’) or left untreated (‘C’), and stained for 
expression of CD80 (A) and CD86 (B). MFI indicates mean fluorescence intensity.  
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Supplemental Figure 5 
 
 
 
 
Supplemental Figure 5: TLR-2-/- mice develop greatly accelerated gastric preneoplastic 
pathology and efficiently reduce H. felis infection. 
(A,B) TLR-2-/- mice were infected for one month with H. felis and analyzed with regard to gastric 
histopathology (A) and H. felis colonization (B). Representative Giemsa-stained sections and 
histopathology scores are shown in A; colonization levels as determined by flaB-specific 
quantitative PCR on total gastric genomic DNA are shown in B. The scale bar indicates 50μm. 
 
 
 
 
 
 
  
  
 
